WO2013179143A2 - Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors - Google Patents
Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors Download PDFInfo
- Publication number
- WO2013179143A2 WO2013179143A2 PCT/IB2013/001583 IB2013001583W WO2013179143A2 WO 2013179143 A2 WO2013179143 A2 WO 2013179143A2 IB 2013001583 W IB2013001583 W IB 2013001583W WO 2013179143 A2 WO2013179143 A2 WO 2013179143A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- molecule
- receptor
- soluble
- body fluid
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 99
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title claims abstract description 16
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title claims abstract description 16
- 201000011510 cancer Diseases 0.000 title claims description 22
- 206010070834 Sensitisation Diseases 0.000 title description 5
- 230000008313 sensitization Effects 0.000 title description 5
- 210000001124 body fluid Anatomy 0.000 claims abstract description 113
- 239000010839 body fluid Substances 0.000 claims abstract description 113
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 97
- 238000011282 treatment Methods 0.000 claims abstract description 95
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 75
- 230000009149 molecular binding Effects 0.000 claims abstract description 48
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 39
- 239000007787 solid Substances 0.000 claims abstract description 30
- 230000001235 sensitizing effect Effects 0.000 claims abstract description 20
- 102000003675 cytokine receptors Human genes 0.000 claims description 117
- 108010057085 cytokine receptors Proteins 0.000 claims description 117
- 239000008280 blood Substances 0.000 claims description 86
- 210000004369 blood Anatomy 0.000 claims description 85
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 62
- 229960001924 melphalan Drugs 0.000 claims description 60
- 210000002381 plasma Anatomy 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 36
- 239000012528 membrane Substances 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 210000001519 tissue Anatomy 0.000 claims description 25
- 102000004127 Cytokines Human genes 0.000 claims description 24
- 108090000695 Cytokines Proteins 0.000 claims description 24
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 19
- 230000005855 radiation Effects 0.000 claims description 19
- 239000011324 bead Substances 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 150000003384 small molecules Chemical class 0.000 claims description 15
- 239000011148 porous material Substances 0.000 claims description 14
- 210000002751 lymph Anatomy 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 11
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 11
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 10
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 9
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 9
- 229940100198 alkylating agent Drugs 0.000 claims description 9
- 239000002168 alkylating agent Substances 0.000 claims description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 8
- 239000007943 implant Substances 0.000 claims description 8
- 239000011325 microbead Substances 0.000 claims description 7
- 239000002102 nanobead Substances 0.000 claims description 7
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 5
- 210000002744 extracellular matrix Anatomy 0.000 claims description 5
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 102000019298 Lipocalin Human genes 0.000 claims description 4
- 108050006654 Lipocalin Proteins 0.000 claims description 4
- 229960004961 mechlorethamine Drugs 0.000 claims description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 4
- 230000000770 proinflammatory effect Effects 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 3
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 claims description 3
- 210000001601 blood-air barrier Anatomy 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 108010085650 interferon gamma receptor Proteins 0.000 claims description 3
- 102000002467 interleukin receptors Human genes 0.000 claims description 3
- 108010093036 interleukin receptors Proteins 0.000 claims description 3
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims description 2
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 2
- 102000004560 Interleukin-12 Receptors Human genes 0.000 claims description 2
- 108010017515 Interleukin-12 Receptors Proteins 0.000 claims description 2
- 102000004557 Interleukin-18 Receptors Human genes 0.000 claims description 2
- 108010017537 Interleukin-18 Receptors Proteins 0.000 claims description 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims description 2
- 101710195550 Interleukin-23 receptor Proteins 0.000 claims description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 2
- 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 1
- 238000002617 apheresis Methods 0.000 description 92
- 241001465754 Metazoa Species 0.000 description 52
- -1 succinimidyl ester Chemical class 0.000 description 46
- 230000037396 body weight Effects 0.000 description 33
- 241000700159 Rattus Species 0.000 description 32
- 230000027455 binding Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 22
- 230000004614 tumor growth Effects 0.000 description 17
- 238000002512 chemotherapy Methods 0.000 description 13
- 229920002684 Sepharose Polymers 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 230000003252 repetitive effect Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 102000015696 Interleukins Human genes 0.000 description 10
- 108010063738 Interleukins Proteins 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 10
- 238000002616 plasmapheresis Methods 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 230000036760 body temperature Effects 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 9
- 230000009826 neoplastic cell growth Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229920002873 Polyethylenimine Polymers 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 7
- 230000000973 chemotherapeutic effect Effects 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 239000000956 alloy Substances 0.000 description 6
- 229910045601 alloy Inorganic materials 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 229920000298 Cellophane Polymers 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 5
- 108010092160 Dactinomycin Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 5
- 239000004677 Nylon Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 239000000919 ceramic Substances 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 229960000640 dactinomycin Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000011343 solid material Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000002729 3-dimensional conformal radiation therapy Methods 0.000 description 4
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000002786 image-guided radiation therapy Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002721 intensity-modulated radiation therapy Methods 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 229960001428 mercaptopurine Drugs 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000002720 stereotactic body radiation therapy Methods 0.000 description 4
- 238000002719 stereotactic radiosurgery Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000251730 Chondrichthyes Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 102100040557 Osteopontin Human genes 0.000 description 3
- 102100030304 Platelet factor 4 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 238000004555 blood preservation Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000921 morphogenic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 229960001278 teniposide Drugs 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DGSRXKGBZHMWTF-UHFFFAOYSA-N (12-hydroxy-5-methoxy-2,2,9-trimethyl-11-oxo-8,10-dihydronaphtho[3,2-h]chromen-9-yl) acetate Chemical compound O1C(C)(C)C=CC2=C1C1=C(O)C(C(=O)CC(C)(C3)OC(C)=O)=C3C=C1C=C2OC DGSRXKGBZHMWTF-UHFFFAOYSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- GCNSBSLHQZFIMO-UHFFFAOYSA-N 1-[3-[(8-acetyl-3,5,7-trihydroxy-2,2-dimethyl-3,4-dihydrochromen-6-yl)methyl]-2,6-dihydroxy-4-methoxy-5-methylphenyl]ethanone Chemical compound COC1=C(C)C(O)=C(C(C)=O)C(O)=C1CC(C(=C1C(C)=O)O)=C(O)C2=C1OC(C)(C)C(O)C2 GCNSBSLHQZFIMO-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- MTVOSXTZNVKGIF-UHFFFAOYSA-N 2,3-dimethoxy-12-methyl-13h-[1,3]benzodioxolo[5,6-c]phenanthridine Chemical compound C1=C2C(N(C)CC=3C=C(C(=CC=33)OC)OC)=C3C=CC2=CC2=C1OCO2 MTVOSXTZNVKGIF-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- KKWJCGCIAHLFNE-UHFFFAOYSA-N 22R-hydroxylanosterol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(C(O)CC=C(C)C)C)CCC21C KKWJCGCIAHLFNE-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- YSFGBPCBPNVLOK-UHFFFAOYSA-N 6-hydroxy-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCO YSFGBPCBPNVLOK-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 2
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 2
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 description 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CSYGXJQNODZRQO-UHFFFAOYSA-N Inotodiol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CC(O)C12C)C4(C)CCC(O)C(C)(C)C4CC3 CSYGXJQNODZRQO-UHFFFAOYSA-N 0.000 description 2
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 2
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
- 102100020990 Interferon lambda-1 Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 102100039879 Interleukin-19 Human genes 0.000 description 2
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 2
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 102100036680 Interleukin-25 Human genes 0.000 description 2
- 108010066979 Interleukin-27 Proteins 0.000 description 2
- 102100033502 Interleukin-37 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- ANFSXHKDCKWWDB-UHFFFAOYSA-N Justicidin A Chemical compound C1=C2OCOC2=CC(C=2C=3C(=O)OCC=3C(OC)=C3C=C(C(=CC3=2)OC)OC)=C1 ANFSXHKDCKWWDB-UHFFFAOYSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 2
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 description 2
- 108010081689 Osteopontin Proteins 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 102000002938 Thrombospondin Human genes 0.000 description 2
- 108060008245 Thrombospondin Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- RUKXXSDGTORZFO-OAQYLSRUSA-N Vismione B Natural products O(C)c1c2c(OC(C)(C)C=C2)c2c(O)c3C(=O)C[C@@](O)(C)Cc3cc2c1 RUKXXSDGTORZFO-OAQYLSRUSA-N 0.000 description 2
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003972 antineoplastic antibiotic Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- ZEKAIRFOYPDZNC-UHFFFAOYSA-N aristolactam-aii Chemical compound O=C1NC2=CC3=CC=CC=C3C3=C2C1=CC(O)=C3OC ZEKAIRFOYPDZNC-UHFFFAOYSA-N 0.000 description 2
- 229960003272 asparaginase Drugs 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- KKWJCGCIAHLFNE-KFPHZHIMSA-N inotodiol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H]([C@H](O)CC=C(C)C)C)CC[C@]21C KKWJCGCIAHLFNE-KFPHZHIMSA-N 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- RTDRYYULUYRTAN-UHFFFAOYSA-N justicidin B Natural products C1=C2OCOC2=CC(C=2C=3C(=O)OCC=3C=C3C=C(C(=CC3=2)OC)OC)=C1 RTDRYYULUYRTAN-UHFFFAOYSA-N 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- MUMCCPUVOAUBAN-UHFFFAOYSA-N liriodenine Chemical compound C1=NC(C(=O)C=2C3=CC=CC=2)=C2C3=C(OCO3)C3=CC2=C1 MUMCCPUVOAUBAN-UHFFFAOYSA-N 0.000 description 2
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229940117041 melphalan injection Drugs 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000002727 particle therapy Methods 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 229960001237 podophyllotoxin Drugs 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical compound C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 2
- 238000002661 proton therapy Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000004725 rapid separation liquid chromatography Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- MFKPWBJXKCSPGK-KNORBDTNSA-N sinococuline Chemical compound C([C@@H]1NCC2)C3=CC=C(OC)C(O)=C3[C@@]32C1=C(OC)[C@@H](O)[C@@H](O)C3 MFKPWBJXKCSPGK-KNORBDTNSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004215 spore Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 2
- 229940006509 strontium-89 Drugs 0.000 description 2
- LDBQEVDAHSVWKL-UHFFFAOYSA-N taxamairin B Natural products C1=C2C=CC(=O)C(C)(C)C2=CC(=O)C2=CC(C(C)C)=C(OC)C(OC)=C12 LDBQEVDAHSVWKL-UHFFFAOYSA-N 0.000 description 2
- LKWPNJGNAHHUDE-UHFFFAOYSA-N taxamairin a Chemical compound C1=C2C=CC(=O)C(C)(C)C2=CC(=O)C2=C1C(O)=C(OC)C(C(C)C)=C2 LKWPNJGNAHHUDE-UHFFFAOYSA-N 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 238000004724 ultra fast liquid chromatography Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- MHXCIKYXNYCMHY-AUSJPIAWSA-N (+)-lariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 MHXCIKYXNYCMHY-AUSJPIAWSA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- LGSDYQBPJKYJCT-UHFFFAOYSA-N (-)-Akagerine Natural products OC1CC(C(C=O)=CC)CC2N(C)CCC3=C2N1C1=CC=CC=C31 LGSDYQBPJKYJCT-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- RWNHLTKFBKYDOJ-UHFFFAOYSA-N (-)-arjunolic acid Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C RWNHLTKFBKYDOJ-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-FPLPWBNLSA-N (15:1)-Cardanol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-FPLPWBNLSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- XNWZKGMGEINBJE-NIEJHYDOSA-N (1r,4z,6r,8e,10s,12e,14s)-6,10-dihydroxy-4,8,12,15,15-pentamethylbicyclo[12.1.0]pentadeca-4,8,12-trien-11-one Chemical compound C1CC(/C)=C\[C@H](O)C\C(C)=C\[C@H](O)C(=O)\C(C)=C\[C@@H]2C(C)(C)[C@H]12 XNWZKGMGEINBJE-NIEJHYDOSA-N 0.000 description 1
- DGENOXRJSTZHMV-XBLVRJISSA-N (1r,5z,8z,10s,12z,14r)-4,10-dihydroxy-4,8,12,15,15-pentamethylbicyclo[12.1.0]pentadeca-5,8,12-trien-11-one Chemical compound C1CC(C)(O)\C=C/CC(/C)=C\[C@H](O)C(=O)\C(C)=C/[C@H]2C(C)(C)[C@H]12 DGENOXRJSTZHMV-XBLVRJISSA-N 0.000 description 1
- FEOSJHQSWIDLGT-INJUBXAJSA-N (1s,4z,6r,8z,10r,12z,14r,15s)-6,10-dihydroxy-15-(hydroxymethyl)-4,8,12,15-tetramethylbicyclo[12.1.0]pentadeca-4,8,12-trien-11-one Chemical compound C1CC(/C)=C\[C@H](O)C\C(C)=C/[C@@H](O)C(=O)\C(C)=C/[C@H]2[C@](CO)(C)[C@@H]12 FEOSJHQSWIDLGT-INJUBXAJSA-N 0.000 description 1
- JIIKYOGYPVGXIF-RKVYJGGESA-N (1s,4z,8z,10r,12z,14r)-10-hydroxy-4,8,12,15,15-pentamethylbicyclo[12.1.0]pentadeca-4,8,12-triene-6,11-dione Chemical compound C1C\C(C)=C/C(=O)CC(/C)=C\[C@@H](O)C(=O)\C(C)=C/[C@H]2C(C)(C)[C@@H]12 JIIKYOGYPVGXIF-RKVYJGGESA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- IWQKGRNFKYKJHS-UHFFFAOYSA-N (2alpha,3beta,12beta)-2,3,12-Trihydroxypregna-4,7,16-trien-20-one Natural products OC1C(O)CC2(C)C(CC(O)C3(C(C(=O)C)=CCC33)C)C3=CCC2=C1 IWQKGRNFKYKJHS-UHFFFAOYSA-N 0.000 description 1
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- RHCBUXSXDFNUAG-UDMCIFMYSA-N (2s,4r,4as,8as)-4-[(e)-2-(furan-3-yl)ethenyl]-4a,8,8-trimethyl-3-methylidene-2,4,5,6,7,8a-hexahydro-1h-naphthalen-2-ol Chemical compound C(/[C@H]1C(=C)[C@@H](O)C[C@@H]2[C@]1(C)CCCC2(C)C)=C\C=1C=COC=1 RHCBUXSXDFNUAG-UDMCIFMYSA-N 0.000 description 1
- KVTCHSWVSFQOTP-YFPNSAJKSA-N (2z)-2-[(2r,3s,4s)-4-hydroxy-2-(3-hydroxypropyl)-3-[(3e,5r,7e)-5-hydroxy-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dimethylcyclohexylidene]propanal Chemical compound CC(C)=CCC\C(C)=C\C[C@@H](O)C(\C)=C\CC[C@@]1(C)[C@H](CCCO)\C(=C(\C)C=O)CC[C@]1(C)O KVTCHSWVSFQOTP-YFPNSAJKSA-N 0.000 description 1
- KJTPWUVVLPCPJD-AUWJEWJLSA-N (2z)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C\C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-AUWJEWJLSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- LLNJYWAPDLBDRC-DKNITUKRSA-N (3r,6's,7'r,8'as)-6'-ethenyl-7-[(2r)-1-methylpyrrolidin-2-yl]-7'-[[(1s)-2-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]methyl]spiro[1,2-dihydroindole-3,1'-3,5,6,7,8,8a-hexahydro-2h-indolizine]-6-ol Chemical compound CN1CCC[C@@H]1C1=C(NC[C@]23[C@@H]4C[C@H](C[C@H]5C6=C(C7=CC=CC=C7N6)CCN5C)[C@H](C=C)CN4CC3)C2=CC=C1O LLNJYWAPDLBDRC-DKNITUKRSA-N 0.000 description 1
- BGGIZHKHJBQRTI-VTYGAKHASA-N (3s,5s,8r,9s,10s,13r,14s,17r)-5,14-dihydroxy-3-[(2r,3r,4s,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde Chemical compound O1[C@H](C)[C@@H](O)[C@H](OC)[C@@H](OC)[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 BGGIZHKHJBQRTI-VTYGAKHASA-N 0.000 description 1
- BGGIZHKHJBQRTI-HJKWRMQUSA-N (3s,5s,8r,9s,10s,13r,14s,17r)-5,14-dihydroxy-3-[(2r,3r,4s,5s,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](OC)[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 BGGIZHKHJBQRTI-HJKWRMQUSA-N 0.000 description 1
- DYYYQLXAGIXUGM-FKKKBMQXSA-N (3z)-3-[2-[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethylidene]-5-hydroxyoxolan-2-one Chemical compound C([C@@H]1[C@@]2(C)CCCC([C@@H]2CCC1=C)(C)C)\C=C1\CC(O)OC1=O DYYYQLXAGIXUGM-FKKKBMQXSA-N 0.000 description 1
- RWNHLTKFBKYDOJ-WLVUEYHVSA-N (4aS,6aR,6aS,6bR,8aR,9S,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1[C@@H](O)[C@H](O)[C@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C RWNHLTKFBKYDOJ-WLVUEYHVSA-N 0.000 description 1
- ZMSNKXDPESNSSS-SZZHBACVSA-N (4r,4as,6as,6as,6br,8ar,11s,12as,14as,14bs)-8a,11-bis(hydroxymethyl)-4,4a,6a,6b,11,14a-hexamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@@](C)(CO)CC[C@]1(CO)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C ZMSNKXDPESNSSS-SZZHBACVSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- YXHVCZZLWZYHSA-UHFFFAOYSA-N (Z)-6-[8-pentadecenyl]salicylic acid Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-UHFFFAOYSA-N 0.000 description 1
- GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 description 1
- IWQKGRNFKYKJHS-KQFCJCSDSA-N 1-[(2r,3r,9s,10r,12r,13s,14s)-2,3,12-trihydroxy-10,13-dimethyl-2,3,6,9,11,12,14,15-octahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound O[C@H]1[C@H](O)C[C@]2(C)[C@@H](C[C@@H](O)[C@@]3(C(C(=O)C)=CC[C@H]33)C)C3=CCC2=C1 IWQKGRNFKYKJHS-KQFCJCSDSA-N 0.000 description 1
- YOQKJYPYVSGRAG-UHFFFAOYSA-N 1-[6-[(3-acetyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl]-3,5,7-trihydroxy-2,2-dimethyl-3,4-dihydrochromen-8-yl]-2-methylpropan-1-one Chemical compound COC1=C(C)C(O)=C(C(C)=O)C(O)=C1CC(C(=C1C(=O)C(C)C)O)=C(O)C2=C1OC(C)(C)C(O)C2 YOQKJYPYVSGRAG-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- PAQLRHWWLDIBHD-UHFFFAOYSA-N 16-hydroxyiridal Natural products CC(CC=C(C)C)C=CCC(O)C(=CCCC1(C)C(CCCO)C(=C(C)/C=O)CCC1(C)O)C PAQLRHWWLDIBHD-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
- QLDAACVSUMUMOR-UHFFFAOYSA-M 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 QLDAACVSUMUMOR-UHFFFAOYSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- SJSCBAFROHXGCX-MAVWQDHUSA-N 3,16,21,28-Tetrahydroxyolean-12-en-22-yl (2Z)-2-methyl-2-butenoate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@@H](O)[C@@]5(CO)[C@@H](O)[C@H](OC(=O)C(\C)=C/C)C(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C SJSCBAFROHXGCX-MAVWQDHUSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-UHFFFAOYSA-N 3-Delta8-pentadecenylphenol Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- FXZKDRVSINFUOY-GNFMRZGLSA-N 3-[(3s,5r,8r,9s,10r,13r,14s,17r)-14-hydroxy-3-[(2r,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10-(hydroxymethyl)-13-methyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound O1[C@H](C)[C@@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(CC[C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)O)[C@]3(CO)CC1 FXZKDRVSINFUOY-GNFMRZGLSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- AJNRNTOMAOOUFZ-UHFFFAOYSA-N 4,7-Oxycycloanisomelic acid Natural products CC1=C/C2OC(=O)C(=C)C2CCC3(C)CCC(O3)C(=CCC1)C(=O)O AJNRNTOMAOOUFZ-UHFFFAOYSA-N 0.000 description 1
- RNPDONJEBKWTIQ-SEVYOHKTSA-N 4-[2-[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2-hydroxy-2h-furan-5-one Chemical compound C([C@@H]1[C@@]2(C)CCCC([C@@H]2CCC1=C)(C)C)CC1=CC(O)OC1=O RNPDONJEBKWTIQ-SEVYOHKTSA-N 0.000 description 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- TUGAUFMQYWZJAB-FPLPWBNLSA-N 5-[(8Z)-pentadec-8-enyl]resorcinol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC(O)=CC(O)=C1 TUGAUFMQYWZJAB-FPLPWBNLSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- NDCWHEDPSFRTDA-FJMWQILYSA-N 6-hydroxypaclitaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)[C@H](O)[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 NDCWHEDPSFRTDA-FJMWQILYSA-N 0.000 description 1
- FTQNGEYQJGYGFY-BRMFVYFYSA-N 7-[(1S,4aS,8aS)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-hydroxy-4,7-dihydro-3H-dioxepine-5-carbaldehyde Chemical compound C1([C@H]2C(=C)CC[C@@H]3[C@]2(C)CCCC3(C)C)OOC(O)CC(C=O)=C1 FTQNGEYQJGYGFY-BRMFVYFYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- ZGCSNRKSJLVANE-UHFFFAOYSA-N Aglycone-Rebeccamycin Natural products N1C2=C3NC4=C(Cl)C=CC=C4C3=C(C(=O)NC3=O)C3=C2C2=C1C(Cl)=CC=C2 ZGCSNRKSJLVANE-UHFFFAOYSA-N 0.000 description 1
- DGENOXRJSTZHMV-UHFFFAOYSA-N Agroskerin Natural products C1CC(C)(O)C=CCC(C)=CC(O)C(=O)C(C)=CC2C(C)(C)C12 DGENOXRJSTZHMV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- OSSDUQKWVVZIGP-UHFFFAOYSA-N Aromaticin Natural products CC1CC2OC(=O)C(=C)C2CC2(C)C(=O)C=CC12 OSSDUQKWVVZIGP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- PSEBCAMYGWGJMH-UHFFFAOYSA-N Auriculasin Chemical compound CC(C)=CCC1=C2OC(C)(C)C=CC2=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C(O)=C1 PSEBCAMYGWGJMH-UHFFFAOYSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 229930190007 Baccatin Natural products 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- SRLTUZDQBFYLQI-FPLPWBNLSA-N Bilobol Natural products Oc1c(CCCCCCC/C=C\CCCCCC)ccc(O)c1 SRLTUZDQBFYLQI-FPLPWBNLSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 101100208237 Bos taurus THBS2 gene Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- NIPCMFQXEPLEQI-UHFFFAOYSA-N Bruceantinoside C Natural products COC(=O)C12OCC34C(CC5C(C)C=C(OC6OC(CO)C(O)C(O)C6O)C(=O)C5(C)C3C(O)C1O)OC(=O)C(OC(=O)C=C(/C)C(C)COC(=O)C)C24 NIPCMFQXEPLEQI-UHFFFAOYSA-N 0.000 description 1
- BMRNQSAXDJQXEL-ALGYPFNYSA-N Bryophyllin A Natural products O=C[C@@]12[C@H]3[C@H](O)C[C@]4(C)[C@H](C5=COC(=O)C=C5)CC[C@]4(O)[C@@H]3CC[C@]31O[C@]1(C)O[C@@H]2C[C@H](O1)C3 BMRNQSAXDJQXEL-ALGYPFNYSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 102100023705 C-C motif chemokine 14 Human genes 0.000 description 1
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 1
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 101150049756 CCL6 gene Proteins 0.000 description 1
- 101150011672 CCL9 gene Proteins 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102400000730 Canstatin Human genes 0.000 description 1
- 101800000626 Canstatin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- DBXFAPJCZABTDR-KUEXGRMWSA-N Cephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@@H](O)[C@H](NC(=O)/C(=C\C)/C)c1ccccc1 DBXFAPJCZABTDR-KUEXGRMWSA-N 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 102100031186 Chromogranin-A Human genes 0.000 description 1
- FQVNSJQTSOVRKZ-JNRDBWBESA-N Cicutoxin Chemical compound CCC[C@@H](O)\C=C\C=C\C=C\C#CC#CCCCO FQVNSJQTSOVRKZ-JNRDBWBESA-N 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 102100024484 Codanin-1 Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- RNPDONJEBKWTIQ-UHFFFAOYSA-N Coronarin C Natural products C=C1CCC2C(C)(C)CCCC2(C)C1CCC1=CC(O)OC1=O RNPDONJEBKWTIQ-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- XQCGNURMLWFQJR-ZNDDOCHDSA-N Cymarin Chemical compound O1[C@H](C)[C@@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 XQCGNURMLWFQJR-ZNDDOCHDSA-N 0.000 description 1
- XQCGNURMLWFQJR-UESCRGIISA-N Cymarin Natural products O=C[C@@]12[C@@](O)(C[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)CC[C@H]21 XQCGNURMLWFQJR-UESCRGIISA-N 0.000 description 1
- 102100035298 Cytokine SCM-1 beta Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- JMUOPRSXUVOHFE-GZZMZBIISA-N Deoxyelephantopin Chemical compound C1\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2[C@@H](OC(=O)C(=C)C)CC2=C[C@@H]1OC2=O JMUOPRSXUVOHFE-GZZMZBIISA-N 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 101100476962 Drosophila melanogaster Sirup gene Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 102100037354 Ectodysplasin-A Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- NFENNPKUXFGPST-UHFFFAOYSA-N Excisanin A Natural products C1C(O)C(C2O)C(=C)C(=O)C32C(O)CC2C(C)(C)CCC(O)C2(C)C31 NFENNPKUXFGPST-UHFFFAOYSA-N 0.000 description 1
- VAAUVQKKXHANPM-UHFFFAOYSA-N Excisanin B Natural products OC1CC2C(C)(C)CCC(O)C2(C)C2CC(OC(=O)C)C3C(O)C12C(=O)C3=C VAAUVQKKXHANPM-UHFFFAOYSA-N 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical class [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 101100232738 Gallus gallus IFNL3 gene Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical class O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 description 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- ZVLOPMNVFLSSAA-UHFFFAOYSA-N Heleanalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C2(C)C(=O)C=CC12 ZVLOPMNVFLSSAA-UHFFFAOYSA-N 0.000 description 1
- RFBYGVGDYMSKTD-UHFFFAOYSA-N Helenalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C3C(C)C(=O)C=C13 RFBYGVGDYMSKTD-UHFFFAOYSA-N 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 description 1
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 description 1
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 1
- 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 description 1
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 101001034829 Homo sapiens Interferon alpha-10 Proteins 0.000 description 1
- 101001034828 Homo sapiens Interferon alpha-14 Proteins 0.000 description 1
- 101001034835 Homo sapiens Interferon alpha-16 Proteins 0.000 description 1
- 101001034834 Homo sapiens Interferon alpha-17 Proteins 0.000 description 1
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 1
- 101001034833 Homo sapiens Interferon alpha-21 Proteins 0.000 description 1
- 101000959708 Homo sapiens Interferon alpha-4 Proteins 0.000 description 1
- 101000959704 Homo sapiens Interferon alpha-5 Proteins 0.000 description 1
- 101000959714 Homo sapiens Interferon alpha-6 Proteins 0.000 description 1
- 101000961126 Homo sapiens Interferon alpha-7 Proteins 0.000 description 1
- 101000999391 Homo sapiens Interferon alpha-8 Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001044447 Homo sapiens Interferon kappa Proteins 0.000 description 1
- 101001002469 Homo sapiens Interferon lambda-2 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101000960946 Homo sapiens Interleukin-19 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001010591 Homo sapiens Interleukin-20 Proteins 0.000 description 1
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 1
- 101000853009 Homo sapiens Interleukin-24 Proteins 0.000 description 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
- 101000852998 Homo sapiens Interleukin-27 subunit alpha Proteins 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 1
- 101000998132 Homo sapiens Interleukin-34 Proteins 0.000 description 1
- 101000998140 Homo sapiens Interleukin-36 alpha Proteins 0.000 description 1
- 101000998126 Homo sapiens Interleukin-36 beta Proteins 0.000 description 1
- 101001040964 Homo sapiens Interleukin-36 receptor antagonist protein Proteins 0.000 description 1
- 101000998122 Homo sapiens Interleukin-37 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- LZRUVOHMFJDCOH-UHFFFAOYSA-N Hydroxyanopterin Natural products CC=C(/C)C(=O)OC1C(OC(=O)C(=CC)C)C2C34CC(O)C5(O)C6(C)CN(C)C(C3C1C(=C)C4)C25CC(O)C6O LZRUVOHMFJDCOH-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 102000039989 IL-17 family Human genes 0.000 description 1
- 108091069193 IL-17 family Proteins 0.000 description 1
- 108091058536 IL1F9 Proteins 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- SFVVQRJOGUKCEG-CQROYNQRSA-N Indicine Natural products C1C[C@H](O)[C@H]2C(COC(=O)[C@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-CQROYNQRSA-N 0.000 description 1
- OONXNTUZEDPBLV-UHFFFAOYSA-N Indicine+ Natural products C1CC2(C)C3CCC4(C)C(C(O)C)CCC4(O)C3CC=C2CC1OC1CC(O)C(O)C(C)O1 OONXNTUZEDPBLV-UHFFFAOYSA-N 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 101710192051 Interferon alpha-1/13 Proteins 0.000 description 1
- 102100039734 Interferon alpha-10 Human genes 0.000 description 1
- 102100039733 Interferon alpha-14 Human genes 0.000 description 1
- 102100039728 Interferon alpha-16 Human genes 0.000 description 1
- 102100039730 Interferon alpha-17 Human genes 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 102100039729 Interferon alpha-21 Human genes 0.000 description 1
- 102100039949 Interferon alpha-4 Human genes 0.000 description 1
- 102100039948 Interferon alpha-5 Human genes 0.000 description 1
- 102100040007 Interferon alpha-6 Human genes 0.000 description 1
- 102100039350 Interferon alpha-7 Human genes 0.000 description 1
- 102100036532 Interferon alpha-8 Human genes 0.000 description 1
- 102100022469 Interferon kappa Human genes 0.000 description 1
- 102100020989 Interferon lambda-2 Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102100030692 Interleukin-20 Human genes 0.000 description 1
- 102100030704 Interleukin-21 Human genes 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 102100036671 Interleukin-24 Human genes 0.000 description 1
- 102100036679 Interleukin-26 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100033501 Interleukin-32 Human genes 0.000 description 1
- 102100033499 Interleukin-34 Human genes 0.000 description 1
- 102100033474 Interleukin-36 alpha Human genes 0.000 description 1
- 102100033498 Interleukin-36 beta Human genes 0.000 description 1
- 102100033503 Interleukin-36 gamma Human genes 0.000 description 1
- 102100021150 Interleukin-36 receptor antagonist protein Human genes 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- AMTATQQZOONDAP-UHFFFAOYSA-N Isostrychnophylline Natural products CN1CCc2c([nH]c3ccccc23)C1CC4CC5N(CCC56C(=O)Nc7c(C8CCCN8C)c(O)ccc67)CC4C=C AMTATQQZOONDAP-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- YVRYZXAHRGGELT-UHFFFAOYSA-N Lariciresinol Natural products C1=C2OCOC2=CC(C2C(C)C3(OC)C=C(CC=C)C(=O)CC3(O2)OC)=C1 YVRYZXAHRGGELT-UHFFFAOYSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- BSBUOIJYJTWEHV-UHFFFAOYSA-N Leukamenin A Natural products C12CCC(C3O)C(=C)C(=O)C23C(O)CC2C1(C)CC(O)C(OC(=O)C)C2(C)C BSBUOIJYJTWEHV-UHFFFAOYSA-N 0.000 description 1
- ZUYCXZKSCBNOSX-UHFFFAOYSA-N Leukamenin B Natural products C12CCC(C3O)C(=C)C(=O)C23C(O)CC2C1(C)CC(OC(=O)C)C(OC(C)=O)C2(C)C ZUYCXZKSCBNOSX-UHFFFAOYSA-N 0.000 description 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- MEPSBMMZQBMKHM-UHFFFAOYSA-N Lomatiol Natural products CC(=C/CC1=C(O)C(=O)c2ccccc2C1=O)CO MEPSBMMZQBMKHM-UHFFFAOYSA-N 0.000 description 1
- 101001089108 Lotus tetragonolobus Anti-H(O) lectin Proteins 0.000 description 1
- 201000002171 Luteoma Diseases 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- LLMFFOXSSQHNFR-UHFFFAOYSA-N Marchantin A Chemical compound O1C2=C(O)C=CC=C2CCC(C=C2)=CC=C2OC(C=2)=C(O)C(O)=CC=2CCC2=CC=CC1=C2 LLMFFOXSSQHNFR-UHFFFAOYSA-N 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- AFTUDGRDUWDYHE-UHFFFAOYSA-N Mexicanin I Natural products CC1CC2OC(=O)C(=C)C2C(O)C3(C)C1CC=C3C AFTUDGRDUWDYHE-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 101000686934 Mus musculus Prolactin-7D1 Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- BLTCBVOJNNKFKC-QUDYQQOWSA-N N-acetylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O BLTCBVOJNNKFKC-QUDYQQOWSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 101100168274 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-3 gene Proteins 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 241000492493 Oxymeris Species 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- RTMAZVHPRZLMEU-WPLROGRBSA-N Periplocoside A Natural products O=C(O[C@H]1[C@H](OC)[C@@H](O)[C@@H](C)O[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](C)O[C@@H](O[C@H]3[C@@H](C)O[C@H](O[C@H]4[C@H](C)O[C@@]5(OO[C@@H]6[C@@H](C)O[C@H](O[C@H](C)[C@]7(O)[C@]8(C)[C@@H]([C@@H]9[C@H]([C@@]%10(C)C(=CC9)C[C@H](O[C@H]9C(=O)C(OC)=C[C@H](C)O9)CC%10)CC8)CC7)C[C@H]6OC5)C[C@@H]4OC)C[C@H]3OC)C[C@@H]2OC)C[C@H]1OC)C RTMAZVHPRZLMEU-WPLROGRBSA-N 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- QEHOIJJIZXRMAN-UHFFFAOYSA-N Rebeccamycin Natural products OC1C(O)C(OC)C(CO)OC1N1C2=C3NC4=C(Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 QEHOIJJIZXRMAN-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102400001051 Restin Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- CIEYTVIYYGTCCI-UHFFFAOYSA-N SJ000286565 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1 CIEYTVIYYGTCCI-UHFFFAOYSA-N 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- JWBVQJZXSQDXKU-DOAWMXAISA-N Sculponeatin C Chemical compound C([C@@H]1C[C@]2(C(C1=C)=O)C(=O)OC1)[C@@H](O)[C@H]2[C@@]1([C@@H]12)[C@H]3O[C@H]2OC[C@]1(C)CC3 JWBVQJZXSQDXKU-DOAWMXAISA-N 0.000 description 1
- 102100030333 Serpin B5 Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 241000972674 Spathelia Species 0.000 description 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- PHLJPJICTIGOKC-XKYMZAEISA-N Strychnopentamine Chemical compound CN1CCC[C@@H]1C1=C(O)C=CC2=C1NC1=C2CCN2[C@H]1C[C@H](C[C@H]1C3=C(C4=CC=CC=C4N3)CCN1C)[C@@H](C=C)C2 PHLJPJICTIGOKC-XKYMZAEISA-N 0.000 description 1
- PHLJPJICTIGOKC-UHFFFAOYSA-N Strychnopentamine Natural products CN1CCCC1C1=C(O)C=CC2=C1NC1=C2CCN2C1CC(CC1C3=C(C4=CC=CC=C4N3)CCN1C)C(C=C)C2 PHLJPJICTIGOKC-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- QGGGTLQHMHIOKZ-GQJGGXIMSA-N Tomenphantopin A Natural products O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2[C@](C)(O2)C[C@@H]2O[C@@H](OC)C(=C2)C1)C(=C)C QGGGTLQHMHIOKZ-GQJGGXIMSA-N 0.000 description 1
- HAZJAYURMWWXAM-OFGAZGMUSA-N Tomenphantopin B Natural products O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2[C@](C)(O2)C[C@@H]2O[C@@H](O)C(=C2)C1)C(=C)C HAZJAYURMWWXAM-OFGAZGMUSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930187911 Tubeimoside Natural products 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102400000089 Tumor necrosis factor-binding protein 1 Human genes 0.000 description 1
- 101800002836 Tumor necrosis factor-binding protein 1 Proteins 0.000 description 1
- 102400000091 Tumor necrosis factor-binding protein 2 Human genes 0.000 description 1
- 101800002837 Tumor necrosis factor-binding protein 2 Proteins 0.000 description 1
- BGGIZHKHJBQRTI-UHFFFAOYSA-N UNPD92725 Natural products O1C(C)C(O)C(OC)C(OC)C1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CCC3C2(C=O)CC1 BGGIZHKHJBQRTI-UHFFFAOYSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- VUMZOPMHFVDIMF-NLLHOBBWSA-N Usambarensine Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C[C@H]1C[C@H]2C(NC=3C4=CC=CC=3)=C4CCN2C/C1=C/C VUMZOPMHFVDIMF-NLLHOBBWSA-N 0.000 description 1
- JICXOAIUPFUZPK-DXBSEXLMSA-N Usambarine Chemical compound N1C2=CC=CC=C2C(CCN2C[C@@H]3C=C)=C1[C@@H]2C[C@@H]3C[C@H]1C(NC=2C3=CC=CC=2)=C3CCN1C JICXOAIUPFUZPK-DXBSEXLMSA-N 0.000 description 1
- JICXOAIUPFUZPK-UHFFFAOYSA-N Usambarine Natural products N1C2=CC=CC=C2C(CCN2CC3C=C)=C1C2CC3CC1C(NC=2C3=CC=CC=2)=C3CCN1C JICXOAIUPFUZPK-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- KICSREDCVHEFSG-UHFFFAOYSA-N Vismione A Natural products C1C(C)(OC(C)=O)CC(=O)C2=C1C=C1C=C(OC)C(C=CC(C)C)=C(O)C1=C2O KICSREDCVHEFSG-UHFFFAOYSA-N 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000011704 WAG rat Methods 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 229930182763 Yadanzioside Natural products 0.000 description 1
- KYBLAIAGFNCVHL-VKWWBDAGSA-N Zeorin Natural products OC(C)(C)[C@@H]1[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@@H]([C@@H](O)C4)C(C)(C)CCC5)CC3)CC2)CC1 KYBLAIAGFNCVHL-VKWWBDAGSA-N 0.000 description 1
- FWXLVXABZRYLST-XUOZYSPWSA-N [(3r,4r,4ar,5s,6r,6ar,6as,6br,8ar,10s,12ar,14bs)-5,6,10-trihydroxy-4a-(hydroxymethyl)-2,2,6a,6b,9,9,12a-heptamethyl-4-[(z)-2-methylbut-2-enoyl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicen-3-yl] (e)-2-methylbut-2-enoate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)[C@@H](O)[C@@H](O)[C@@]5(CO)[C@@H](OC(=O)C(\C)=C/C)[C@H](OC(=O)C(/C)=C/C)C(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C FWXLVXABZRYLST-XUOZYSPWSA-N 0.000 description 1
- DNAWGBOKUFFVMB-PZIGJSDBSA-N [(7r,8r)-7-hydroxy-4-oxido-5,6,7,8-tetrahydro-3h-pyrrolizin-4-ium-1-yl]methyl (2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@](O)([C@H](C)O)C(C)C)=CC[N+]21[O-] DNAWGBOKUFFVMB-PZIGJSDBSA-N 0.000 description 1
- KICSREDCVHEFSG-VOTSOKGWSA-N [5,10-dihydroxy-7-methoxy-2-methyl-6-[(e)-3-methylbut-1-enyl]-4-oxo-1,3-dihydroanthracen-2-yl] acetate Chemical compound C1C(C)(OC(C)=O)CC(=O)C2=C1C=C1C=C(OC)C(\C=C\C(C)C)=C(O)C1=C2O KICSREDCVHEFSG-VOTSOKGWSA-N 0.000 description 1
- RTMAZVHPRZLMEU-UHFFFAOYSA-N [5-hydroxy-2-[6-[6-[6-[7-[1-[17-hydroxy-3-[(4-methoxy-2-methyl-5-oxo-2h-pyran-6-yl)oxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethoxy]-4'-methoxy-2',9-dimethylspiro[4,5a,6,7,9,9a-hexahydropyrano[3,4-c][1,2,5] Chemical compound O1C(C)C(OC2OC(C)C(OC3C(C(OC)C(O)C(C)O3)OC(C)=O)C(OC)C2)C(OC)CC1OC(C(C1)OC)C(C)OC1OC(C(C1)OC)C(C)OC1(OOC1C(C)O2)COC1CC2OC(C)C(C1(CCC2C3(C)CC4)C)(O)CCC1C2CC=C3CC4OC1OC(C)C=C(OC)C1=O RTMAZVHPRZLMEU-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 201000004471 adenofibroma Diseases 0.000 description 1
- 201000001256 adenosarcoma Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- XNWZKGMGEINBJE-UHFFFAOYSA-N agrostistachin Natural products C1CC(C)=CC(O)CC(C)=CC(O)C(=O)C(C)=CC2C(C)(C)C12 XNWZKGMGEINBJE-UHFFFAOYSA-N 0.000 description 1
- LGSDYQBPJKYJCT-YTLNUPAMSA-N akagerine Chemical compound O[C@H]1C[C@H](C(\C=O)=C/C)C[C@@H]2N(C)CCC3=C2N1C1=CC=CC=C31 LGSDYQBPJKYJCT-YTLNUPAMSA-N 0.000 description 1
- YQIYGKCKHVXNPT-UHFFFAOYSA-N akagerine Natural products CC=C(C=O)/C1CC(O)n2c3C(C1)NCCc3c4ccccc24 YQIYGKCKHVXNPT-UHFFFAOYSA-N 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- KYBLAIAGFNCVHL-UHFFFAOYSA-N alpha-zeroin Natural products C12CCC3C4(C)CCCC(C)(C)C4C(O)CC3(C)C1(C)CCC1C2(C)CCC1C(C)(O)C KYBLAIAGFNCVHL-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003377 anti-microbal effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 229960003982 apatinib Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- ZKXBFLQGGFVSGB-UHFFFAOYSA-N aristolactam AII Natural products COc1ccc2C(=O)Nc3cc4ccc(O)cc4c1c23 ZKXBFLQGGFVSGB-UHFFFAOYSA-N 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 229930192649 bafilomycin Natural products 0.000 description 1
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000002937 blood-testis barrier Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 238000011685 brown norway rat Methods 0.000 description 1
- QSNVEJIGBNLCQI-KMRSUJGASA-N bruceanol-a Chemical compound O([C@@H]1[C@@H]2C34CO[C@]2([C@H]([C@H](O)[C@@H]4[C@@]2(C)[C@H](O)C(=O)C=C(C)[C@@H]2C[C@H]3OC1=O)O)C(=O)OC)C(=O)C1=CC=CC=C1 QSNVEJIGBNLCQI-KMRSUJGASA-N 0.000 description 1
- NZDAVMOPAYYVCK-FIUJHEBUSA-N bruceanol-b Chemical compound O[C@@H]([C@]1(C)[C@H]2[C@@H](O)[C@H](O)[C@@]3(OC4)C(=O)OC)C(=O)C=C(C)[C@@H]1C[C@@H]1C24[C@H]3[C@@H](OC(=O)CCCCC)C(=O)O1 NZDAVMOPAYYVCK-FIUJHEBUSA-N 0.000 description 1
- XJIAVYYCXSQJAZ-SRHNQKLESA-N bruceantinoside c Chemical compound C([C@@H](C)[C@@H]1C[C@H]2OC(=O)[C@H](OC(=O)\C=C(/C)C(C)(C)OC(C)=O)[C@@H]3[C@]22CO[C@]3([C@H]([C@H](O)[C@@H]2[C@@]1(C)C1=O)O)C(=O)OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJIAVYYCXSQJAZ-SRHNQKLESA-N 0.000 description 1
- BMRNQSAXDJQXEL-BGJAGFQLSA-N bryophyllin a Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5([C@H]6C[C@H]7C[C@@]5(O[C@](C)(O7)O6)CC4)C=O)[C@H](O)C[C@@]32C)C=CC(=O)OC=1 BMRNQSAXDJQXEL-BGJAGFQLSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- DBXFAPJCZABTDR-WBYYIXQISA-N cephalomannine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 DBXFAPJCZABTDR-WBYYIXQISA-N 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- SPFPWBZAPXGZPE-KRRRKNKYSA-N chembl2368536 Chemical compound CC1=CC(=O)[C@@H](O)[C@]2(C)[C@@H]([C@@H](O)[C@@H]3O)[C@@]45CO[C@]3(C(=O)OC)[C@@H]5[C@@H](OC(=O)\C=C(/C)C(C)(C)OC(C)=O)C(=O)O[C@@H]4C[C@H]21 SPFPWBZAPXGZPE-KRRRKNKYSA-N 0.000 description 1
- VAAUVQKKXHANPM-DQHXIWAQSA-N chembl470766 Chemical compound CC([C@H]1C[C@H]2O)(C)CC[C@H](O)[C@@]1(C)[C@@H]1C[C@H](OC(=O)C)[C@@H]3[C@@H](O)[C@]21C(=O)C3=C VAAUVQKKXHANPM-DQHXIWAQSA-N 0.000 description 1
- NPHHLSOQKLWOCK-AHIYZFNLSA-N chembl499134 Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(CO)C[C@H]5O[C@@]6(O)[C@H](O)C[C@@H](CO)O[C@H]6O[C@@H]5C[C@@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 NPHHLSOQKLWOCK-AHIYZFNLSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960002328 chloroquine phosphate Drugs 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- DJZCTUVALDDONK-HQMSUKCRSA-N concanamycin A Chemical compound O1C(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)C\C(C)=C\C=C\[C@H](OC)[C@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](\C=C\C)[C@@H](C)[C@H](O[C@@H]2O[C@H](C)[C@@H](OC(N)=O)[C@H](O)C2)C1 DJZCTUVALDDONK-HQMSUKCRSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- RHCBUXSXDFNUAG-UHFFFAOYSA-N coronarin A Natural products CC1(C)CCCC2(C)C1CC(O)C(=C)C2C=CC=1C=COC=1 RHCBUXSXDFNUAG-UHFFFAOYSA-N 0.000 description 1
- VUWOGLPICKGRDI-UHFFFAOYSA-N coronarin B Natural products CC1(C)CCCC2(C)C1CCC(=C)C2C3CC(CC(O)OO3)C=O VUWOGLPICKGRDI-UHFFFAOYSA-N 0.000 description 1
- DYYYQLXAGIXUGM-MIALQEHNSA-N coronarin D Natural products CC1(C)CCC[C@]2(C)[C@@H](CC=C/3C[C@H](O)OC3=O)C(=C)CC[C@@H]12 DYYYQLXAGIXUGM-MIALQEHNSA-N 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- YCRACNDSQDCXLH-UHFFFAOYSA-N cudraisoflavone-A Natural products CC(C)=CCC1=C(O)C=CC(O)=C1C(C(C1=C2O)=O)=COC1=CC1=C2C=CC(C)(C)O1 YCRACNDSQDCXLH-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229960003083 cymarin Drugs 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
- 239000000430 cytokine receptor antagonist Substances 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 108010038764 cytoplasmic linker protein 170 Proteins 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- JRHMMVBOTXEHGJ-UHFFFAOYSA-N daphnoretin Chemical compound C1=CC(=O)OC2=CC(OC3=CC=4C=C(C(=CC=4OC3=O)O)OC)=CC=C21 JRHMMVBOTXEHGJ-UHFFFAOYSA-N 0.000 description 1
- UJRSXAFBORHKBS-UHFFFAOYSA-N daphnoretin Natural products COC1=CC2C=C(Oc3ccc4C=CC(=O)Oc4c3)C(=O)OC2C=C1O UJRSXAFBORHKBS-UHFFFAOYSA-N 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- NMPPLGMVCCNRTJ-UHFFFAOYSA-N echinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)CCN21 NMPPLGMVCCNRTJ-UHFFFAOYSA-N 0.000 description 1
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- NFENNPKUXFGPST-WEMBNSTNSA-N excisanin a Chemical compound C1[C@H](O)[C@H]([C@H]2O)C(=C)C(=O)[C@@]32[C@H](O)C[C@@H]2C(C)(C)CC[C@H](O)[C@@]2(C)[C@@H]31 NFENNPKUXFGPST-WEMBNSTNSA-N 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960000297 fosfestrol Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- NPHHLSOQKLWOCK-UHFFFAOYSA-N ghalakinoside Natural products C1CC(C2C(C3(CO)CC4OC5(O)C(O)CC(CO)OC5OC4CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 NPHHLSOQKLWOCK-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- ZVLOPMNVFLSSAA-XEPQRQSNSA-N helenalin Chemical compound C[C@@H]1C[C@H]2OC(=O)C(=C)[C@H]2[C@H](O)[C@]2(C)C(=O)C=C[C@@H]12 ZVLOPMNVFLSSAA-XEPQRQSNSA-N 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- KNOSIOWNDGUGFJ-UHFFFAOYSA-N hydroxysesamone Natural products C1=CC(O)=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1O KNOSIOWNDGUGFJ-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- SFVVQRJOGUKCEG-XTWPYSKKSA-N indicine Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@](O)([C@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-XTWPYSKKSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229950002133 iniparib Drugs 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108010018844 interferon type III Proteins 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 102000004114 interleukin 20 Human genes 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BIXXDPOEXJMBRN-UHFFFAOYSA-N iso-iridogermanal Natural products CC(CCC=C(C)C)C=CC(O)C(=CCCC1(C)C(CCCO)C(=C(C)/C=O)CCC1(C)O)C BIXXDPOEXJMBRN-UHFFFAOYSA-N 0.000 description 1
- FQVNSJQTSOVRKZ-UHFFFAOYSA-N isocicutoxin Natural products CCCC(O)C=CC=CC=CC#CC#CCCCO FQVNSJQTSOVRKZ-UHFFFAOYSA-N 0.000 description 1
- SFVVQRJOGUKCEG-UHFFFAOYSA-N isoechinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-UHFFFAOYSA-N 0.000 description 1
- BBEFSDNXXNECSY-UHFFFAOYSA-N isojusticidin B Natural products C1=C2OCOC2=CC(C2=C3C(=O)OCC3=CC3=CC=C(C(=C32)OC)OC)=C1 BBEFSDNXXNECSY-UHFFFAOYSA-N 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- PQFYSRLXICNMSR-UHFFFAOYSA-N justicidine B Natural products COc1ccc(cc1OC)c2c3OCC(=O)c3cc4cc5OCOc5cc24 PQFYSRLXICNMSR-UHFFFAOYSA-N 0.000 description 1
- WHSUEVLJUHPROF-BIGDWJEQSA-N kamebakaurin Chemical compound C1C[C@H]([C@H]2O)C(=C)C(=O)[C@@]32[C@H](O)C[C@@H]2C(C)(C)CC[C@H](O)[C@@]2(CO)[C@@H]31 WHSUEVLJUHPROF-BIGDWJEQSA-N 0.000 description 1
- 229930184156 kamebakaurin Natural products 0.000 description 1
- WHSUEVLJUHPROF-UHFFFAOYSA-N kamebakaurin A Natural products C1CC(C2O)C(=C)C(=O)C32C(O)CC2C(C)(C)CCC(O)C2(CO)C31 WHSUEVLJUHPROF-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- CWPGNVFCJOPXFB-UHFFFAOYSA-N lapachol Chemical compound C1=CC=C2C(=O)C(=O)C(CC=C(C)C)=C(O)C2=C1 CWPGNVFCJOPXFB-UHFFFAOYSA-N 0.000 description 1
- SIUGQQMOYSVTAT-UHFFFAOYSA-N lapachol Natural products CC(=CCC1C(O)C(=O)c2ccccc2C1=O)C SIUGQQMOYSVTAT-UHFFFAOYSA-N 0.000 description 1
- 235000006826 lariciresinol Nutrition 0.000 description 1
- QHOZSLCIKHUPSU-PNFBIMPKSA-N lasiocarpine Chemical compound C1C[C@H](OC(=O)C(\C)=C/C)[C@H]2C(COC(=O)[C@](O)([C@H](C)OC)C(C)(C)O)=CCN21 QHOZSLCIKHUPSU-PNFBIMPKSA-N 0.000 description 1
- YHPCSAOULAHGKY-UHFFFAOYSA-N lasiocarpine Natural products CC=C(C)/C(=O)OC1CCN2CC=C(COC(=O)C(O)(C(C)C)C(C)(C)O)C12 YHPCSAOULAHGKY-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- XVUQHFRQHBLHQD-UHFFFAOYSA-N lonazolac Chemical compound OC(=O)CC1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1 XVUQHFRQHBLHQD-UHFFFAOYSA-N 0.000 description 1
- 229960003768 lonazolac Drugs 0.000 description 1
- JMCGQPHJXFUMBU-UHFFFAOYSA-N longikaurin B Natural products C=C1C(=O)C23C(O)C1CCC2C12CCCC(COC(=O)C)(C)C1C(O)C3(O)OC2 JMCGQPHJXFUMBU-UHFFFAOYSA-N 0.000 description 1
- JMCGQPHJXFUMBU-YEJWVSDBSA-N longikaurin b Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12CCC[C@](COC(=O)C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 JMCGQPHJXFUMBU-YEJWVSDBSA-N 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000024169 luteoma of pregnancy Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000009014 mansonin Substances 0.000 description 1
- SCWKUSONPRYOHV-UHFFFAOYSA-N marchantin A Natural products Oc1cccc2CCc3ccc(Oc4cc(CCc5ccccc5Oc12)cc(O)c4O)cc3 SCWKUSONPRYOHV-UHFFFAOYSA-N 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- ZMSNKXDPESNSSS-UHFFFAOYSA-N maytenfoliol Natural products CC12CCC3(C)C4CC(C)(CO)CCC4(CO)CCC3(C)C2CCC2(C)C1CCC(=O)C2C ZMSNKXDPESNSSS-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- CPTIBDHUFVHUJK-NZYDNVMFSA-N mitopodozide Chemical compound C1([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(=O)NNCC)=CC(OC)=C(OC)C(OC)=C1 CPTIBDHUFVHUJK-NZYDNVMFSA-N 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960000739 myrtecaine Drugs 0.000 description 1
- BZRYYBWNOUALTQ-HOTGVXAUSA-N myrtecaine Chemical compound CCN(CC)CCOCCC1=CC[C@@H]2C(C)(C)[C@H]1C2 BZRYYBWNOUALTQ-HOTGVXAUSA-N 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 230000009635 nitrosylation Effects 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 229960004036 nonivamide Drugs 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- QGGGTLQHMHIOKZ-UHFFFAOYSA-N orthopappolide methacrylate Natural products C1C2(C)OC2C2OC(=O)C(=C)C2C(OC(=O)C(C)=C)CC2=CC1OC2OC QGGGTLQHMHIOKZ-UHFFFAOYSA-N 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960005113 oxaceprol Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229960002226 polidocanol Drugs 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000575 polymersome Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960000214 pralatrexate Drugs 0.000 description 1
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229960005567 rebeccamycin Drugs 0.000 description 1
- INSACQSBHKIWNS-QZQSLCQPSA-N rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- VKNAGQVZXQTVMW-UHFFFAOYSA-N retrochinensinaphthol methyl ether Natural products C1=C(OC)C(OC)=CC=C1C(C1=C2)=C(OCC3=O)C3=C(OC)C1=CC1=C2OCO1 VKNAGQVZXQTVMW-UHFFFAOYSA-N 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- LFBIHCZSRPAPHS-UHFFFAOYSA-N rutamontine Natural products COc1cc2OC(=O)C(=Cc2cc1O)Oc3ccc4C=CC(=O)Oc4c3 LFBIHCZSRPAPHS-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- RLISWLLILOTWGG-UHFFFAOYSA-N salamidacetic acid Chemical compound NC(=O)C1=CC=CC=C1OCC(O)=O RLISWLLILOTWGG-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- JSTADIGKFYFAIY-GJNDDOAHSA-F samarium-153(3+);n,n,n',n'-tetrakis(phosphonatomethyl)ethane-1,2-diamine Chemical compound [153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-F 0.000 description 1
- 229940084560 sanguinarine Drugs 0.000 description 1
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- JWBVQJZXSQDXKU-UHFFFAOYSA-N sculponeatin C Natural products C1OC(=O)C2(C(C3=C)=O)CC3CC(O)C2C1(C12)C3OC2OCC1(C)CC3 JWBVQJZXSQDXKU-UHFFFAOYSA-N 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- RWMIDFKXUZOZMK-UHFFFAOYSA-N strebloside Natural products COC1C(O)C(C)OC(OC2CCC3(C=O)C(CCC4C3CCC5(C)C(CCC45O)C6=CC(=O)OC6)C2)C1OC RWMIDFKXUZOZMK-UHFFFAOYSA-N 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- ODJLBQGVINUMMR-HZXDTFASSA-N strophanthidin Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC4)C=O)CC[C@@]32C)=CC(=O)OC1 ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical compound BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- VUMZOPMHFVDIMF-UHFFFAOYSA-N usambarensine Natural products C12=CC=CC=C2NC2=C1C=CN=C2CC1CC2C(NC=3C4=CC=CC=3)=C4CCN2CC1=CC VUMZOPMHFVDIMF-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229950007952 vapiprost Drugs 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 108010060757 vasostatin Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- QTXVAVXCBMYBJW-UHFFFAOYSA-N warfarin Chemical compound OC=1OC2=CC=CC=C2C(=O)C=1C(CC(=O)C)C1=CC=CC=C1 QTXVAVXCBMYBJW-UHFFFAOYSA-N 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- KYBLAIAGFNCVHL-PMVHANJISA-N zeorin Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1[C@@H](O)C[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1C(C)(O)C KYBLAIAGFNCVHL-PMVHANJISA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a molecule binding to soluble tumor necrosis factor receptor (sTNFR) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is immobilized on a solid support that is contacted with a body fluid of said patient.
- the present invention refers to a method for sensitizing a tumor cell and to a body fluid from which sTNFR has been removed for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent.
- the present invention refers to a chemotherapeutic agent for use in a method for treating a tumor in a patient for sensitizing a tumor cell of said tumor in said patient to a treatment with said chemotherapeutic agent.
- cancer is one of the major causes of death throughout the population. Therefore, various therapeutic methods have been developed since decades. However, so far, no therapeutic approach is fully satisfying.
- cancer therapy is mainly based on chemotherapy, targeted small molecules, radiation therapy, surgery, immunotherapy, monoclonal antibody therapy and/or other methods.
- chemotherapeutic cancer therapy is based on the use of comparably high concentrations of agents that have cytotoxic effects predominantly on neoplastic cells.
- the predominant killing of neoplastic cells occurs due to the fact that cancer cells replicate faster than most other cells of the adult human body.
- chemotherapeutic agents required for effective chemotherapeutic treatments, also other cell types replicating relatively fast, such as, e.g., hair follicle cells and mucosa cells, are severely impaired. Therefore, the patient is exposed to undesired side effects.
- Adverse effects related to the chemotherapeutic treatment can lead to the premature discontinuation of the therapeutic treatment. In some instances chemotherapy can even cause the death of the patient.
- a surgical procedure may even require the amputation of a limb, a breast, a testicle, an inner organ, a part of the skin and/or parts of one or more of the aforementioned. Further, a surgical procedure may lead to an artificial anus and/or to a bladder catheter. Likewise, radiation may lead to severe symptoms of intoxication.
- cancer can be treated by immunotherapy (e.g., therapeutic vaccines such as sipuleucel-T, or cytokine-based immunotherapy (e.g. Interleukin-2, Interferon-alpha)), monoclonal antibody therapy (e.g. bevacizumab), targeted small molecules (e.g., imatinib) and/or other methods, such as, e.g., cryoablation or isolated organ perfusion.
- immunotherapy e.g., therapeutic vaccines such as sipuleucel-T, or cytokine-based immunotherapy (e.g. Interleukin-2, Interferon-alpha)
- monoclonal antibody therapy e.g. bevacizumab
- targeted small molecules e.g., imatinib
- cryoablation e.g., cryoablation or isolated organ perfusion.
- cytokines such as, e.g., tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN- ⁇ ), and interleukin-2 (IL-2) have been used clinically, but have led to durable remissions only in small numbers of patients treated and produced no significant clinical responses in overall target populations.
- TNF-alpha tumor necrosis factor alpha
- IFN- ⁇ interferon gamma
- IL-2 interleukin-2
- a still further therapeutic strategy is the removal of molecules based on the molecular weight by means of ultrapheresis (therapeutic apheresis, plasmapheresis) promoting an immune attack on the tumors by the patient's own white blood cells (cf, US 4,708,713).
- ultrapheresis therapeutic apheresis, plasmapheresis
- the removal of components present in the blood having a molecular weight of 120,000 Da (dalton) or less can lead to an induction of an immune response against transformed, infected or diseased tissue (cf, US 6,620,382).
- the unspecific removal of a large fraction of components having a molecular weight of 120,000 Da may lead to significant disadvantages as also molecules that have positive effects on the patient's vitality such as, e.g., TNF- , IL-2, or IFN- ⁇ are removed from the high-molecular weight components containing, e.g., antibodies.
- a patient may also be treated by the selective removal of one or more cytokine receptors, wherein it is intended to provoke and/or stimulate the patient's immune response against the tumor cells.
- the most promising therapy is still the treatment by means of a chemotherapeutic agent or by means of a combination of several chemotherapeutic agents.
- chemotherapeutic agents are so high that considerable undesired side effects inevitably occur the patient severely suffers from.
- many patients become increasingly insensible to the agent and would require increasing amounts thereof to achieve the therapeutic aim up to concentrations that are not tolerable any more.
- the present invention refers to a molecule binding to soluble tumor necrosis factor receptor 2 (sTNFR2) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is used to remove sTNFR2 from a body fluid of said patient.
- sTNFR2 soluble tumor necrosis factor receptor 2
- said molecule is immobilized on a solid support that is contacted with a body fluid of said patient.
- the concentration of sTNFR2 is decreased in blood.
- soluble tumor necrosis factor receptor 2 refers to a polypeptide that has a sequence identity of at least at least 75%, even more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, and most preferably 100% of the sequence of SEQ ID NO: 1.
- sTNFR2 soluble tumor necrosis factor receptor 2
- soluble tumor necrosis factor receptor type II soluble tumor necrosis factor receptor IB
- soluble tumor necrosis factor receptor superfamily member I B soluble tumor necrosis factor receptor superfamily IB
- soluble tumor necrosis factor-binding protein 2 sTNF-alpha receptor
- TNFR1B soluble tumor necrosis factor receptor type II
- soluble tumor necrosis factor receptor IB soluble tumor necrosis factor receptor superfamily member I B
- soluble tumor necrosis factor receptor superfamily IB soluble tumor necrosis factor-binding protein 2
- sTNF-alpha receptor TNFR1B
- sTNFR-II sTNFRSFIB
- sTBP-2 sTBP-II
- sTBP2 sTBPII
- p75 p80
- sTNF-R2 or "CD 120b.
- sTNFR2 polypeptide may bear the property to bind to tumor necrosis factor (TNF).
- TNF may be, e.g., TNF-alpha.
- TNF tumor necrosis factor
- sTNFR2 may be generated by shedding, thus, by proteolytic cleavage of the full-length TNFR2 associated with the membrane. Typically, shedding will be executed by one or more matrix metalloprotease(s).
- sTNFR2 In the blood stream, one of the major functions of sTNFR2 is capturing TNF and, thereby, lowering the TNF concentration locally in the proximity of the cells producing sTNFR2 and systemically in the entire blood stream.
- a molecule structurally and functionally related to sTNFR2 is sTNFRl .
- sTNFRl is released from the cells and is able to lower the TNF concentration locally in the proximity of the cells producing sTNFRl and systemically in the entire blood stream. Therefore, the person skilled in the art will notice, that instead of sTNFR2, also sTNFRl may be used in the context of the present invention.
- the present invention also refers to a molecule binding to soluble tumor necrosis factor receptor 1 (sTNFRl) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is used to remove sTNFRl from a body fluid of said patient.
- sTNFRl soluble tumor necrosis factor receptor 1
- the term “removal” may be understood in the broadest sense as the decrease of the concentration of a soluble cytokine receptor in the body fluid.
- the term “decrease”, “lower” and “deplete” may be understood interchangeably.
- the concentration of the soluble cytokine receptor may be decreased to less than 50%, less than 25%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1 % of the initial concentration.
- the initial concentration may be the concentration found in any fluid, in particular the concentration naturally found in a body fluid.
- the molecule binding to sTNFR2 or to at least one other soluble cytokine receptor may be any molecule binding to the soluble cytokine receptor of interest with a dissociation constant (Kd) of less than 10 mM, less than 1 mM, less than 100 ⁇ , less than 10 ⁇ , less than 1 ⁇ , less than 100 nM, or less than 10 nM.
- Kd dissociation constant
- the molecule is immobilized on a solid support.
- the term "immobilized to a solid support” means that the molecule is bound to any solid material.
- the term “bound” means that the molecule is covalently or quasi-covalently bound.
- a quasi-covalent bond is a non-covalent bond with a binding affinity with a Kd of less than 50 nM, such as, e.g., the dihydrofolate-methotrexate interaction, or the streptavidin-biotin interaction.
- the molecule binding to the soluble cytokine receptor may be immobilized directly or via linker. For instance a bispecific linker can bind to the surface of the solid support with one active group whereas it binds to the molecule binding to the soluble cytokine receptor with another active group.
- a glass surface of a solid support may be activated by silane conditioning as known in the art. Then, the surface of the solid support may further be conjugated with bispecific linker carrying, e.g., a maleimide or a succinimidyl ester (e.g., N- hydroxysuccinimidyl (NHS) esters) on the other end.
- bispecific linker carrying, e.g., a maleimide or a succinimidyl ester (e.g., N- hydroxysuccinimidyl (NHS) esters) on the other end.
- a succinimidyl ester can bind to free amino groups of the molecule binding to the soluble cytokine receptor
- a maleimide preferably binds to free thiol groups of the molecule binding to the soluble cytokine receptor.
- An active ester such as an acid halogenide (e.g., an acid chloride or an acid bromide) may bind to free amino groups or free hydroxy 1 groups of the molecule binding to the soluble cytokine receptor.
- an acid halogenide e.g., an acid chloride or an acid bromide
- the molecule binding to the soluble cytokine receptor is immobilized on the surface of the solid support.
- antibodies binding to the molecule binding to the soluble cytokine receptor can be immobilized on the surface of a solid support.
- a fluid containing the molecule binding to the soluble cytokine receptor is incubated with the antibody-coated surface.
- the term "coated” may be understood in the broadest sense as the conjugation of any molecular structure(s) to the surface of the solid support.
- tumor cell may be understood in the broadest sense as any cell from neoplastic tissue.
- the neoplastic tissue may be benign or malignant and may be of any tissue origin.
- the neoplastic tissue is malignant, semi-malignant or is at risk of being malignant (pre-malignant).
- the neoplasia may be a palpable and tactile lump, may or may not be detectible by molecular imaging, or may be a microscopic lesion of a single cell or few cells such as, e.g., a metastasis.
- the tumor cell may be a cell of a primary tumor or a secondary tumor.
- the tumor cell may origin from any tissue that can develop a tumor, such as, e.g., sarcoma (e.g., myxosarcoma, histiocytoma, liposarcoma, chondrosarcoma, osteosarcoma, angiosarcoma, leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma, synovialcarcinoma, Ewing sarcoma, hemangiosarcoma, lymphangiosarcoma, adenosarcoma, carciosarcoma), bronchiocarcinoma, prostate carcinoma, cervix carcinoma, ovarian carcinoma, mamma carcinoma, bronchial carcinoma, melanoma, esophagus carcinoma, rectal carcinoma,
- sarcoma e.g., myxosarcoma, histiocytoma, liposarcoma, chondrosarcoma, osteosarcom
- the tumor cell may be located in any organ, such as, e.g., brain, eye, skin, lung, liver, oral cavity, pharynx, stomach, small intestine, duodenum, colon, urinary bladder, kidney, gall bladder, pancreas, vaginal tract, testicles, breast, a muscle, blood, lymph, a lymph node, esophagus, heart, a bone, bone marrow, spleen, a blood vessel, a lymphatic vessel, cervix, uterus, spinal cord, or an ovary or may be located in connective tissue, mucosa tissue, or nerve tissue.
- organ such as, e.g., brain, eye, skin, lung, liver, oral cavity, pharynx, stomach, small intestine, duodenum, colon, urinary bladder, kidney, gall bladder, pancreas, vaginal tract, testicles, breast, a muscle, blood, lymph, a lymph node, esophagus, heart,
- the tumor cell may also be a single cell or an aggregate of or few cells floating through the patient's body such as, e.g., via the blood stream or the lymphatic system.
- the term "blood stream” as used herein may be understood in the broadest sense as circulating blood.
- the blood stream may be in a vessel of a patient or may be in a tube, a filter, a column or any other device outside of the body.
- the term "sensitizing a tumor cell” means that the tumor cell is rendered more sensitive to a treatment with a chemotherapeutic agent. According to the present invention, this may be mainly achieved by removing at least one soluble cytokine receptor from a body fluid of the patient.
- the therapeutic potency of the chemotherapeutic agent with respect to the tumor cells subjected to the sensitization according to the present invention is increased compared to congeneric tumor cells without said sensitization. That means that the concentration of the chemotherapeutic agent may be decreased whereas the therapeutic effect with respect to the tumor cells of interest is extensively maintained or even increased.
- the required concentration to maintain the therapeutic activity may be decrease by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or even 90% or more of the concentration required without the removal of the soluble cytokine receptor.
- the chemotherapeutic agent as used herein may be any chemotherapeutic agent known in the art, preferably an alkylating agent, more preferably a nitrogen mustard alkylating agent, in particular Melphalan.
- body fluid may be understood in the broadest sense as any fluid obtainable from a patient's body any fluid obtainable from a body after one or more processing step(s).
- the body fluid is blood, blood plasma, blood serum, a blood fraction or lymph. More preferably, the body fluid is blood obtained from a patient.
- the term "blood” may be understood in the broadest sense as blood of a human or an animal.
- the blood is the blood of the patient who receives the blood, plasma or blood fraction of which the soluble cytokine receptor has been removed.
- the patient will retrieve his own blood (autologous blood) that is returned into his blood stream after being treated by means of the molecule and/or the method of the present invention.
- autologous blood typically, the blood is withdrawn from the patient, treated by means of the molecule and/or the method of the present invention and, subsequently, immediately conducted back into the patient's blood stream.
- the patient's autologous blood may also be stored before treatment and/or after treatment and conducting it back into the patient's blood stream.
- the blood may also be blood originating from another individual (heterologous blood) or a mixture of autologous and heterologous blood.
- the term "plasma” may be understood in the broadest sense as blood from which the cells (e.g., red blood cells (RBCs) and leucocytes) as well as the platelets have been removed.
- the plasma is obtained from the blood of the patient who receives the plasma, blood or blood fraction of which the soluble cytokine receptor has been removed.
- blood fraction may be understood in the broadest sense as any fraction of blood from which one or more factors have been removed.
- the RBCs, some types of or all leucocytes, platelets, and/or one or more proteins may be removed.
- blood fraction refers to (blood) serum, thus, plasma of which further one or more coagulation factor(s) has/have been removed.
- serum in serum, at least fibrin and/or fibrinogen has been removed.
- a blood fraction may also be plasma or serum of which further proteins of a certain molecular weight range have been removed.
- proteins of a molecular weight above a certain threshold or below a certain threshold preferably proteins above a certain threshold are removed, more preferably proteins of more than 50,000 Da, more than 100,000 Da, more than 120,000 Da, more than 150,000 Da or more than 200,000 Da. Even more preferably, proteins of a molecular weight of more than 120,000 Da may be removed from the blood fraction.
- sTNFR2 may also be removed from any other body fluid such as, e.g., lymph (endolymph and/or perilymph), cerebrospinal fluid ⁇ liquor cerebrospinalis).
- the term "patient” may be understood in the broadest sense as any subject or individual bearing a tumor cell treated or to be treatment with a chemotherapeutic agent.
- the patient may be any animal, preferably a mammal, in particular a human.
- the patient is a human suffering from a malignant neoplasia, including cancer, or a benignant neoplasia.
- the term "suffering from” may be understood in the broadest sense as having a certain disease.
- the patient may or may not bear any symptoms of said disease.
- the disease may be any disease, in particular a tumorous disease, cancer.
- the patient may or may not show any further symptoms caused by increased soluble cytokine receptor level such as faster tumor growth, depleted immune response against tumorous or neoplastic tissue.
- the patient is a cancer patient.
- the patient may have or may be free of clinical symptoms occurring from said neoplasia.
- the patient may also be a patient who had a malignant or benignant neoplasia that has already been removed by any means (e.g., by surgical means, radiation and/or chemotherapeutic means) who is subjected to an after- treatment with a chemotherapeutic agent.
- the patient has increased blood levels of one or more cytokine receptor(s).
- the patient is a cancer patient having increased blood levels of one or more cytokine receptor(s).
- a molecule binding to at least one soluble cytokine receptor may be any molecule binding to the soluble cytokine receptor of interest with a dissociation constant (Kd) of less than 10 mM, less than 1 mM, less than 100 ⁇ , less than 10 ⁇ , less than 1 ⁇ , less than 100 nM, or less than 10 nM.
- the molecule may be a small molecule (low-molecular weight compound) having a molecular weight of not more than 5000 Da or may be a high- molecular weight compound having a molecular weight of more than 5000 Da.
- the molecule is a high-molecular weight compound.
- the molecule is a polypeptide.
- polypeptide may be understood in the broadest sense as a linear or branched polymer mainly composed of amino acids.
- a polypeptide may be a protein.
- the polypeptide may further contain posttranslational modifications.
- Posttranslational modifications are well-known in the art and may comprise but may not be limited to lipidation, phosphorylation, sulfatation, glucosylation, truncation, cyclization of several amino acid moieties, cyclization of the polypeptide strand, oxidation, reduction, decarboxylation, acetylation, amidation, deamidation, nitration, nitrosylation, disulfide bond formation, pyroglutamate formation, amino acid addition, cofactor addition (e.g., biotinylation, heme addition) and complexation of metal ions, non-metal ions, peptides or small molecules and addition of iron-sulfide clusters.
- cofactor addition e.g., biotinylation, heme addition
- co-factors such as, e.g., ATP, ADP, NAD+, NADH+H + , NADP + , NADPH+H + , metal ions, cations, anions, lipids may be bound to the polypeptide, irrespective on their biological impact.
- the protein may be elongated by one or more amino acids.
- the molecule is selected from the group consisting of: an antibody, a cofactor, a cytokine, a synthetic polypeptide, human LDL receptor, lipocalin or fibronectin and/or a small molecule. Even more preferably, the molecule is an antibody.
- the antibody may be a polyclonal or a monoclonal antibody.
- the antibody may also be a single domain antibody (sdAB) such as, e.g., a camelid antibody (e.g., a llama antibody).
- sdAB single domain antibody
- the terms "cameloid species antibody” and “camelid antibody” may be understood interchangeably.
- sdABs have a molecular weight of approximately 12-15 kDa.
- sdAB may be obtained from camelids (e.g., dromedaries, camels, llamas, alpacas) and Chondrichthyes (cartilaginous fishes, such as, e.g., sharks, rays and skates).
- camelids e.g., dromedaries, camels, llamas, alpacas
- Chondrichthyes cartilaginous fishes, such as, e.g., sharks, rays and skates.
- An alternative approach to obtain sdAB is to split the dimeric variable domains from common immunoglobulins (e.g., IgG) from a mammal into monomers.
- IgG immunoglobulins
- the at least one soluble cytokine receptor may be any soluble cytokine receptor known in the art.
- further another soluble cytokine receptor of an immunomodulatory cytokine is removed from the body fluid of said patient, preferably said receptor is a receptor of a proinflammatory cytokine, more preferably a receptor of a Thl-type cytokine.
- immunomodulatory cytokine may be understood in the broadest sense as any cytokine that has an influence on the activity of the patient's immune system.
- proinflammatory cytokine may be understood in the broadest sense as any cytokine that has a positive influence on the patient's immune system.
- a receptor of a proinflammatory cytokine may be a receptor of a chemokine (e.g., CCL (e.g., CCL1, CCL2/MCP- 1 , CCL3/MIP-l , CCL4/MIP-lp, CCL5/RANTES, CCL6, CCL7, CCL8, CCL9, CCL11, CCL 12, CCL13, CCL14, CCL 15, CCL 16, CCL 17, CCL18, CCL 19, CCL20, CCL21 , CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28), CXCL (e.g., CXCL1 KC, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8/IL8, CXCL9, CXCLIO, CXCL11, CXCL 12, CXCL 13, CXCL14, CXCL 15, CXCL 16, CXCL 17), CX3CL (
- the soluble cytokine receptor is selected from the group consisting of soluble tumor necrosis factor receptor 1 (sTNFRl), soluble interleukin-2 receptor (sIL2R), soluble interleukin-1 receptor (sILlR),soluble interleukin-6 receptor (sIL6R), soluble interleukin- 12 receptor (sIL12R), soluble interleukin- 18 receptor (sIL18R), soluble interleukin-23 receptor (sIL23R), soluble granulocyte macrophage colony-stimulating factor receptor (sGM-CSFR), soluble transforming growth factor beta receptor (sTGFpR) or soluble interferon gamma receptor (sIFNyR).
- sTNFRl soluble tumor necrosis factor receptor 1
- sTNFRl soluble interleukin-2 receptor
- sILlR soluble interleukin-1 receptor
- sIL6R soluble interleukin-6 receptor
- sIL12R soluble interleukin- 12 receptor
- the soluble cytokine receptor is a soluble tumor necrosis factor receptor or a soluble interleukin receptor, more preferably wherein said soluble cytokine receptor is selected from the group consisting of:
- soluble tumor necrosis factor receptor 1 refers to a polypeptide that has a sequence identity of at least at least 75%, even more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, and most preferably 100% of the sequence of SEQ ID NO:2.
- sTNFRl soluble tumor necrosis factor receptor 1
- soluble tumor necrosis factor receptor type I soluble tumor necrosis factor receptor 1A
- soluble tumor necrosis factor receptor superfamily member 1A soluble tumor necrosis factor receptor superfamily 1A
- soluble tumor necrosis factor-binding protein 1 soluble TNF-alpha receptor
- soluble tumor necrosis factor receptor type I soluble tumor necrosis factor receptor 1A
- soluble tumor necrosis factor receptor superfamily member 1A soluble tumor necrosis factor receptor superfamily 1A
- soluble tumor necrosis factor-binding protein 1 soluble TNF-alpha receptor
- TNFRIA soluble tumor necrosis factor receptor 1
- soluble tumor necrosis factor receptor type I soluble tumor necrosis factor receptor 1A
- soluble tumor necrosis factor receptor superfamily member 1A soluble tumor necrosis factor receptor superfamily 1A
- soluble tumor necrosis factor-binding protein 1 soluble TNF-alpha receptor
- TNFRIA soluble tumor necrosis factor receptor
- sTNFRl may be generated by shedding, thus, by proteolytic cleavage of the full length TNFR1 associated with the membrane. Typically, shedding will be executed by one or more matrix metalloprotease(s).
- soluble interleukin-2 receptor alpha sILR2
- soluble IL-2 receptor alpha sIL-2R
- sIL2aR soluble IL-2 receptor alpha
- sIL2aR soluble IL-2 receptor alpha
- sIL2-R soluble IL2-R alpha
- CD25 alpha CD25 alpha
- the soluble cytokine receptor binding to the molecule of the present invention is sTNFR2. It will, however, be understood that alternatively or additionally other soluble cytokine receptors may be also used in the context of the present invention. Such methods are e.g. described in WO 05/107802.
- the molecule binding to the soluble cytokine receptor may be any molecule binding to the soluble cytokine receptor of interest with a dissociation constant (Kd) of less than 10 mM, less than 1 mM, less than 100 ⁇ , less than 10 ⁇ , less than 1 ⁇ , less than 100 nM, or less than 10 nM.
- Kd dissociation constant
- the molecule is preferably a polypeptide.
- a small molecule may be used as the molecule of the present invention.
- the molecule binding the soluble cytokine receptor may bind to the soluble cytokine receptor with a Kd of less than 1 nM, more preferably less than 100 ⁇ , even more preferably less than 10 ⁇ , even more preferably less than 1 ⁇ , in particular less than 100 nM.
- the molecule binding to the soluble cytokine receptor may be understood as any binding partner of the soluble cytokine receptor or any soluble cytokine receptor - binding molecule.
- said molecule binding to the soluble cytokine receptor may have a higher binding affinity to the soluble cytokine receptor than to other proteins present in blood or plasma such as, e.g., albumins (e.g., serum albumin), globulins (e.g., immunoglobulins), other cytokines, interleukins, chemokines, fibrinogens, antitrypsins and/or complement factors.
- albumins e.g., serum albumin
- globulins e.g., immunoglobulins
- other cytokines e.g., interleukins, chemokines, fibrinogens, antitrypsins and/or complement factors.
- said molecule binding to the soluble cytokine receptor may bear a significantly higher affinity to the soluble cytokine receptor than to other soluble cytokine receptors.
- said molecule binding to the soluble cytokine receptor may bear more than 5fold, preferably more than l Ofold, more preferably more than 50fold, even more preferably more than l OOfold higher binding affinity to the soluble cytokine receptor than to any other soluble cytokine receptor.
- the molecules binding to the soluble cytokine receptor may be of natural or of synthetical origin.
- the molecules binding to the soluble cytokine receptor may be conjugated or bound to other molecules that may refer to but may not be limited to one or more protein tag(s) (e.g., dihydrofo late, polyhistidine tag(s) ((poly)His tag(s)), streptavidin), one or more binding moiety/moieties comprising, e.g., biotin, methotrexate, glycocorticoid(s), one or more active ester(s) (e.g., N-hydroxysuccinimidyl (NHS) ester(s)), one or more isothiocyanate(s), one or more maleimide(s), one or more glutaraldehyde derivative(s), one or more carbodiimide derivative(s) or combinations thereof, one or more insoluble and/or soluble polymer(s) (e.g., polyethylene glycol (PEG), hydroxypropyl methacrylate (HPMA), polyethylene imine (PEI)), one or more
- the molecule is selected from the group consisting of:
- an antibody preferably a monoclonal antibody, a single domain antibody, an antibody fragment or an antibody mimetic
- cytokine in particular tumor necrosis factor alpha (TNFSF2) or TNFSF2 mutein;
- a synthetic polypeptide in particular Staphylococcus aureus Protein A, human LDL receptor, lipocalin or fibronectin; and/or
- a small molecule in particular an ensemblin, a macrocyclic scaffold, an Aptamers and/or a peptide staple; more preferably wherein said molecule is an antibody, in particular wherein said molecule is a monoclonal antibody or a single domain antibody.
- an antibody according to the present invention may also be a polyclonal antibody, such as a polyclonal antibody binding to the soluble and the membrane associated forms of the TNFR2 concomitantly.
- An antibody may be a monoclonal or a polyclonal antibody of any species or origin. It may bind to any epitope(s) comprised in the soluble cytokine receptor polypeptide of interest (e.g., linear epitope(s), structural epitope(s), primary epitope(s), secondary epitope(s)), including its posttranslational modifications.
- the epitope may be accessible by the antibody in the natural configuration of the soluble cytokine receptor of interest or may be a hidden epitope.
- the epitope is accessible in the natural configuration of the soluble cytokine receptor of interest.
- the antibodies may be of natural origin, of gene technologic origin and/or of synthetical origin.
- the antibody may also be a CovX antibody.
- the antibody may also be a camelid antibody.
- antibody fragments may be understood in the broadest sense as any fragment of an antibody that still bears binding affinity to its target.
- the antibody fragment may be a fragment antigen binding (Fab fragment), a truncated antibody comprising one or both complementarity determining region(s) (CDR(s)) or the variable fragment (Fv) of an antibody.
- the antibody fragments may be of natural origin, of gene technologic origin and/or of synthetical origin.
- antibody mimetic may be understood in the broadest sense as organic compounds that, like antibodies, can specifically bind antigens and that typically have a molecular mass in a range of from approximately 3 kDa to approximately 25 kDa.
- Antibody mimetics may be, e.g., Affibody molecules (Affibodies), Affilins, Affitins, Anticalins, Avimers, DARPins, Fynomers, Kunitz domain peptides, single-domain antibodies (e.g., VHH antibodies or VNAR antibodies) Monobodies, Diabodies, Triabodies, flexibodies and tandabs.
- the antibody mimetics may be of natural origin, of gene technologic origin and/or of synthetical origin.
- cytokine may be understood in the broadest sense as a molecule binding to the soluble cytokine receptor in the natural environment to facilitate or enhance binding affinity or any other function thereof.
- cytokine may be understood in the broadest as any small protein, peptide, or glycoprotein secreted in the body to signal in intercellular communication, that may bind to the soluble cytokine receptor, such as, e.g., tumor necrosis factor alpha (sTNFSF2).
- sTNFSF2 tumor necrosis factor alpha
- mutein refers to any mutated protein.
- the amino acid sequence of the mutein may comprise alterations or substitutions in the primary amino acid residues, may be truncated and/or may be elongated compared to the corresponding wildtype protein.
- the mutein may have more than 50%, preferably more than 60%, more preferably more than 70%, even more preferably more than 80%, even more preferably more than 90%, most preferably more than 95% sequence homology to the corresponding wildtype protein.
- synthetic polypeptide refers to any polypeptide that binds to the soluble cytokine receptor.
- a synthetic polypeptide may be obtained from chemical synthesis or from gene technological processes.
- a synthetic polypeptide may be, e.g., Staphylococcus aureus Protein A, low-density lipoprotein (LDL) receptor, lipocalin or fibronectin.
- LDL low-density lipoprotein
- small molecule refers to any molecule that binds to the soluble cytokine receptor that has a molecular mass of less than 5000 Da, preferably less than 2000 Da, more preferably less than 1500 Da, even more preferably less than 1000 Da, even more preferably less than 800 Da.
- the small molecule may be, e.g., an ensemblin, a macrocyclic scaffold (e.g., an ensemblin), an Aptamer and/or a peptide staple. Further, the small molecule may also be any other small molecule. It may be obtained from a natural source and be identified in a screening process.
- the small molecule may also be conjugated to a polymeric scaffold, such as, e.g., hydroxypropyl methacrylamide (HPMA), polyethylene imine (PEI), carboxymethyl cellulose (CMC), polyethylene glycol (PEG), collagen fiber, a silk fiber, an agarose fiber, or a micro- or nanobead.
- a polymeric scaffold such as, e.g., hydroxypropyl methacrylamide (HPMA), polyethylene imine (PEI), carboxymethyl cellulose (CMC), polyethylene glycol (PEG), collagen fiber, a silk fiber, an agarose fiber, or a micro- or nanobead.
- the molecule binding to at least one cytokine receptor is an antibody, in particular a monoclonal antibody.
- the molecule is a monoclonal antibody binding to at least one Thl -type cytokine, preferably sTNFRl , sTNFR2 and/or sIL2Rin, in particular binding to sTNFR2.
- the solid support further has one or more molecules binding to other plasma protein(s) immobilized on a solid support, preferably wherein said molecules are molecules binding to cytokines, chemokines, soluble cytokine receptors, soluble chemokine receptors, other soluble decoy receptors, angiogenic factors, growth factors, and bone morphogenic factors more preferably molecules binding to soluble interleukin receptors (sILRs), in particular molecules binding to soluble interleukin-2 receptor alpha (sIL2R).
- sILRs soluble interleukin receptors
- sIL2R soluble interleukin-2 receptor alpha
- other plasma protein may be understood in the broadest sense as any protein found in blood plasma that may modulate an immune response and/or may control cell growth, angiogenesis and/or apoptosis, except for sTNFRl .
- said plasma protein may be a cytokine.
- a cytokine may be an interleukin (IL) (e.g., IL-la, IL- ⁇ ⁇ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9 IL-10, IL-1 1 , IL-12, IL- 13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, 1L-21 , IL-22, IL-23, IL-24, IL-25, IL- 26, macrophage- inhibitory factor- 1), a lymphokine (e.g., granulocyte-macrophage colony- stimulating factor (GM-CSF), an interferon (e.g., IFN-a, IFN- ⁇ , IFN- ⁇ ), a chemokine (e.g., a CCL, a CXCL, an XCL, growth-related oncogene-alpha, CX3CL or a mon
- an "other plasma protein” may also be a soluble cytokine receptor (e.g., sIL2R, or the soluble interferon-gamma receptor), a colony stimulating factor (e.g., M-CSF, G-CSF), an angiogenic factor, a growth factor (e.g., TGF-beta 1 , TGF-beta 3, HGF, VEGF, basic FGF, IGF-1, IGF-2, PDGFR, EGF, CTGF), a bone morphogenic factor (e.g., osteoprotegerin, osteopontin, macrophage inhibitory cytokine- 1 other soluble decoy receptors (e.g., soluble VCAM-1 , soluble E-selectin, soluble P- selectin, soluble E-cadherin, soluble ILT-3, soluble MICA, soluble MICB, sULBP2, sICAM-1 , soluble Fas) or one or more mutein(s) of the
- the molecule binding to at least one cytokine receptor is immobilized on a solid support.
- This solid support may be any solid material known in the art, the molecule can be immobilized on in a way the molecule extensively maintains its binding activity to the soluble cytokine receptor.
- the solid support forms part of an extracorporeal device through which the patient's body fluid can be circulated prior to being returned into said patient or forms part of an implant, in particular wherein said solid support is an extracorporeal device comprising at least one of the following:
- a filter in particular a capillary membrane filter with a pore size of between about 0.04 and 0.05 ⁇ or a parallel plate filter with a pore size of between about 0.04 and 0.08 ⁇ ;
- semi-permeable material preferably a membrane, in particular a dialysis membrane;
- a bead in particular a microbead or a nanobead
- extracorporeal device may be understood in the broadest sense as any device that is used ex vivo, thus, outside of the living body of the patient.
- the extracorporeal device may be a column, optionally coated with a molecule binding to the soluble cytokine receptor and/or filled with a column matrix coated with a molecule binding to the soluble cytokine receptor, a filter system coated with a molecule binding to the soluble cytokine receptor, a membrane, in particular a dialysis membrane, coated with a molecule binding to the soluble cytokine receptor, a tubing coated with a molecule binding to the soluble cytokine receptor, or any other device coated having a molecule binding to the soluble cytokine receptor immobilized on a solid support.
- the extracorporeal device may get in contact with the body fluid containing the soluble cytokine receptor directly.
- the body fluid containing the soluble cytokine receptor may first be subjected to a previous purification step and may subsequently get in contact with the body fluid containing the soluble cytokine receptor.
- the suspended or emulsified cells of a body fluid such as, e.g., blood cells, may first be removed from the body fluid. Then, blood plasma is generated. The blood plasma may get in contact with the extracorporeal device that enables the removal of the soluble cytokine receptor. Subsequently, the cells may optionally be remixed with the plasma or returned into the patient separately.
- the separation of cells and body fluid may be used to protect the column(s), the filter or membrane device from being clogged.
- a size exclusion filter may be suited upstream the extracorporeal device that enables the removal of the soluble cytokine receptor. This filter may be used to protect a column, filter or membrane device from being clogged.
- the term "get in contact” may be understood in the broadest sense as exposing the molecules binding to the soluble cytokine receptor to the body fluid, enabling the soluble cytokine receptor to bind to the molecules binding to the soluble cytokine receptor.
- one or more type(s) of molecule(s) or one or more type(s) of cell(s) may be removed by other means such as, e.g., affinity chromatography, anion exchange chromatography, cation exchange chromatography, hydrophobicity chromatography, or electrophoresis. This process may be conducted upstream and/or downstream to the removal of the soluble cytokine receptor or may be conducted on the same solid support as the removal of the soluble cytokine receptor.
- the extracorporeal device may be used offline, online or a combination thereof.
- the term "offline" may be understood in the broadest sense as a system that is used batch-wise. Therefore, a certain volume of the body fluid extracted from a patient, is exposed to the device of the present invention and the soluble cytokine receptor is removed. Subsequently, the body fluid, from which the soluble cytokine receptor has been removed, is further analyzed and/or is optionally returned to the patient from whom the fluid has been obtained or to one or more other patient(s), in particular other patient(s) of the same patient as the graft patient the body fluid is obtained from.
- the term "online” may be understood in the broadest sense as a system that is used in a continuous flow and/or is connected with the patient's blood or lymphatic vessel(s). Highly preferably, the body fluid extracted from a patient, is directly obtained from said patient, conducted through the extracorporeal device and, thereby, exposed to the molecules binding to the soluble cytokine receptor and is finally led back to said patient. This process may preferably be controlled manually and/or computer-assisted.
- the body fluid may be brought to or kept at any temperature sufficient for treating a body fluid, preferably the body fluid may be cooled to a temperature in the range of between 2°C and 5°C, between 5°C and 10°C, between 10°C and 15°C, between 15°C and 25°C, between 25°C and 37°C, or may be kept at body temperature, preferably at approximately 37°C. More preferably, the body fluid is cooled to a temperature in the range of between 2°C and 5°C or kept at body temperature, preferably at approximately 37°C, in particular kept at approximately 37°C. When returned into the patient, the body fluid may preferably bear body temperature, thus a temperature of approximately 37°C.
- the extracorporeal device may also serve as a combination of an offline and an online method. Then, e.g., the body fluid may be extracted from a patient in a pulsed mode, the soluble cytokine receptor may be removed in the extracorporeal device in a pulsed mode and/or the body fluid may be led back to the patient in a pulsed mode.
- pulsed mode means that there is no continuous flow, but the sample is rather treated batch-wise every few seconds or every few minutes, whereas the process comprising extracting the body fluid and removing the soluble cytokine receptor is conducted automatically.
- the extracorporeal device has been sterilized and/or endotoxin has been removed from the device.
- Sterilization may lead to a decreased concentration of pathogens and/or microorganisms such as, e.g., bacteria, viruses, fungals, moulds, bacterial spores, fungal spores, mould spores, worms, worm eggs, or eukaryotic protocoa.
- Sterilization may be accomplished by any means known in the art such as, e.g., employment of radiation (e.g., UV radiation, gamma radiation) or one or more antimicrobic agent(s) known in the art.
- An endotoxin may be any endotoxin known in the art, such as e.g., lipopolysaccharide (LPS) or delta endotoxin.
- LPS lipopolysaccharide
- delta endotoxin e.g., delta endotoxin.
- an endotoxin originates from the cell wall of a gram- negative bacterium.
- the term “column” refers to any hollow chromatography device that is itself coated with a molecule binding to the soluble cytokine receptor and/or filled with a column matrix bearing a molecule binding to the soluble cytokine receptor.
- the term “column matrix” refers to any chromatographic material and may preferably be a bead material. The beads may be spherical or may bear any other shape known in the art to conduct chromatographic material.
- the beads may be of any material known in the art to be useful for preparing chromatographic material such as, e.g., silica, sugar-based bead material (e.g., agarose, sepharose), plastic bead material (e.g., polystyrene).
- the beads may bear a neutral, a positive or a negative zeta potential.
- the column may be a flow-through device or may be used batch-wise.
- the column may be, e.g, an ultrapheresis column, a high performance liquid chromatography (HPLC) column, a fast protein liquid chromatography (FPLC) column, a flash chromatography (flash) column, a Rapid Refluid Liquid Chromatography (RRLC) column, a Rapid Separation Liquid Chromatography (RSLC) column, an Ultra Fast Liquid Chromatography (UFLC) column, an Ultra Performance Liquid Chromatography (UPLC) column or any other chromatography column known by those skilled in the art. Chromatography is widely used in protein purification.
- HPLC high performance liquid chromatography
- FPLC fast protein liquid chromatography
- flash flash chromatography
- RRLC Rapid Refluid Liquid Chromatography
- RSLC Rapid Separation Liquid Chromatography
- ULC Ultra Fast Liquid Chromatography
- UPLC Ultra Performance Liquid Chromatography
- an affinity chromatographic device When the molecule binding to the soluble cytokine receptor is immobilized on the surface of the column device and/or on the column matrix an affinity chromatographic device is obtained. However, this device may concomitantly separate molecules by size exclusion chromatography, hydrophobicity chromatography, etc.
- the chromatographic methods may be combined with one or more filter(s), membrane(s) and/or semi-permeable material(s).
- the term "filter” as used herein may refer to any device bearing pores.
- the pores may have an average pore size of an average pore size in the range of few nanometers or even less for separating high-molecular weight molecules, such as. proteins, of different molecular weights from another or the pores may have an average pore size of few micrometers for separating solid particles such as cells (e.g., red blood cells (RBCs), leucocytes, tumor cells), from another and/or from the liquid compartments of a body fluid (e.g., blood or lymph).
- RBCs red blood cells
- leucocytes e.g., tumor cells
- the filter may have a molecular exclusion size that excludes molecules of less than 1 ,000 Da, less than 10,000 Da, less than 25,000 Da, less than 50,000 Da, less than 75,000 Da, less than 100,000 Da less than 125,000 Da, less than 150,000 Da, less than 175,000 Da, less than 200,000 Da, less than 250,000 Da, or less than 300,000 Da.
- the filter may preferably be a capillary membrane filter with a pore size of between 0.001 and 10 ⁇ , more preferably of between 0.01 and 1 ⁇ , even more preferably of between 0.01 and 0.1 ⁇ , even more preferably of between 0.01 and 0.09 ⁇ , ⁇ , even more preferably of between 0.01 and 0.08 ⁇ , even more preferably of between 0.01 and 0.07, even more preferably of between 0.02 and 0.07 ⁇ , even more preferably of between 0.02 and 0.06, even more preferably of between 0.03 and 0.06 ⁇ , even more preferably of between 0.04 and 0.06 ⁇ , and most preferably of between 0.04 and 0.05 ⁇ .
- the a preferred filter may be a parallel plate filter with a pore size of between 0.001 and 10 ⁇ , more preferably of between 0.01 and 1 ⁇ , even more preferably of between 0.01 and 0.1 ⁇ , even more preferably of between 0.01 and 0.09 ⁇ , even more preferably of between 0.01 and 0.08 ⁇ , even more preferably of between 0.01 and 0.07 ⁇ , even more preferably of between 0.02 and 0.1 ⁇ , even more preferably of between 0.02 and 0.09 ⁇ , even more preferably of between 0.04 and 0.08 ⁇ , even more preferably of between 0.04 and 0.07 ⁇ , and most preferably of between 0.04 and 0.06 ⁇ .
- filters with the same, similar or different pore size(s) may be combined with another.
- the filter may be any kind of filter.
- the filter may be of any material, such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material.
- the filter may be hydrophobic or hydrophilic.
- the surface of the filter may be neutral or positively charged or negatively charged.
- the filter may be a part of a plasmapheresis and/or an ultrapheresis device as known in the art (see, e.g., WO 99/61085 and WO 01/37873).
- the filter may be a dead-end filter.
- the filter may also be a cross- flow filter.
- cross-flow filter As used herein, the terms “cross-flow filter”, “crossflow filter”, “tangential flow filter” may be understood interchangeably. Filtration may be conducted batch-wise of in a continuous flow method. Preferably, the filtration is conducted in a continuous flow method. The filter may be combined with one or more column(s), membrane(s) and/or semi-permeable material(s).
- membrane as used in the context of the solid support may be understood in the broadest sense as any thin, flexible solid material.
- the membrane may contain pores and serve as filter. Then at least part of the fluid flow goes through the membrane. Alternatively, the membrane may also be impermeable. Then, the fluid flow passes by the membrane on which molecules binding to the soluble cytokine receptor are immobilized.
- Several or even numerous membranes may be used in one device and form a functional array of membranes.
- the membrane may be a dialysis membrane. Then the membrane is permeable for some molecules (in particular small molecules) (semi-permeable). Dialysis is based on diffusion and osmosis, respectively, and is well known in the art.
- the membrane may be of any material, such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material.
- the membrane may be hydrophobic or hydrophilic.
- the surface of the membrane may be neutral or positively charged or negatively charged.
- the membrane may be combined with one or more column(s), filter(s) and/or semi-permeable material(s).
- the term "semi-permeable material” may refer to any material that allows the passage of some molecules whereas other molecules can not or nearly not pass.
- the semi- permeability can base, e.g., on size exclusion and/or on the charge of the semi-permeable material.
- the semi-permeable material may be a solid material.
- the semi-permeable material may be a membrane or a thick material and may be of any material, such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material.
- the semi-permeable material may be hydrophobic or hydrophilic.
- the surface of the semi-permeable material may be neutral or positively charged or negatively charged.
- the semi-permeable material may have a smooth or porous surface structure.
- the semi-permeable material may be combined with one or more column(s), filter(s) and/or membrane(s).
- bead may refer to any small spherical particle.
- a bead may be a microbead or a nanobead.
- a microbead typically bears an average diameter in the range of approximately from 1 ⁇ and 1000 ⁇ .
- a nanobead typically bears an average diameter in the range of approximately from 1 nm and 1000 nm.
- the bead may be of any material such as, e.g., of silica, of metal- or alloy-based material, of sugar-based material (e.g., agarose, sepharose), of plastic (e.g., polystyrene) or may be a quantumdot.
- the bead may be hydrophobic or hydrophilic.
- the surface of the bead may have a neutral, a positive or a negative zeta potential.
- the beads may be compact or may be porous.
- a bead may be used in a column or may be used in fluid.
- the beads may be combined with one or more column(s), filter(s), semi-permeable material(s) and/or membrane(s).
- tubing may be understood as any hollow solid material through which a fluid may flow. It may be flexible or inflexible. A tubing may be column filed with a matrix, but may also be not filled with a matrix. Optionally, the tubing may be the tubing of a capillary electrophoresis (CE). The tubing may also be any kind of semi-permeable material.
- the tubing may be of any material, such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material and may be hydrophobic or hydrophilic. The surface of the tubing may be neutral, positively charged or negatively charged.
- a tubing may be combined with one or more column(s), filter(s), semi-permeable material(s) and/or membrane(s).
- the term "surface of a device" may refer to any kind of device.
- the device may be a therapeutic, a medical, or a laboratory device.
- the surface of the device may be of any material, such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material.
- the surface of the device may be hydrophobic or hydrophilic.
- the surface of the device may be neutral or positively charged or negatively charged.
- the term "implant” may be understood in the broadest sense as any device that is located or intended to be located inside the patients body (e.g., a subdermal implant). Typically, the implant thereby will get in contact with one or more body fluids, in particular extracellular matrix and/or blood.
- the implant may be a macroscopic device of few millimeters or even centimeters in size or may be a microscopic device such as a micro- or nanobead.
- the implant may be a therapeutically acceptable plastic material, a coated metal device (e.g., a titanium device) or may be a polysaccharide or polyacid that aggregates upon injection and thereby forms a depot (e.g., poly(lactic-co-glycolic acid) (PLGA)).
- PLGA poly(lactic-co-glycolic acid)
- the implant may or may not have a connection to the outside allowing to change the solid support the molecule binding to the at least one soluble cytokine receptors is immobilized on.
- the solid support forms part of an extracorporeal device further comprising at least one of the following:
- the term "primary filter” may be understood as a filter that is connected upstream to the solid support on which the soluble cytokine receptor-binding molecules are immobilized.
- the primary filter may protect said solid support from cells.
- the term “ultrafiltrate” may be understood in the broadest sense as a solution, emulsion or suspension from which parts of the high- molecular weight components have been removed.
- the ultrafiltrate is a solution from which at least the blood cells (e.g., red blood cells (RBCs) and lymphocytes) have been removed.
- the cellular fragments such as e.g., platelets have been removed.
- the person skilled in the art will recognize plasma.
- further one or more coagulation factors may be removed.
- serum the person skilled in the art will recognize serum.
- protein fraction(s) above a given size exclusion level may be removed.
- the size exclusion level may be more than 1 ,000 Da, more than 10,000 Da, more than 25,000 Da, more than 50,000 Da, more than 75,000 Da, more than 100,000 Da more than 125,000 Da, more than 150,000 Da, more than 175,000 Da, more than 200,000 Da, more than 250,000 Da, or more than 300,000 Da.
- molecules of a molecular weight of more than 120,000 Da may be removed from the ultrafiltrate.
- the ultrafiltrate may be generated by any means known in the art. Exemplarily, it may be generated by means of a filter or by centrifugation. Centrifugation may be any centrifugation of liquids known in the art. Centrifugation may be conducted batch-wise of in a continuous flow method. Preferably, the centrifugation is conducted in a continuous flow method. Filtration and centrifugation may be combined with another, in particular in a continuous flow method, or may be combined with any other method known in the art. Optionally, centrifugation may be gradient centrifugation (e.g., sucrose gradient centrifugation, equilibrium centrifugation).
- gradient centrifugation e.g., sucrose gradient centrifugation, equilibrium centrifugation.
- the cells and/or protein faction(s) may optionally be reunited with the ultrafiltrate from which the soluble cytokine receptor has been removed.
- the cells and/or protein faction(s) may optionally be reunited with the ultrafiltrate from which the soluble cytokine receptor has been removed.
- at least most of the cells are added to the purified ultrafiltrate prior to being re- injected into the patient.
- administering radiation to patent's tissue may comprise, but may not be limited to expose the patient, a patient's limb, a patient's organ, or a patient's tissue to any kind of radiation used for therapeutic purposes, such as, e.g., x-ray radiation, ultraviolet (UV) radiation (e.g., UV-A, UV-B, and/or UV-C radiation), alpha radiation, beta radiation, gamma radiation, or cosmic radiation.
- UV radiation ultraviolet
- Radiation therapy may also include, but may not be limited to Intensity-Modulated Radiation Therapy (IMRT), 3-Dimensional Conformal Radiotherapy (3DCRT), Stereotactic body radiation therapy (SBRT), Stereotactic radiosurgery (SRS), image-guided radiation therapy (IGRT), Particle Therapy (e.g, proton therapy), Brachytherapy, Radioisotope Therapy (RIT) (e.g., with iodine- 131 , lutetium-177, strontium-89 and samarium ( 153 Sm) lexidronam and/or yttrium-90).
- IMRT Intensity-Modulated Radiation Therapy
- 3DCRT Stereotactic body radiation therapy
- SBRT Stereotactic radiosurgery
- IGRT image-guided radiation therapy
- Particle Therapy e.g, proton therapy
- Brachytherapy e.g., Radioisotope Therapy (RIT) (e.g., with iodine
- the present invention refers to the sensitization of a tumor cell to a treatment with a chemotherapeutic agent.
- the chemotherapeutic agent may be any chemotherapeutic agent known in the art or a combination of two or more of the chemotherapeutics drugs in the arts.
- the chemotherapeutic agent may be selected from the group consisting of alkylating agents (e.g., melphalan, mechlorethamine, cyclophosphamide, chlorambucil, Ifosfamide), anti-metabolites (e.g., 5-fluorouracil, azathioprine, 6-mercaptopurine, mercaptopurine, pyrimidines, thioguanine, fludarabine, floxuridine, cytosine arabinoside (cytarabine), pemetrexed, raltitrexed, pralatrexate, methotrexate), plant alkaloids and terpenoids (e.g., vinca alkaloids (vincristine, vinblastine, vinorelbine, vindesine), taxanes (e.g., paclitaxel), Cytoxan), topoisomerase inhibitors (e.g., camptothecins: irinotecan, topot
- the person skilled in the art will know how to administer the particular chemotherapeutic agent to the patient.
- it may be injected (e.g., subcutaneously (is.), intraperitoneal ly (i.p.) or intravenously ( .v.), intramusculary (i.m.), intraarterially (i.a.)), may be administered orally (e.g., via a pill, a capsule, a sirup, a juice), nasally (e.g., via a spray) or subdermally (e.g., via an ointment or a plaster).
- chemotherapeutic agent may also comprise one or more pharmaceutically acceptable carriers.
- a pharmaceutically acceptable carrier according the present invention may be any additive that is pharmaceutically acceptable, therefore, any additive that is non-toxic to the patient.
- a pharmaceutically acceptable carrier may comprise a solvent such as, e.g., water, dimethyl sulfoxide (DMSO), ethanol, vegetable oil, paraffin oil or combinations thereof.
- a carrier may contain one or more detergents, one or more foaming agents (e.g., sodium lauryl sulfate (SLS)/ sodium doceyl sulfate (SDS)), one or more coloring agents (e.g., Ti0 2 , food coloring), one or more vitamins, one or more salts (e.g., sodium, potassium, calcium, zinc salts), one or more humectants (e.g., sorbitol, glycerol, mannitol, propylene glycol, polydextrose), one or more enzymes, one or more preserving agents (e.g., benzoic acid, methylparabene), one or more texturing agents (e.g., carboxymethyl cellulose (CMC), polyethylene glycol (PEG), sorbitol), one or more emulsifiers , one or more bulking agents, one or more glacing agents, one or more separating agents, one or more antioxidants, one or more herbal and plant extracts, one or more
- the molecule binding to at least one soluble cytokine receptor according to the present invention may be contacted with the body fluid of the patient at any time before, during or after the chemotherapeutic agent is administered to the patient for the treatment or prevention of a neoplasia, preferably cancer.
- the molecule is contacted with the body fluid of the patient prior to, concomitantly with and/or subsequent to administering the chemotherapeutic agent to said patient.
- the molecule When the molecule is contacted with the body fluid of the patient prior to administering the chemotherapeutic agent to said patient, it may be a pre-treatment for making the tumor cells in the patient more sensitive to the subsequently administered chemotherapeutic agent.
- the molecule is contacted with the body fluid of the patient not more than a month, more preferably not more than two weeks, even more preferably not more than one week, even more preferably not more than five days, even more preferably not more than four days, even more preferably not more than three days and most preferably not more than two days before the administration of the chemotherapeutic agent to said patient.
- the body fluid of the patient may also be contacted with the molecule according to the present invention few hours or even few minutes before the chemotherapeutic agent is administered to said patient.
- the body fluid of the patient When the molecule is contacted with the body fluid of the patient concomitantly with administering the chemotherapeutic agent to said patient, the body fluid of the patient may be contacted with the body fluid of the patient while the chemotherapeutic agent is administered.
- the molecule When the molecule is contacted with the body fluid of the patient subsequent to administering the chemotherapeutic agent to said patient, it may be an after-treatment for making or maintaining the tumor cells in the patient more sensitive to the previously administered chemotherapeutic agent.
- the molecule is contacted with the body fluid of the patient not more than a month, more preferably not more than two weeks, even more preferably not more than one week, even more preferably not more than five days, even more preferably not more than four days, even more preferably not more than three days and most preferably not more than two days after the administration of the chemotherapeutic agent to said patient is terminated.
- the body fluid of the patient may also be contacted with the molecule according to the present invention few hours or even few minutes after the chemotherapeutic agent is administered to said patient.
- the contacting of the molecule binding to at least one soluble cytokine receptor may lower the concentration of said soluble cytokine receptor in the body fluid of the patient before, during and/or after the administration of the chemotherapeutic agent to the patient.
- the concentration of the soluble cytokine receptor is lowered in the body fluid of the patient when the chemotherapeutic agent is administered to said patient.
- this may preferably be achieved by a single or a repeated treatment previous to or concomitantly with the administration of the chemotherapeutic agent to the patient.
- the time interval between contacting said molecule with the body fluid of the patient and administering said chemotherapeutic agent is not longer than seven days, preferably not longer than 5 days, in particular not longer than 3 days.
- the contacting of the body fluid of the patient and/or administering of the chemotherapeutic agent may be repeated two, three, four, five or even more often. Then the treatment is a repeated treatment.
- the molecule is contacted with the body fluid of the patient repeatedly, preferably at least three times.
- the concentration of the soluble cytokine receptor of interest is maintained at a lower level compared to the level observable without contacting the body fluid with the molecule according to the present invention for at least twelve h, at least 24 h, at least 48 h or even a week or longer.
- the chemotherapeutic agent is administered to the patient repeatedly, preferably at least three times.
- the concentration of the chemotherapeutic agent is maintained at a therapeutically active level for at least twelve h, at least 24 h, at least 48 h or even a week or longer. This may be achieved by repeated administration and/or by using a retard and/or depot administration method(s) well-known in the art.
- the concentration of the soluble cytokine receptor of interest is maintained at a lower level compared to the level observable without contacting the body fluid with the molecule according to the present invention and, concomitantly, the concentration of the chemotherapeutic agent is maintained at a therapeutically active level for at least twelve h, at least 24 h, at least 48 h or even a week or longer.
- body fluid may be understood in the broadest sense as any fluid obtainable from a body such as, e.g., blood, urine, cerebrospinal fluid, lymph, saliva and/or one or more secret(s) from any gland(s).
- the body fluid is selected from the group consisting of blood, plasma, lymph and extracellular matrix.
- the body fluid is blood, in particular blood in a patient who may bear one or more tumor cell(s) or who is at risk of having or developing one or more tumor cell(s).
- the patient may have or may have no clinical symptoms of a neoplasia, in particular cancer.
- the patient is at least partly resistant to the chemotherapeutic agent and/or is suffering from at least one undesired side effect caused by said chemotherapeutic agent.
- the term "partly resistant” may be understood in the broadest sense as a decrease in sensitivity to the chemotherapeutic agent.
- a partly resistant cell may require a chemotherapeutic agent concentration that is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 2foId, at least 3fold or even higher concentration to show the desired effect, i.e., for most chemotherapeutic agents to become apoptotic.
- An undesired side effect may be, beside others, selected from the group consisting of hair loss, depression of the immune system, infections due to naturally occurring microorganisms in the patient's own gastrointestinal tract (including oral cavity) and skin anemia, cardiotoxicity (heart damage), hepatotoxicity (liver damage), nephrotoxicity (kidney damage), ototoxicity (damage to the inner ear), producing vertigo, encephalopathy (brain dysfunction), immunosuppression and myelosuppression, chemotherapy-induced nausea and vomiting (CINV), secondary neoplasm, infertility, teratogenic effects, neurological adverse effects, tumor lysis syndromered skin (erythema), dry skin, damaged fingernails, a dry mouth (xerostomia), water retention, and sexual impotence.
- CINV chemotherapy-induced nausea and vomiting
- secondary neoplasm infertility, teratogenic effects
- neurological adverse effects tumor lysis syndromered skin (erythema), dry skin, damaged fingernails, a dry
- the terms “undesired side effect”, “adverse effect” and “adverse side effect” may be understood interchangeably.
- the molecule binding to at least one soluble cytokine receptor according to the present invention may be used for the treatment or prevention of any neoplasia.
- the molecule is for use in a method for treating cancer in the patient.
- the treatment of cancer may also include the prevention of a recurrence of cancer in a patient who has been subjected to an anticancer treatment before.
- a further aspect of the present invention refers to a body fluid from which at least one soluble cytokine receptor has been removed for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent.
- body fluid as described above may also include any fluid obtainable from a body after one or more processing step(s) (e.g., centrifugation, filtration, cross filtration, precipitation and/or any other known method for fractioning biological fluids) such as, e.g., blood serum or blood plasma.
- processing step(s) e.g., centrifugation, filtration, cross filtration, precipitation and/or any other known method for fractioning biological fluids
- blood serum and “serum” may be understood interchangeably.
- blood plasma and “plasma” may be understood interchangeably.
- the body fluid is blood, blood plasma, blood serum or lymph.
- the body fluid may be obtained from the same patient who is subsequently treated therewith after at least one soluble cytokine receptor has been removed (autologous graft). Then, the obtained body fluid from which the soluble cytokine receptor has been removed may be re-injected or re-circulated into the patient the sample has been extracted from. Most preferably, the patient will retrieve his own blood (autologous blood) that is returned into his blood stream after being treated by means of the molecule and/or the method of the present invention.
- autologous blood autologous blood
- the body fluid is withdrawn from the patient, treated by means of the molecule and/or the method of the present invention and, subsequently, immediately conducted back into the patient's blood stream.
- the patient's autologous blood may also be stored before treatment and/or after treatment and conducting it back into the patient's blood stream.
- the body fluid may be obtained from an individual and is infused into another patient (xenograft) or a mixture of autologous and heterologous body fluid(s).
- the body fluid may more preferably be used directly obtained from the patient or within few minutes or few days.
- the samples may preferably be stored at room temperature or in the fridge.
- room temperature and “ambient temperature” may be understood interchangeably.
- the samples may also be stored in a frozen, deep-frozen or freeze dried state and may then be stored at any temperature below the freezing point, such as, e.g., at -20°, -80°C or in liquid nitrogen.
- a freeze-dried powder may also be stored at ambient temperature.
- Obtaining the body fluid from a patient is typically of no health risk for the patient and can be also conducted by persons who are no medical experts such as, e.g., even the patient at home.
- the term "obtained from a patient” may be understood in the broadest sense as receiving a body fluid from the body of a patient by any means.
- blood may be collected from a blood vessel
- lymph may be corrected from a lymph vessel
- cerebrospinal liquid may be obtained from the cerebrospinal lumen and/or urine and/or sweat may be collected.
- the body fluid may also be processed further.
- blood plasma or blood serum may be extracted from the blood by any means known in the art.
- the body fluid may be used in any method of the present invention or may be stored at appropriate conditions for up to one hour, up to two hours, up to six hours, up to twelve hours, up to a day or even longer.
- a sample of body fluid stored for more than one day may be designated as a preserved sample.
- prefferved sample may be understood in the broadest sense as any sample that has been stored for more than one day, more than two days, more than a week, more than two weeks, more than a month, more than two months, more than six months or more than a year.
- the body fluid sample may be stored as the pure body fluid or may be stored as a sample further comprising other components of the sample as summarized in detail above. In general, all storage conditions suitable for the body fluid may be used. Exemplarily, the body fluid sample may be stored at room temperature, at 4°C, at -20°C, at -80°C or in liquid nitrogen. Therefore, the body fluid sample may be stored in a liquid or frozen state. Alternatively, the body fluid sample may be stored in a freeze-dried or dried state.
- the preserved sample may exemplarily be an autologous or heterologous blood preservation, a serum or plasma preservation, or a lymph preservation. Preferably, a blood preservation is an autologous blood preservation.
- the body fluid is blood that is obtained from a patient and is re-injected and re-circulated into said patient by any means known in the art.
- the sample may be injected by means of a tubing and/or an acus, a needle, a spicule or the like. These means are well-known in the context of dialyzers and kidney machines and can be used without particular expert skills.
- the present invention refers to the removal of the at least one soluble cytokine receptor from a body fluid
- this removal may have an impact on the whole organism systemically, independent on where the tumor is located. Therefore, the effect is independent on barriers, such as the blood-brain barrier, the blood-testis barrier, the blood-milk barrier or the mother-embryo/fetus barrier. Therefore, the molecule of the present invention may also enable the systemic treatment of target tissue beyond the barrier.
- a patient suffering from a brain disease such as, e.g., e brain tumor (e.g., an astrocytome, or a glioblastome) may be treated by systemic treatment without targeting the brain directly.
- a fetus or embryo may be treated indirectly by treating the pregnant mother systemically.
- a body fluid such as, e.g., blood
- a body fluid such as, e.g., blood
- the extracorporeal device of the present invention may be extracted somewhere from the patient's body (e.g., from the basilica vein), conducted through the extracorporeal device of the present invention and, subsequently, being injected or recirculated somewhere in the patient's body (e.g., recirculated in the same or the other basilica vein), whereas the tissue to be treated (e.g., cancer tissue) may be located somewhere else in the patient's body (e.g., somewhere in the inner organs).
- the treatment may be successful as a body fluid such as blood is circulating through the entire body of the patient.
- a treatment may be successful when the local concentration, but also when the overall concentration of the soluble cytokine receptor in the patient is depleted.
- the therapy may also include the oral intake of an agent or a pharmaceutically acceptable composition thereof, the injection of an agent or a pharmaceutically acceptable composition thereof, the perfusion of an agent or a pharmaceutically acceptable composition thereof.
- the removal of the soluble cytokine receptor may be combined with any surgical procedure known in the art such as, e.g., the section or resection of the tumor, the amputation of a limb, a breast, a testicle, or a certain tissue or parts thereof.
- the removal of the soluble cytokine receptor may be combined with radiation therapy.
- the body fluid is selected from the group consisting of blood, plasma, lymph and extracellular matrix. More preferably, the body fluid is blood. Most preferably, the body fluid is autologous blood, i.e., blood obtained from a patient from which TNFR has been removed re-infused into the same patient. In this context, the soluble cytokine receptor may be removed from the body fluid by any means.
- TNFR may be sTNFR2 or sTNFRl .
- the soluble cytokine receptor has been removed by means of a molecule according to the present invention as defined above.
- the present invention refers to chemotherapeutic agent for use in a method for treating a tumor in a patient, wherein at least one soluble cytokine receptor has been removed from a body fluid of said patient by means of a molecule according the present invention as defined above for sensitizing a tumor cell of said tumor in said patient to a treatment with said chemotherapeutic agent.
- the patient is a cancer patient, preferably wherein said patient is at least partly resistant to the chemotherapeutic agent and/or is suffering from at least one undesired side effect caused by said chemotherapeutic agent.
- the present invention also relates to a method for sensitizing a tumor patient to a treatment with a chemotherapeutic agent, comprising the step of removing soluble TNF receptor 2 (sTNFR2) from the blood of said patient.
- a chemotherapeutic agent comprising the step of removing soluble TNF receptor 2 (sTNFR2) from the blood of said patient.
- the present inventors have found that by removing soluble TNF receptor 2 from the blood, the treated subject is sensitized for the treatment with a chemotherapeutic agent. Consequently, by removing sTNFR2 from the blood from the patient, it is possible to reduce the dose of the chemotherapeutic agent, which reflects an important improvement in tumor treatment.
- the method may be combined with the removal of one or more other plasma protein(s), preferably cytokines, chemokines, soluble cytokine receptors, other soluble decoy receptors, angiogenic factors, growth factors, and bone morphogenic factors more preferably molecules binding to sILRs, in particular molecules binding to sIL2R.
- the method is for treating cancer in the patient, preferably further comprising administering a chemotherapeutic agent.
- the patient may also be treated by a combination therapy comprising administering two or more chemotherapeutic agent(s).
- the molecule according the present invention as defined above is contacted with the body fluid of the patient prior to, concomitantly with and/or subsequent to administering the chemotherapeutic agent to said patient.
- the time interval between contacting said molecule with the body fluid of the patient and administering said chemotherapeutic agent is not longer than seven days, preferably not longer than 5 days, in particular not longer than 3 days.
- the molecule is contacted with the body fluid of the patient repeatedly, preferably at least three times.
- chemotherapeutic drugs can be used in the methods or uses of the invention. These compounds fall into several different categories, including, for example, alkylating agents, antineoplastic antibiotics, antimetabolites, and natural source derivatives.
- alkylating agents examples include busulfan, caroplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide (i.e., Cytoxan), dacarbazine, ifosfamide, lomustine, mecholarethamine, melphalan, procarbazine, streptozocin, and thiotepa.
- antineoplastic antibiotics include bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitomycin (e.g., mitomycin C), mitoxantrone, pentostatin, and plicamycin.
- antimetabolites include fluorodeoxyuridine, cladribine, cytarabine, floxuridine, fludarabine, flurouracil (e.g., 5-fluorouracil (5FU)), gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and thioguanine.
- natural source derivatives include docetaxel, etoposide, irinotecan, taxanes (e.g. paclitaxel), teniposide, topotecan, vinblastine, vincristine, vinorelbine, prednisone, and tamoxifen.
- chemotherapeutic agents that can be used in the invention include asparaginase and mitotane.
- C2 ceramide can be used.
- the chemotherapeutic drug is selected from the group consisting of actinomycin-D, mitomycin C, cisplatin, doxorubicin, etoposide, verapamil, podophyllotoxin, 5-FU, taxans such as paclitaxel, and carboplatin.
- sTNFR2 can be removed by any means known to the person skilled in the art. Preferably, sTNFR2 is removed with the help of a molecule binding to sTNFR2. Such molecules are discussed in detail above. Furthermore, such molecules also include molecules that do not bind specifically to sTNFR2, as e.g. polyclonal antibodies recognizing soluble TNF receptor 2 and soluble TNF receptor 1.
- said molecule is an antibody against sTNFR2, preferably a monoclonal antibody against sTNFR2.
- sTNFR2 preferably a monoclonal antibody against sTNFR2.
- the invention further relates to a molecule binding to sTNR2 for use in a method for sensitizing a tumor patient to a treatment with a chemotherapeutic agent.
- a molecule binding to sTNR2 for use in a method for sensitizing a tumor patient to a treatment with a chemotherapeutic agent.
- the molecule is an antibody against sTNFR2, preferably a monoclonal antibody against sTNFR2.
- the invention further relates to a method for treating a tumor in a patient, comprising administering to a patient a chemotherapeutic drug in an amount sufficient for the treatment of the tumor, wherein from the blood of said patient sTNFR2 has been removed.
- chemotherapeutic agents is a standard procedure known to the person skilled in the art. All embodiments defined above also apply to this aspect of the invention. Examples of chemotherapeutic agents which can be used in the context of the present invention are given above.
- the present invention also relates to a chemotherapeutic agent for use in a method for treating a tumor in a patient, wherein from the blood of said patient sTNFR2 has been removed. All embodiments discussed above also apply to this aspect of the invention.
- Figure 1 shows an exemplary treatment scheme.
- Figure 2 shows the apheresis equipment.
- blood was pumped from the animal (A. carotis) via a plasma separator and retraced to the animal by a venous catheter.
- the separated plasma entered the second circuit (double- lined arrow, — and passed the adsorber before it was returned to the rat ( V. jugular is).
- Figure 3 shows the mean tumor diameter in tumor-bearing Brown Norway rats treated with Sham apheresis (dashed line, open circles) or sTNFR2 apheresis (solid line, filled squares), respectively, and 0.25 mg/kg melphalan.
- Figure 4 shows the change of mean tumor diameter during course of treatment of tumor- bearing Wag/Rij rats treated with Sham apheresis and 0.25 mg/kg low dose melphalan (Sham low, solid line, diamonds) or sT FR2 apheresis (sTNFR2 low, dotted line, squares), respectively Sham apheresis or sTNFR2 apheresis at high melphalan concentrations of 0.50 mg/kg (Sham high, dotted line, triangles, respectively sTNFR2 high, solid line, circles)
- Figure 5 shows the body weight of Wag/Rij rats during the course of treatment with low doses of melphalan (0.25 mg/kg), Sham apheresis (Sham low, solid line, diamonds), sTNFR2 apheresis (sTNFR2 low, dotted line, squares) and with high doses of melphalan (0.50 mg/kg) and Sham apheresis (Sham high, dotted line, triangles), respectively sTNFR2 apheresis (sTNFR2 high, solid line, circles).
- Figure 6 shows the mean tumor diameter measured in tumor-bearing WAG/Rij rats during the course of treatment.
- CO-low and CO-high are control data where animals have been treated with "empty HiTrap columns” (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high).
- Oncosorb-low are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2, sTNFRl and IL-2R and repetitive administration of 0.25 mg/kg Melphalan.
- FIG. 7 shows the body weight of tumor-bearing WAG/Rij rats during the course of treatment.
- CO-low and CO-high are control data where animals have been treated with "empty HiTrap columns” (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high).
- Oncosorb-low are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2, sTNFRl and IL-2R and repetitive administration of 0.25 mg/kg Melphalan.
- Example 1 shows the influence of the removal of sTNFR2 in Wag/Rij rats bearing the immunogenic ROS-1 osteosarcoma on tumor growth and animal weight in the presence of systemically administered melphalan.
- the project aimed to confirm the efficacy of the combination of Melphalan chemotherapy and the removal of sTNFR2 by apheresis in a tumor model using Wag/Rij rats bearing the immunogenic ROS-1 osteosarcoma.
- the experiments also aimed to find the optimal dosage of highly toxic Melphalan, combined with apheresis treatment.
- ROS-1 tumor cells (1.500.000 in 500 ⁇ per animal) were injected under the skin of the left flank region of the WAG rat to induce cancer growth (the method was detailed by Prof, ten Hagen; Rotterdam).
- Rats with palpable tumors were instrumented with a chronic arterial and venous catheter.
- the catheters were inserted under general anaesthesia (i.p. injection of 0.8 mg Rompun ® , Bayer and 4 mg Ketamin ® , Sanofi, Germany) into the Arteria carotis and the Vena jugularis.
- Catheters were flushed with heparinized saline three times per week before the study.
- blood was pumped (multi-channel pump, Petro Gas Ausriistungen, Berlin, Germany) from the animal (A. carotis) via a plasma separator (Saxonia medical and Alpha Plan, Radeberg, Germany) and retraced to the animal by a venous catheter.
- the separated plasma entered the second circuit and passed the adsorber before it was returned to the rat (V. jugularis).
- Bound sTNFR2 was determined by elution of the respective (bound) protein from the column after each apheresis by analysis of the eluate. 2. The following parameters were determined before and after each plasmapheresis: a. ) Hematocrit
- the rats were sacrificed 21 days after first apheresis treatment. 50 % of the tumor (maximally a piece of 2 x 2 cm) was fixed in formalin to determine necrotic tissue and a comparable piece was shock-frozen and stored at -70°C for later histological investigation.
- each column was flushed with at least 6 ml 0.9% saline. After the apheresis treatment, each column was treated in the following way:
- apheresis treatment was combined with intra-venous chemotherapy directly after the apheresis treatment . All animals were repeatedly administered a chemotherapeutic drug (Melphalan: Alkeran ® , GlaxoSmithKline).
- Each animal was treated with up to 6 apheresis cycles in intervals of 2-3 days (2-3 cycles per week). The duration of each plasmapheresis was one hour.
- the adsorbers for the plasmapheresis procedure with a volume of 1 ml were provided by BioPheresis GmbH.
- Table 1 Treatment scheme The first apheresis therapy was initiated directly when the tumor was grown to a mean diameter of 11 ⁇ 3 mm, followed by application of melphalan chemotherapy (day 0). On day 2, the second apheresis was performed and also the second Melphalan injection was administered. Melphalan was administered two times per week, for two weeks (four injections). Apheresis treatments were performed three times per week, for two weeks.
- the animals were monitored without further treatment up to day 21.
- Tumour growth (delta mean tumour diameter)
- the animals met inclusion criteria (mean diameter 1 1 ⁇ 3 mm) 26 to 29 days after tumor cell injection.
- tumour size increased continuously during the twenty-one days of monitoring.
- sTNFR2 / melphalan group a tendency to a reduced tumour growth was shown from day 5 on.
- Sham low and Sham high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high).
- sTNFR2 high and low, respectively are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2.
- sTNFR2 high and low are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2.
- the rats had a body weight of 242 ⁇ 8 g.
- the procedure of catheter insertion was followed by a decline of body weight during the next days and the initial body weight was reached again after 4 to 7 days.
- the start of apheresis treatments and Melphalan applications was followed by a decline in body weight gain surprisingly only in the Sham apheresis control group.
- the interruption of Melphalan treatment from day 2 to 7 followed by a slight reincrease of body weight in the both groups and the treatment with chemotherapeutic on day 7 induced a slight reduction again.
- Sham low and Sham high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high).
- sTNFR2 high and low, respectively are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2.
- the first apheresis started on day 0. Sham low and Sham high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high).
- sTNFR2 high and low, respectively, are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR.2.
- Example 2 shows the influence of the removal of sTNFR2 simultaneous with sTNFR2 and IL-2R (Oncosorb® columns) in Wag/Rij rats bearing the immunogenic ROS-1 osteosarcoma on tumor growth and animal weight in the presence of systemically administered melphalan.
- the project aimed to study if the efficacy of the combination of Oncosorb® Apheresis (the simultaneous removal of sTNFR2, sTNFRl and IL-2R) and Melphalan in a tumor model is comparable to the removal of sTNFR2 alone.
- the experiments also aimed to find the optimal dosage of low toxic Melphalan, combined with Oncosorb® apheresis treatment.
- WAG/Rij rats with a mean body weight of 200 g were purchased from Harlan Laboratories (Niederlander) on 5 th of April 2012. They were housed individually in separated cages under identical conditions as described for example 1. The rats were periodically handled in order to limit animal stress during the study phase.
- AF-425-PB AF-425-PB
- 0.2 mg of affinity purified mouse anti-rat IL-2R ALPHA CHAIN antibodies purchased from AbD SEROTEC Order No. MCA273EL
- sTNFR2 antibodies were from the same batch as used in Example 1 to ensure optimal comparability.
- Tumor tissue handling and transfer was identical as described in Example 1.
- the first apheresis therapy was initiated directly when the tumor was grown to a mean diameter of 1 1 ⁇ 3 mm, followed by application of melphalan chemotherapy (day 0).
- day 0 the second apheresis was performed and also the second Melphalan injection was administered.
- Melphalan was administered two times per week, for two weeks (four injections). Apheresis treatments were performed three times per week, for two weeks. The animals were monitored without further treatment up to day 21.
- Tumour growth (delta mean tumour diameter)
- the animals met inclusion criteria (mean diameter 11 ⁇ 3 mm) 26 to 29 days after tumor cell injection.
- tumour size increased continuously during the twenty-one days of monitoring.
- Oncosorb® apheresis in combination with low doses Melphalan treatment (Oncosorb®-low), was equally strong as that of high dose melphalan treatment and Sham apheresis (CO-high).
- a reduced tumour growth was observed both during treatment from day 2 to 9 (compared with CO-low) as well as after the end of the apheresis treatment and chemotherapeutic medication period from day 12 on. 4.2. Additional Findings
- sTNFR2 high and low are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2.
- the body weight (cf., Figure 7) of the tested animals at the start of treatment was comparable between the investigated groups. Two days after tumor tissue transfer the rats had a weight of 242 ⁇ 8 g. The procedure of catheter insertion followed a decline of body weight for several days. The initial body weight was reached again after 4 to 7 days.
- the body weight of Melphalan/apheresis treated animals was followed by a decline in body weight gain in the both control groups (CO-low and CO-high). The weight loss was more prominent and with a longer duration in the group administered the higher Melphalan dose (CO-high; 0.5 mg/kg).
- the interruption of Melphalan treatment from day 2 to 7 was followed by a slight increase of body weight in the both groups. Repetitive treatment with chemotherapeutic agent on day 7 induced once more a slight body weight reduction.
- CO-low and CO-high are control data where animals ha been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high).
- Oncosorb-low are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2, sTNFRl and IL-2R and repetitive administratio of 0.25 mg/kg Melphalan.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a molecule binding to soluble tumor necrosis factor receptor (sTNFR) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is immobilized on a solid support that is contacted with a body fluid of said patient. Furthermore, the present invention refers to a method for sensitizing a tumor cell and to a body fluid from which sTNFR has been removed for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent. Moreover, the present invention refers to a chemotherapeutic agent for use in a method for treating a tumor in a patient for sensitizing a tumor cell of said tumor in said patient to a treatment with said chemotherapeutic agent.
Description
Sensitization of Cancer Cells by the Removal of Soluble Tumor Necrosis Factor Receptors
The present invention relates to a molecule binding to soluble tumor necrosis factor receptor (sTNFR) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is immobilized on a solid support that is contacted with a body fluid of said patient. Furthermore, the present invention refers to a method for sensitizing a tumor cell and to a body fluid from which sTNFR has been removed for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent. Moreover, the present invention refers to a chemotherapeutic agent for use in a method for treating a tumor in a patient for sensitizing a tumor cell of said tumor in said patient to a treatment with said chemotherapeutic agent.
In the developed countries, cancer is one of the major causes of death throughout the population. Therefore, various therapeutic methods have been developed since decades. However, so far, no therapeutic approach is fully satisfying. Today, cancer therapy is mainly based on chemotherapy, targeted small molecules, radiation therapy, surgery, immunotherapy, monoclonal antibody therapy and/or other methods.
Conventional chemotherapeutic cancer therapy is based on the use of comparably high concentrations of agents that have cytotoxic effects predominantly on neoplastic cells. The predominant killing of neoplastic cells occurs due to the fact that cancer cells replicate faster than most other cells of the adult human body. However, it is widely known that due to the high concentrations of chemotherapeutic agents required for effective chemotherapeutic treatments, also other cell types replicating relatively fast, such as, e.g., hair follicle cells and mucosa cells, are severely impaired. Therefore, the patient is exposed to undesired side effects. Adverse effects related to the chemotherapeutic treatment can lead to the premature discontinuation of the therapeutic treatment. In some instances chemotherapy can even cause the death of the patient.
Alternatively or additionally, surgery and radiation are used to reduce tumor bulk. Success rates for these therapeutic approaches are limited due to the inoperability of several organs or sites of the human body, insensitivity of organs to radiation, or acquired radioresistance of primary or metastatic tumor lesions. A surgical procedure may even require the
amputation of a limb, a breast, a testicle, an inner organ, a part of the skin and/or parts of one or more of the aforementioned. Further, a surgical procedure may lead to an artificial anus and/or to a bladder catheter. Likewise, radiation may lead to severe symptoms of intoxication.
Other treatments have been tried in an attempt to improve mortality and morbidity. Today, some types of cancer can be treated by immunotherapy (e.g., therapeutic vaccines such as sipuleucel-T, or cytokine-based immunotherapy (e.g. Interleukin-2, Interferon-alpha)), monoclonal antibody therapy (e.g. bevacizumab), targeted small molecules (e.g., imatinib) and/or other methods, such as, e.g., cryoablation or isolated organ perfusion. These treatments may bear significant advantages in comparison to the conventional chemotherapeutic treatments described above. However, many of these treatments have limited efficacy, are associated with severe toxicities, and/or can only be used for one or few types of cancer. Therefore, there are numerous types of cancer which can, so far, only be treated with conventional cytotoxic agents, or which cannot be treated effectively at all. Irrespective of recent advances there remains a high unmet medical need associated with common malignancies with high mortality, high morbidity, high rates of recurrence, short periods of disease- or progression-free survival, rapid tumor growth, and high risk of formation of (micro-) metastases.
The addition of cytokines, alone or in combination, such as, e.g., tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-γ), and interleukin-2 (IL-2) have been used clinically, but have led to durable remissions only in small numbers of patients treated and produced no significant clinical responses in overall target populations.
A still further therapeutic strategy is the removal of molecules based on the molecular weight by means of ultrapheresis (therapeutic apheresis, plasmapheresis) promoting an immune attack on the tumors by the patient's own white blood cells (cf, US 4,708,713). In particular, it has been demonstrated that the removal of components present in the blood having a molecular weight of 120,000 Da (dalton) or less can lead to an induction of an immune response against transformed, infected or diseased tissue (cf, US 6,620,382). However, the unspecific removal of a large fraction of components having a molecular weight of 120,000 Da may lead to significant disadvantages as also molecules that have positive effects on the patient's vitality such as, e.g., TNF- , IL-2, or IFN-γ are removed from the high-molecular weight components containing, e.g., antibodies. A patient may also be treated by the selective removal of one or more cytokine receptors, wherein it is intended to provoke and/or stimulate the patient's immune response against the tumor cells.
However, today, for a majority of patients, the most promising therapy is still the treatment by means of a chemotherapeutic agent or by means of a combination of several chemotherapeutic agents. In this context, a well-known problem is that the required concentrations of chemotherapeutic agents are so high that considerable undesired side effects inevitably occur the patient severely suffers from. Moreover, during the treatment, many patients become increasingly insensible to the agent and would require increasing amounts thereof to achieve the therapeutic aim up to concentrations that are not tolerable any more.
Therefore, there is still a need for improved cancer therapeutic means that allow usage of lower concentrations of chemotherapeutic agents and nevertheless show comparable efficiency of the therapy.
Surprisingly, it could be demonstrated that the removal of sTNFR2 alone or together with one or more cytokine receptors sensitizes tumor cells to a treatment with a chemotherapeutic agent allowing the decrease of the required amount of said chemotherapeutic agent.
In a first aspect, the present invention refers to a molecule binding to soluble tumor necrosis factor receptor 2 (sTNFR2) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is used to remove sTNFR2 from a body fluid of said patient.
Preferably, said molecule is immobilized on a solid support that is contacted with a body fluid of said patient.
When the molecule binding to sTNFR2 is contacted with a body fluid of said patient, this will lead to a removal of sTNFR2 from said body fluid and thereby decrease the concentration of sTNFR2 in the body fluid. Most preferably, the concentration of sTNFR2 is decreased in blood.
As used herein, the term "soluble tumor necrosis factor receptor 2 (sTNFR2)" refers to a polypeptide that has a sequence identity of at least at least 75%, even more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, and most preferably 100% of the sequence of SEQ ID NO: 1. In the art, several designations are common for sTNFR2, such as, e.g., "soluble tumor necrosis factor receptor 2", "soluble tumor necrosis factor receptor type II", "soluble tumor
necrosis factor receptor IB", "soluble tumor necrosis factor receptor superfamily member I B", "soluble tumor necrosis factor receptor superfamily IB", "soluble tumor necrosis factor-binding protein 2", "sTNF-alpha receptor", "TNFR1B", "sTNFR-II", "TNFRSFIB", "sTBP-2", "sTBP-II", "sTBP2", "sTBPII", "p75", "p80", "sTNF-R2" or "CD 120b". It will be understood that these names may be understood interchangeably.The sTNFR2 polypeptide may bear the property to bind to tumor necrosis factor (TNF). TNF may be, e.g., TNF-alpha. As used herein, the terms "TNF", "cachexin" or "cachectin", TNF-a and "tumor necrosis factor-alpha" may be understood interchangeably. In nature, sTNFR2 may be generated by shedding, thus, by proteolytic cleavage of the full-length TNFR2 associated with the membrane. Typically, shedding will be executed by one or more matrix metalloprotease(s).
In the blood stream, one of the major functions of sTNFR2 is capturing TNF and, thereby, lowering the TNF concentration locally in the proximity of the cells producing sTNFR2 and systemically in the entire blood stream. A molecule structurally and functionally related to sTNFR2 is sTNFRl . In fact, also sTNFRl is released from the cells and is able to lower the TNF concentration locally in the proximity of the cells producing sTNFRl and systemically in the entire blood stream. Therefore, the person skilled in the art will notice, that instead of sTNFR2, also sTNFRl may be used in the context of the present invention.
Accordingly, the present invention also refers to a molecule binding to soluble tumor necrosis factor receptor 1 (sTNFRl) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is used to remove sTNFRl from a body fluid of said patient.
As used herein, the term "removal" may be understood in the broadest sense as the decrease of the concentration of a soluble cytokine receptor in the body fluid. As used herein, the term "decrease", "lower" and "deplete" may be understood interchangeably. After removal, the concentration of the soluble cytokine receptor may be decreased to less than 50%, less than 25%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1 % of the initial concentration. The initial concentration may be the concentration found in any fluid, in particular the concentration naturally found in a body fluid.
As laid out in detail below, the molecule binding to sTNFR2 or to at least one other soluble cytokine receptor (see below) may be any molecule binding to the soluble cytokine receptor of interest with a dissociation constant (Kd) of less than 10 mM, less than 1 mM, less than
100 μΜ, less than 10 μΜ, less than 1 μΜ, less than 100 nM, or less than 10 nM. As used in the context of the present invention, the molecule is immobilized on a solid support.
As used herein, the term "immobilized to a solid support" means that the molecule is bound to any solid material. Herein, the term "bound" means that the molecule is covalently or quasi-covalently bound. A quasi-covalent bond is a non-covalent bond with a binding affinity with a Kd of less than 50 nM, such as, e.g., the dihydrofolate-methotrexate interaction, or the streptavidin-biotin interaction. The molecule binding to the soluble cytokine receptor may be immobilized directly or via linker. For instance a bispecific linker can bind to the surface of the solid support with one active group whereas it binds to the molecule binding to the soluble cytokine receptor with another active group. For instance, a glass surface of a solid support may be activated by silane conditioning as known in the art. Then, the surface of the solid support may further be conjugated with bispecific linker carrying, e.g., a maleimide or a succinimidyl ester (e.g., N- hydroxysuccinimidyl (NHS) esters) on the other end. A succinimidyl ester can bind to free amino groups of the molecule binding to the soluble cytokine receptor, a maleimide preferably binds to free thiol groups of the molecule binding to the soluble cytokine receptor. An active ester such as an acid halogenide (e.g., an acid chloride or an acid bromide) may bind to free amino groups or free hydroxy 1 groups of the molecule binding to the soluble cytokine receptor. Thereby, the molecule binding to the soluble cytokine receptor is immobilized on the surface of the solid support. Alternatively, antibodies binding to the molecule binding to the soluble cytokine receptor can be immobilized on the surface of a solid support. Then, in a second step, a fluid containing the molecule binding to the soluble cytokine receptor is incubated with the antibody-coated surface. As used herein, the term "coated" may be understood in the broadest sense as the conjugation of any molecular structure(s) to the surface of the solid support.
In this context, the term "tumor cell" may be understood in the broadest sense as any cell from neoplastic tissue. The neoplastic tissue may be benign or malignant and may be of any tissue origin. Preferably, the neoplastic tissue is malignant, semi-malignant or is at risk of being malignant (pre-malignant). The neoplasia may be a palpable and tactile lump, may or may not be detectible by molecular imaging, or may be a microscopic lesion of a single cell or few cells such as, e.g., a metastasis. The tumor cell may be a cell of a primary tumor or a secondary tumor. As used herein, the terms "tumor", "cancerous swelling", "neoplasia", "lesion" and "carcinoma in situ"'' may be understood interchangeably. The tumor cell may origin from any tissue that can develop a tumor, such as, e.g., sarcoma (e.g., myxosarcoma, histiocytoma, liposarcoma, chondrosarcoma, osteosarcoma, angiosarcoma, leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma, synovialcarcinoma,
Ewing sarcoma, hemangiosarcoma, lymphangiosarcoma, adenosarcoma, carciosarcoma), bronchiocarcinoma, prostate carcinoma, cervix carcinoma, ovarian carcinoma, mamma carcinoma, bronchial carcinoma, melanoma, esophagus carcinoma, rectal carcinoma, pancreas carcinoma, bladder carcinoma, kidney carcinoma, blastoma (e.g., hepatoblastoma, retinoblastoma, nephroblastoma, neuroblastoma, medulloblastoma, glioblastoma), head and neck tumor, cerebral tumor, lymphoma (e.g., Hodgkin lymphoma, Non-Hodgkin lymphoma, multiple lymphoma, malignant lymphoma), fibroma (e.g., adenofibroma, neurofibroma), leukemia (e.g., acute myeloic leukemia, chronic myeloic leukemia), endothelioma (e.g., hemangioendothelioma), adenoma (e.g., fibroadenoma), semioma, dysgerminoma, luteoma, mesenchymal tumors, granulose cell tumor, ymphangioma, meningeoma, mesothelioma, schwannoma, chorionepitheliom, hepatoma, leukemia, teratoma, basaliom, neurodoctrine tumors, insulinoma, pheochromocytoma, melanoma, astrocytoma, anaplastic meningeoma, carcinoides, and/or (aggressive) fibromatosa.
The tumor cell may be located in any organ, such as, e.g., brain, eye, skin, lung, liver, oral cavity, pharynx, stomach, small intestine, duodenum, colon, urinary bladder, kidney, gall bladder, pancreas, vaginal tract, testicles, breast, a muscle, blood, lymph, a lymph node, esophagus, heart, a bone, bone marrow, spleen, a blood vessel, a lymphatic vessel, cervix, uterus, spinal cord, or an ovary or may be located in connective tissue, mucosa tissue, or nerve tissue. The tumor cell may also be a single cell or an aggregate of or few cells floating through the patient's body such as, e.g., via the blood stream or the lymphatic system. The term "blood stream" as used herein may be understood in the broadest sense as circulating blood. The blood stream may be in a vessel of a patient or may be in a tube, a filter, a column or any other device outside of the body.
As used herein, the term "sensitizing a tumor cell" means that the tumor cell is rendered more sensitive to a treatment with a chemotherapeutic agent. According to the present invention, this may be mainly achieved by removing at least one soluble cytokine receptor from a body fluid of the patient. The therapeutic potency of the chemotherapeutic agent with respect to the tumor cells subjected to the sensitization according to the present invention is increased compared to congeneric tumor cells without said sensitization. That means that the concentration of the chemotherapeutic agent may be decreased whereas the therapeutic effect with respect to the tumor cells of interest is extensively maintained or even increased. Depending on the chemotherapeutic agent and the type of the removed soluble cytokine receptor and the degree of removal, the required concentration to maintain the therapeutic activity may be decrease by at least 5%, at least 10%, at least 20%, at least
30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or even 90% or more of the concentration required without the removal of the soluble cytokine receptor.
As laid out in detail below, the chemotherapeutic agent as used herein may be any chemotherapeutic agent known in the art, preferably an alkylating agent, more preferably a nitrogen mustard alkylating agent, in particular Melphalan.
The term "body fluid" may be understood in the broadest sense as any fluid obtainable from a patient's body any fluid obtainable from a body after one or more processing step(s). Preferably, the body fluid is blood, blood plasma, blood serum, a blood fraction or lymph. More preferably, the body fluid is blood obtained from a patient.
As used herein, the term "blood" may be understood in the broadest sense as blood of a human or an animal. Preferably, the blood is the blood of the patient who receives the blood, plasma or blood fraction of which the soluble cytokine receptor has been removed. Most preferably, the patient will retrieve his own blood (autologous blood) that is returned into his blood stream after being treated by means of the molecule and/or the method of the present invention. Typically, the blood is withdrawn from the patient, treated by means of the molecule and/or the method of the present invention and, subsequently, immediately conducted back into the patient's blood stream. However, the patient's autologous blood may also be stored before treatment and/or after treatment and conducting it back into the patient's blood stream. Alternatively, the blood may also be blood originating from another individual (heterologous blood) or a mixture of autologous and heterologous blood.
As used herein, the term "plasma" may be understood in the broadest sense as blood from which the cells (e.g., red blood cells (RBCs) and leucocytes) as well as the platelets have been removed. Preferably, the plasma is obtained from the blood of the patient who receives the plasma, blood or blood fraction of which the soluble cytokine receptor has been removed.
As used herein, the term "blood fraction" may be understood in the broadest sense as any fraction of blood from which one or more factors have been removed. Exemplarily, the RBCs, some types of or all leucocytes, platelets, and/or one or more proteins may be removed. Preferably, the term "blood fraction" refers to (blood) serum, thus, plasma of which further one or more coagulation factor(s) has/have been removed. Preferably, in serum, at least fibrin and/or fibrinogen has been removed. A blood fraction may also be plasma or serum of which further proteins of a certain molecular weight range have been removed. This can be proteins of a molecular weight above a certain threshold or below a
certain threshold, preferably proteins above a certain threshold are removed, more preferably proteins of more than 50,000 Da, more than 100,000 Da, more than 120,000 Da, more than 150,000 Da or more than 200,000 Da. Even more preferably, proteins of a molecular weight of more than 120,000 Da may be removed from the blood fraction. Alternatively, sTNFR2 may also be removed from any other body fluid such as, e.g., lymph (endolymph and/or perilymph), cerebrospinal fluid {liquor cerebrospinalis).
As used in the context of the present invention, the term "patient" may be understood in the broadest sense as any subject or individual bearing a tumor cell treated or to be treatment with a chemotherapeutic agent. The patient may be any animal, preferably a mammal, in particular a human. Preferably, the patient is a human suffering from a malignant neoplasia, including cancer, or a benignant neoplasia. As used herein, the term "suffering from" may be understood in the broadest sense as having a certain disease. The patient may or may not bear any symptoms of said disease. The disease may be any disease, in particular a tumorous disease, cancer. The patient may or may not show any further symptoms caused by increased soluble cytokine receptor level such as faster tumor growth, depleted immune response against tumorous or neoplastic tissue.
Highly preferably, the patient is a cancer patient. The patient may have or may be free of clinical symptoms occurring from said neoplasia. The patient may also be a patient who had a malignant or benignant neoplasia that has already been removed by any means (e.g., by surgical means, radiation and/or chemotherapeutic means) who is subjected to an after- treatment with a chemotherapeutic agent. Preferably, the patient has increased blood levels of one or more cytokine receptor(s). Most preferably, the patient is a cancer patient having increased blood levels of one or more cytokine receptor(s).
As indicated above, a molecule binding to at least one soluble cytokine receptor may be any molecule binding to the soluble cytokine receptor of interest with a dissociation constant (Kd) of less than 10 mM, less than 1 mM, less than 100 μΜ, less than 10 μΜ, less than 1 μΜ, less than 100 nM, or less than 10 nM. The molecule may be a small molecule (low-molecular weight compound) having a molecular weight of not more than 5000 Da or may be a high- molecular weight compound having a molecular weight of more than 5000 Da. Preferably, the molecule is a high-molecular weight compound. Even more preferably, the molecule is a polypeptide. As used in the context of the present invention, the term "polypeptide" may be understood in the broadest sense as a linear or branched polymer mainly composed of amino acids. A polypeptide may be a protein. The polypeptide may further contain posttranslational modifications. Posttranslational modifications are well-known in the art and may comprise but may not be limited to lipidation, phosphorylation, sulfatation,
glucosylation, truncation, cyclization of several amino acid moieties, cyclization of the polypeptide strand, oxidation, reduction, decarboxylation, acetylation, amidation, deamidation, nitration, nitrosylation, disulfide bond formation, pyroglutamate formation, amino acid addition, cofactor addition (e.g., biotinylation, heme addition) and complexation of metal ions, non-metal ions, peptides or small molecules and addition of iron-sulfide clusters. Further, co-factors, such as, e.g., ATP, ADP, NAD+, NADH+H+, NADP+, NADPH+H+, metal ions, cations, anions, lipids may be bound to the polypeptide, irrespective on their biological impact. Moreover, the protein may be elongated by one or more amino acids.
Even more preferably, the molecule is selected from the group consisting of: an antibody, a cofactor, a cytokine, a synthetic polypeptide, human LDL receptor, lipocalin or fibronectin and/or a small molecule. Even more preferably, the molecule is an antibody. The antibody may be a polyclonal or a monoclonal antibody. The antibody may also be a single domain antibody (sdAB) such as, e.g., a camelid antibody (e.g., a llama antibody). As used herein, the terms "cameloid species antibody" and "camelid antibody" may be understood interchangeably.
As used herein, the terms "single-domain antibody" and "nanobody" may be understood interchangeably as an antibody fragment consisting of a single monomeric variable antibody domain that is able to bind to a specific antigen selectively. Typically, sdABs have a molecular weight of approximately 12-15 kDa. Exemplarily, sdAB may be obtained from camelids (e.g., dromedaries, camels, llamas, alpacas) and Chondrichthyes (cartilaginous fishes, such as, e.g., sharks, rays and skates). An alternative approach to obtain sdAB is to split the dimeric variable domains from common immunoglobulins (e.g., IgG) from a mammal into monomers.
The at least one soluble cytokine receptor may be any soluble cytokine receptor known in the art.
In a preferred embodiment, further another soluble cytokine receptor of an immunomodulatory cytokine is removed from the body fluid of said patient, preferably said receptor is a receptor of a proinflammatory cytokine, more preferably a receptor of a Thl-type cytokine.
This may be achieved by the use of a molecule binding to said soluble cytokine receptor. All embodiments described above relating to the molecule binding to sTNFR2 also apply to said molecule binding to another soluble cytokine receptor.
The term "immunomodulatory cytokine" may be understood in the broadest sense as any cytokine that has an influence on the activity of the patient's immune system. The term "proinflammatory cytokine" may be understood in the broadest sense as any cytokine that has a positive influence on the patient's immune system. Exemplarily, a receptor of a proinflammatory cytokine may be a receptor of a chemokine (e.g., CCL (e.g., CCL1, CCL2/MCP- 1 , CCL3/MIP-l , CCL4/MIP-lp, CCL5/RANTES, CCL6, CCL7, CCL8, CCL9, CCL11, CCL 12, CCL13, CCL14, CCL 15, CCL 16, CCL 17, CCL18, CCL 19, CCL20, CCL21 , CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28), CXCL (e.g., CXCL1 KC, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8/IL8, CXCL9, CXCLIO, CXCL11, CXCL 12, CXCL 13, CXCL14, CXCL 15, CXCL 16, CXCL 17), CX3CL (e.g., CX3CL1), XCL (e.g., XCL1, XCL2)) , a tumor necrosis factor (TNF) (e.g., TNFA, lymphotoxin (TNFB/LTA, TNFC/LTB), TNFSF2, TNFSF4, TNFSF5/CD40LG, TNFSF6, TNFSF7, TNFSF8, TNFSF9, TNFSF10, TNFSF11, TNFSF13B, EDA), an interleukin (IL) (e.g., type I IL (e.g., γ-chain IL (e.g., IL2/IL15, IL4/IL13, IL7, IL9, IL21), β-chain IL (e.g., IL3, IL5, GM-CSF) IL6 like/gpl30 (e.g., IL6, IL1 1, IL27, IL30, IL31 (+non IL OSM, LIF, CNTF, CTF 1)), IL-12 family/IL12RBl (IL12, IL23, IL27, IL35), others (e.g., IL14, IL16, IL32, IL34)), type II IL (e.g., IL-10 family (e.g., IL10/IL22, IL19, IL20, IL24, IL26), interferon type III, IL28/IFNL2+3, IL29/IFNL1))), an interferon (IFN) (e.g., type I IFN (e.g., IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21, IFNB1, IFNK, IFNWl), type II IFN (e.g., IFNG))), a member of the IG superfamily (e.g., ILIA/ILIFI, IL1B/IL1F2, lRa/ILlF3, IL1F5, IL1F6, IL1F7, IL1F8, IL1F9, ILIFIO, 33/IL1F1 1, 18/IL1G), an IL-17 family member (e.g., IL17/IL25 (IL17A)), a growth factor or a hematopoietic (KITLG, colony- stimulating factor) (e.g., SPP1).
In a more preferred embodiment, the soluble cytokine receptor is selected from the group consisting of soluble tumor necrosis factor receptor 1 (sTNFRl), soluble interleukin-2 receptor (sIL2R), soluble interleukin-1 receptor (sILlR),soluble interleukin-6 receptor (sIL6R), soluble interleukin- 12 receptor (sIL12R), soluble interleukin- 18 receptor (sIL18R), soluble interleukin-23 receptor (sIL23R), soluble granulocyte macrophage colony-stimulating factor receptor (sGM-CSFR), soluble transforming growth factor beta receptor (sTGFpR) or soluble interferon gamma receptor (sIFNyR).
In an even more preferred embodiment, the soluble cytokine receptor is a soluble tumor necrosis factor receptor or a soluble interleukin receptor, more preferably wherein said soluble cytokine receptor is selected from the group consisting of:
i) sTNFRl ; and
ii) sIL2R,
in case that sTNFR2 is removed.
As used herein, the term "soluble tumor necrosis factor receptor 1 (sTNFRl)" refers to a polypeptide that has a sequence identity of at least at least 75%, even more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, and most preferably 100% of the sequence of SEQ ID NO:2. In the art, several designations are common for sTNFRl , such as, e.g., "soluble tumor necrosis factor receptor 1 ", "soluble tumor necrosis factor receptor type I", "soluble tumor necrosis factor receptor 1A", "soluble tumor necrosis factor receptor superfamily member 1A", "soluble tumor necrosis factor receptor superfamily 1A", " soluble tumor necrosis factor-binding protein 1" , "soluble TNF-alpha receptor", "TNFRIA", "sTNFR-I", "TNFRSFIA", "sTBP-1", "sTBP-I", "sTBPl", "sTBPI", "p55", "p60", "sTNF-Rl", "sTNF-R55", or "CD 120a". It will be understood that these names may be understood interchangeably. In nature, sTNFRl may be generated by shedding, thus, by proteolytic cleavage of the full length TNFR1 associated with the membrane. Typically, shedding will be executed by one or more matrix metalloprotease(s).
As used herein, the terms "soluble interleukin-2 receptor alpha (sILR2)", "soluble IL-2 receptor alpha", "sIL-2R", "sIL2aR", "sIL2aR", "sIL2-R", "sIL2-RA" and "CD25 alpha" may be understood interchangeably.
Most preferably, the soluble cytokine receptor binding to the molecule of the present invention is sTNFR2. It will, however, be understood that alternatively or additionally other soluble cytokine receptors may be also used in the context of the present invention. Such methods are e.g. described in WO 05/107802.
As indicated above, the molecule binding to the soluble cytokine receptor may be any molecule binding to the soluble cytokine receptor of interest with a dissociation constant (Kd) of less than 10 mM, less than 1 mM, less than 100 μΜ, less than 10 μΜ, less than 1 μΜ, less than 100 nM, or less than 10 nM. As already laid out above, the molecule is preferably a polypeptide. However, also a small molecule may be used as the molecule of the present invention.
Preferably, the molecule binding the soluble cytokine receptor may bind to the soluble cytokine receptor with a Kd of less than 1 nM, more preferably less than 100 μΜ, even more preferably less than 10 μΜ, even more preferably less than 1 μΜ, in particular less than 100 nM. The molecule binding to the soluble cytokine receptor may be understood as
any binding partner of the soluble cytokine receptor or any soluble cytokine receptor - binding molecule. Preferably, said molecule binding to the soluble cytokine receptor may have a higher binding affinity to the soluble cytokine receptor than to other proteins present in blood or plasma such as, e.g., albumins (e.g., serum albumin), globulins (e.g., immunoglobulins), other cytokines, interleukins, chemokines, fibrinogens, antitrypsins and/or complement factors. Further, said molecule binding to the soluble cytokine receptor may bear a significantly higher affinity to the soluble cytokine receptor than to other soluble cytokine receptors. Therefore, said molecule binding to the soluble cytokine receptor may bear more than 5fold, preferably more than l Ofold, more preferably more than 50fold, even more preferably more than l OOfold higher binding affinity to the soluble cytokine receptor than to any other soluble cytokine receptor. The molecules binding to the soluble cytokine receptor may be of natural or of synthetical origin. Further, the molecules binding to the soluble cytokine receptor may be conjugated or bound to other molecules that may refer to but may not be limited to one or more protein tag(s) (e.g., dihydrofo late, polyhistidine tag(s) ((poly)His tag(s)), streptavidin), one or more binding moiety/moieties comprising, e.g., biotin, methotrexate, glycocorticoid(s), one or more active ester(s) (e.g., N-hydroxysuccinimidyl (NHS) ester(s)), one or more isothiocyanate(s), one or more maleimide(s), one or more glutaraldehyde derivative(s), one or more carbodiimide derivative(s) or combinations thereof, one or more insoluble and/or soluble polymer(s) (e.g., polyethylene glycol (PEG), hydroxypropyl methacrylate (HPMA), polyethylene imine (PEI)), one or more antibody/antibodies or derivative(s) thereof, micro- or nanobeads (e.g., functionalized silica beads, polysaccharide-based beads), polymersomes, liposomes, one or more linker or spacer molecule(s) such as, e.g., peptide linker(a), a polyethylene glycol (PEG) linker(s), saccharide linker(s), fatty acid linker(s), alkyl Iinker(s), antibody linker(s), or a combination of two or more thereof. The molecule binding to sTNFR2 may be conjugated to one or more binding moieties and/or one or more linker molecules during synthesis (i.e., as fusion protein) or ex post synthesis or expression.
In a preferred embodiment, the molecule is selected from the group consisting of:
(i) an antibody, preferably a monoclonal antibody, a single domain antibody, an antibody fragment or an antibody mimetic;
(ii) a cofactor,
(iii) a cytokine, in particular tumor necrosis factor alpha (TNFSF2) or TNFSF2 mutein;
(iv) a synthetic polypeptide, in particular Staphylococcus aureus Protein A, human LDL receptor, lipocalin or fibronectin; and/or
(v) a small molecule, in particular an ensemblin, a macrocyclic scaffold, an Aptamers and/or a peptide staple;
more preferably wherein said molecule is an antibody, in particular wherein said molecule is a monoclonal antibody or a single domain antibody.
However, as described above, an antibody according to the present invention may also be a polyclonal antibody, such as a polyclonal antibody binding to the soluble and the membrane associated forms of the TNFR2 concomitantly.
An antibody may be a monoclonal or a polyclonal antibody of any species or origin. It may bind to any epitope(s) comprised in the soluble cytokine receptor polypeptide of interest (e.g., linear epitope(s), structural epitope(s), primary epitope(s), secondary epitope(s)), including its posttranslational modifications. The epitope may be accessible by the antibody in the natural configuration of the soluble cytokine receptor of interest or may be a hidden epitope. Preferably, the epitope is accessible in the natural configuration of the soluble cytokine receptor of interest. The antibodies may be of natural origin, of gene technologic origin and/or of synthetical origin. Optionally, the antibody may also be a CovX antibody. Optionally, the antibody may also be a camelid antibody.
As used herein, the term "antibody fragments" may be understood in the broadest sense as any fragment of an antibody that still bears binding affinity to its target. Exemplarily, the antibody fragment may be a fragment antigen binding (Fab fragment), a truncated antibody comprising one or both complementarity determining region(s) (CDR(s)) or the variable fragment (Fv) of an antibody. The antibody fragments may be of natural origin, of gene technologic origin and/or of synthetical origin.
As used herein, the term "antibody mimetic" may be understood in the broadest sense as organic compounds that, like antibodies, can specifically bind antigens and that typically have a molecular mass in a range of from approximately 3 kDa to approximately 25 kDa. Antibody mimetics may be, e.g., Affibody molecules (Affibodies), Affilins, Affitins, Anticalins, Avimers, DARPins, Fynomers, Kunitz domain peptides, single-domain antibodies (e.g., VHH antibodies or VNAR antibodies) Monobodies, Diabodies, Triabodies, flexibodies and tandabs. The antibody mimetics may be of natural origin, of gene technologic origin and/or of synthetical origin.
The term "cofactor" may be understood in the broadest sense as a molecule binding to the soluble cytokine receptor in the natural environment to facilitate or enhance binding affinity or any other function thereof.
As used herein, the term "cytokine" may be understood in the broadest as any small protein, peptide, or glycoprotein secreted in the body to signal in intercellular communication, that may bind to the soluble cytokine receptor, such as, e.g., tumor necrosis factor alpha (sTNFSF2).
As used throughout the invention, the term "mutein" refers to any mutated protein. The amino acid sequence of the mutein may comprise alterations or substitutions in the primary amino acid residues, may be truncated and/or may be elongated compared to the corresponding wildtype protein. The mutein may have more than 50%, preferably more than 60%, more preferably more than 70%, even more preferably more than 80%, even more preferably more than 90%, most preferably more than 95% sequence homology to the corresponding wildtype protein.
As used herein, the term "synthetic polypeptide" refers to any polypeptide that binds to the soluble cytokine receptor. A synthetic polypeptide may be obtained from chemical synthesis or from gene technological processes. A synthetic polypeptide may be, e.g., Staphylococcus aureus Protein A, low-density lipoprotein (LDL) receptor, lipocalin or fibronectin.
As used herein, the term "small molecule" refers to any molecule that binds to the soluble cytokine receptor that has a molecular mass of less than 5000 Da, preferably less than 2000 Da, more preferably less than 1500 Da, even more preferably less than 1000 Da, even more preferably less than 800 Da. The small molecule may be, e.g., an ensemblin, a macrocyclic scaffold (e.g., an ensemblin), an Aptamer and/or a peptide staple. Further, the small molecule may also be any other small molecule. It may be obtained from a natural source and be identified in a screening process. It will be understood by a person skilled in the art, that the small molecule may also be conjugated to a polymeric scaffold, such as, e.g., hydroxypropyl methacrylamide (HPMA), polyethylene imine (PEI), carboxymethyl cellulose (CMC), polyethylene glycol (PEG), collagen fiber, a silk fiber, an agarose fiber, or a micro- or nanobead.
Highly preferably, the molecule binding to at least one cytokine receptor is an antibody, in particular a monoclonal antibody. Most preferably, the molecule is a monoclonal antibody binding to at least one Thl -type cytokine, preferably sTNFRl , sTNFR2 and/or sIL2Rin, in particular binding to sTNFR2.
Optionally the solid support further has one or more molecules binding to other plasma protein(s) immobilized on a solid support, preferably wherein said molecules are molecules
binding to cytokines, chemokines, soluble cytokine receptors, soluble chemokine receptors, other soluble decoy receptors, angiogenic factors, growth factors, and bone morphogenic factors more preferably molecules binding to soluble interleukin receptors (sILRs), in particular molecules binding to soluble interleukin-2 receptor alpha (sIL2R).
As used herein, the term "other plasma protein" may be understood in the broadest sense as any protein found in blood plasma that may modulate an immune response and/or may control cell growth, angiogenesis and/or apoptosis, except for sTNFRl . Exemplarily, said plasma protein may be a cytokine. Exemplarily, a cytokine may be an interleukin (IL) (e.g., IL-la, IL- Ι β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9 IL-10, IL-1 1 , IL-12, IL- 13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, 1L-21 , IL-22, IL-23, IL-24, IL-25, IL- 26, macrophage- inhibitory factor- 1), a lymphokine (e.g., granulocyte-macrophage colony- stimulating factor (GM-CSF), an interferon (e.g., IFN-a, IFN-β, IFN-γ), a chemokine (e.g., a CCL, a CXCL, an XCL, growth-related oncogene-alpha, CX3CL or a monocyte chemoattractant protein (MCP)). An "other plasma protein" may also be a soluble cytokine receptor (e.g., sIL2R, or the soluble interferon-gamma receptor), a colony stimulating factor (e.g., M-CSF, G-CSF), an angiogenic factor, a growth factor (e.g., TGF-beta 1 , TGF-beta 3, HGF, VEGF, basic FGF, IGF-1, IGF-2, PDGFR, EGF, CTGF), a bone morphogenic factor (e.g., osteoprotegerin, osteopontin, macrophage inhibitory cytokine- 1 other soluble decoy receptors (e.g., soluble VCAM-1 , soluble E-selectin, soluble P- selectin, soluble E-cadherin, soluble ILT-3, soluble MICA, soluble MICB, sULBP2, sICAM-1 , soluble Fas) or one or more mutein(s) of the aforementioned. In particular, the plasma protein may be a molecule binding to sIL2R.
As indicated above, the molecule binding to at least one cytokine receptor is immobilized on a solid support. This solid support may be any solid material known in the art, the molecule can be immobilized on in a way the molecule extensively maintains its binding activity to the soluble cytokine receptor.
In a preferred embodiment, the solid support forms part of an extracorporeal device through which the patient's body fluid can be circulated prior to being returned into said patient or forms part of an implant, in particular wherein said solid support is an extracorporeal device comprising at least one of the following:
(i) a column, in particular an adsorbent column;
(ii) a filter, in particular a capillary membrane filter with a pore size of between about 0.04 and 0.05 μιη or a parallel plate filter with a pore size of between about 0.04 and 0.08 μπι;
(iii) semi-permeable material, preferably a membrane, in particular a dialysis membrane;
(iv) a bead, in particular a microbead or a nanobead; and/or
(v) the surface of said device, in particular the surface of a tubing of said device.
As used herein, the term "extracorporeal device" may be understood in the broadest sense as any device that is used ex vivo, thus, outside of the living body of the patient. The extracorporeal device may be a column, optionally coated with a molecule binding to the soluble cytokine receptor and/or filled with a column matrix coated with a molecule binding to the soluble cytokine receptor, a filter system coated with a molecule binding to the soluble cytokine receptor, a membrane, in particular a dialysis membrane, coated with a molecule binding to the soluble cytokine receptor, a tubing coated with a molecule binding to the soluble cytokine receptor, or any other device coated having a molecule binding to the soluble cytokine receptor immobilized on a solid support.
The extracorporeal device may get in contact with the body fluid containing the soluble cytokine receptor directly. Alternatively, the body fluid containing the soluble cytokine receptor may first be subjected to a previous purification step and may subsequently get in contact with the body fluid containing the soluble cytokine receptor. For instance, the suspended or emulsified cells of a body fluid such as, e.g., blood cells, may first be removed from the body fluid. Then, blood plasma is generated. The blood plasma may get in contact with the extracorporeal device that enables the removal of the soluble cytokine receptor. Subsequently, the cells may optionally be remixed with the plasma or returned into the patient separately. The separation of cells and body fluid may be used to protect the column(s), the filter or membrane device from being clogged. Likewise, a size exclusion filter may be suited upstream the extracorporeal device that enables the removal of the soluble cytokine receptor. This filter may be used to protect a column, filter or membrane device from being clogged.
As used herein, the term "get in contact" may be understood in the broadest sense as exposing the molecules binding to the soluble cytokine receptor to the body fluid, enabling the soluble cytokine receptor to bind to the molecules binding to the soluble cytokine receptor.
Alternatively or additionally, one or more type(s) of molecule(s) or one or more type(s) of cell(s) may be removed by other means such as, e.g., affinity chromatography, anion exchange chromatography, cation exchange chromatography, hydrophobicity chromatography, or electrophoresis. This process may be conducted upstream and/or
downstream to the removal of the soluble cytokine receptor or may be conducted on the same solid support as the removal of the soluble cytokine receptor.
The extracorporeal device may be used offline, online or a combination thereof. As used herein, the term "offline" may be understood in the broadest sense as a system that is used batch-wise. Therefore, a certain volume of the body fluid extracted from a patient, is exposed to the device of the present invention and the soluble cytokine receptor is removed. Subsequently, the body fluid, from which the soluble cytokine receptor has been removed, is further analyzed and/or is optionally returned to the patient from whom the fluid has been obtained or to one or more other patient(s), in particular other patient(s) of the same patient as the graft patient the body fluid is obtained from. As used herein, the term "online" may be understood in the broadest sense as a system that is used in a continuous flow and/or is connected with the patient's blood or lymphatic vessel(s). Highly preferably, the body fluid extracted from a patient, is directly obtained from said patient, conducted through the extracorporeal device and, thereby, exposed to the molecules binding to the soluble cytokine receptor and is finally led back to said patient. This process may preferably be controlled manually and/or computer-assisted. In the device, the body fluid may be brought to or kept at any temperature sufficient for treating a body fluid, preferably the body fluid may be cooled to a temperature in the range of between 2°C and 5°C, between 5°C and 10°C, between 10°C and 15°C, between 15°C and 25°C, between 25°C and 37°C, or may be kept at body temperature, preferably at approximately 37°C. More preferably, the body fluid is cooled to a temperature in the range of between 2°C and 5°C or kept at body temperature, preferably at approximately 37°C, in particular kept at approximately 37°C. When returned into the patient, the body fluid may preferably bear body temperature, thus a temperature of approximately 37°C. The extracorporeal device may also serve as a combination of an offline and an online method. Then, e.g., the body fluid may be extracted from a patient in a pulsed mode, the soluble cytokine receptor may be removed in the extracorporeal device in a pulsed mode and/or the body fluid may be led back to the patient in a pulsed mode. Herein, the term "pulsed mode" means that there is no continuous flow, but the sample is rather treated batch-wise every few seconds or every few minutes, whereas the process comprising extracting the body fluid and removing the soluble cytokine receptor is conducted automatically.
Preferably, the extracorporeal device has been sterilized and/or endotoxin has been removed from the device. Sterilization may lead to a decreased concentration of pathogens and/or microorganisms such as, e.g., bacteria, viruses, fungals, moulds, bacterial spores, fungal spores, mould spores, worms, worm eggs, or eukaryotic protocoa. Sterilization may be accomplished by any means known in the art such as, e.g., employment of radiation
(e.g., UV radiation, gamma radiation) or one or more antimicrobic agent(s) known in the art. An endotoxin may be any endotoxin known in the art, such as e.g., lipopolysaccharide (LPS) or delta endotoxin. Typically, an endotoxin originates from the cell wall of a gram- negative bacterium.
As used herein, the term "column" refers to any hollow chromatography device that is itself coated with a molecule binding to the soluble cytokine receptor and/or filled with a column matrix bearing a molecule binding to the soluble cytokine receptor. As used herein, the term "column matrix" refers to any chromatographic material and may preferably be a bead material. The beads may be spherical or may bear any other shape known in the art to conduct chromatographic material. The beads may be of any material known in the art to be useful for preparing chromatographic material such as, e.g., silica, sugar-based bead material (e.g., agarose, sepharose), plastic bead material (e.g., polystyrene). The beads may bear a neutral, a positive or a negative zeta potential. The column may be a flow-through device or may be used batch-wise. When using a flow-through method, the column may be, e.g, an ultrapheresis column, a high performance liquid chromatography (HPLC) column, a fast protein liquid chromatography (FPLC) column, a flash chromatography (flash) column, a Rapid Refluid Liquid Chromatography (RRLC) column, a Rapid Separation Liquid Chromatography (RSLC) column, an Ultra Fast Liquid Chromatography (UFLC) column, an Ultra Performance Liquid Chromatography (UPLC) column or any other chromatography column known by those skilled in the art. Chromatography is widely used in protein purification. When the molecule binding to the soluble cytokine receptor is immobilized on the surface of the column device and/or on the column matrix an affinity chromatographic device is obtained. However, this device may concomitantly separate molecules by size exclusion chromatography, hydrophobicity chromatography, etc. The chromatographic methods may be combined with one or more filter(s), membrane(s) and/or semi-permeable material(s).
The term "filter" as used herein may refer to any device bearing pores. The pores may have an average pore size of an average pore size in the range of few nanometers or even less for separating high-molecular weight molecules, such as. proteins, of different molecular weights from another or the pores may have an average pore size of few micrometers for separating solid particles such as cells (e.g., red blood cells (RBCs), leucocytes, tumor cells), from another and/or from the liquid compartments of a body fluid (e.g., blood or lymph). The filter may have a molecular exclusion size that excludes molecules of less than 1 ,000 Da, less than 10,000 Da, less than 25,000 Da, less than 50,000 Da, less than 75,000 Da, less than 100,000 Da less than 125,000 Da, less than 150,000 Da, less than 175,000 Da, less than 200,000 Da, less than 250,000 Da, or less than 300,000 Da. The
filter may preferably be a capillary membrane filter with a pore size of between 0.001 and 10 μιη, more preferably of between 0.01 and 1 μηι, even more preferably of between 0.01 and 0.1 μπι, even more preferably of between 0.01 and 0.09 μηι, μηι, even more preferably of between 0.01 and 0.08 μιη, even more preferably of between 0.01 and 0.07, even more preferably of between 0.02 and 0.07 μιη, even more preferably of between 0.02 and 0.06, even more preferably of between 0.03 and 0.06 μπι, even more preferably of between 0.04 and 0.06 μηι, and most preferably of between 0.04 and 0.05 μηη. Alternatively, the a preferred filter may be a parallel plate filter with a pore size of between 0.001 and 10 μιη, more preferably of between 0.01 and 1 μιη, even more preferably of between 0.01 and 0.1 μηι, even more preferably of between 0.01 and 0.09 μπι, even more preferably of between 0.01 and 0.08 μπι, even more preferably of between 0.01 and 0.07 μηι, even more preferably of between 0.02 and 0.1 μηι, even more preferably of between 0.02 and 0.09 μηι, even more preferably of between 0.04 and 0.08 μηι, even more preferably of between 0.04 and 0.07 μηι, and most preferably of between 0.04 and 0.06 μπι. Several filters with the same, similar or different pore size(s) may be combined with another. The filter may be any kind of filter. The filter may be of any material, such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material. The filter may be hydrophobic or hydrophilic. The surface of the filter may be neutral or positively charged or negatively charged. The filter may be a part of a plasmapheresis and/or an ultrapheresis device as known in the art (see, e.g., WO 99/61085 and WO 01/37873). The filter may be a dead-end filter. Alternatively, the filter may also be a cross- flow filter. As used herein, the terms "cross-flow filter", "crossflow filter", "tangential flow filter" may be understood interchangeably. Filtration may be conducted batch-wise of in a continuous flow method. Preferably, the filtration is conducted in a continuous flow method. The filter may be combined with one or more column(s), membrane(s) and/or semi-permeable material(s).
The term "membrane" as used in the context of the solid support may be understood in the broadest sense as any thin, flexible solid material. The membrane may contain pores and serve as filter. Then at least part of the fluid flow goes through the membrane. Alternatively, the membrane may also be impermeable. Then, the fluid flow passes by the membrane on which molecules binding to the soluble cytokine receptor are immobilized. Several or even numerous membranes may be used in one device and form a functional array of membranes. The membrane may be a dialysis membrane. Then the membrane is permeable for some molecules (in particular small molecules) (semi-permeable). Dialysis is based on diffusion and osmosis, respectively, and is well known in the art. Dialysis is widely used in protein purification and is also used to provide an artificial replacement for lost kidney function in people with renal failure. The membrane may be of any material,
such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material. The membrane may be hydrophobic or hydrophilic. The surface of the membrane may be neutral or positively charged or negatively charged. The membrane may be combined with one or more column(s), filter(s) and/or semi-permeable material(s).
The term "semi-permeable material" may refer to any material that allows the passage of some molecules whereas other molecules can not or nearly not pass. The semi- permeability can base, e.g., on size exclusion and/or on the charge of the semi-permeable material. The semi-permeable material may be a solid material. The semi-permeable material may be a membrane or a thick material and may be of any material, such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material. The semi-permeable material may be hydrophobic or hydrophilic. The surface of the semi-permeable material may be neutral or positively charged or negatively charged. The semi-permeable material may have a smooth or porous surface structure. The semi-permeable material may be combined with one or more column(s), filter(s) and/or membrane(s).
The term "bead" may refer to any small spherical particle. In particular a bead may be a microbead or a nanobead. A microbead typically bears an average diameter in the range of approximately from 1 μηι and 1000 μιη. A nanobead typically bears an average diameter in the range of approximately from 1 nm and 1000 nm. The bead may be of any material such as, e.g., of silica, of metal- or alloy-based material, of sugar-based material (e.g., agarose, sepharose), of plastic (e.g., polystyrene) or may be a quantumdot. The bead may be hydrophobic or hydrophilic. The surface of the bead may have a neutral, a positive or a negative zeta potential. The beads may be compact or may be porous. A bead may be used in a column or may be used in fluid. The beads may be combined with one or more column(s), filter(s), semi-permeable material(s) and/or membrane(s).
The term "tubing" may be understood as any hollow solid material through which a fluid may flow. It may be flexible or inflexible. A tubing may be column filed with a matrix, but may also be not filled with a matrix. Optionally, the tubing may be the tubing of a capillary electrophoresis (CE). The tubing may also be any kind of semi-permeable material. The tubing may be of any material, such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material and may be hydrophobic or hydrophilic. The surface of the tubing may be neutral, positively charged or negatively charged. A tubing may be combined with one or more column(s), filter(s), semi-permeable material(s) and/or membrane(s).
The term "surface of a device" may refer to any kind of device. In particular, the device may be a therapeutic, a medical, or a laboratory device. The surface of the device may be of any material, such as, e.g., plastic (e.g., nylon, polysterene), metal, alloy, glass, ceramics, cellophane, cellulose, or composite material. The surface of the device may be hydrophobic or hydrophilic. The surface of the device may be neutral or positively charged or negatively charged.
As used herein, the term "implant" may be understood in the broadest sense as any device that is located or intended to be located inside the patients body (e.g., a subdermal implant). Typically, the implant thereby will get in contact with one or more body fluids, in particular extracellular matrix and/or blood. The implant may be a macroscopic device of few millimeters or even centimeters in size or may be a microscopic device such as a micro- or nanobead. The implant may be a therapeutically acceptable plastic material, a coated metal device (e.g., a titanium device) or may be a polysaccharide or polyacid that aggregates upon injection and thereby forms a depot (e.g., poly(lactic-co-glycolic acid) (PLGA)). The implant may or may not have a connection to the outside allowing to change the solid support the molecule binding to the at least one soluble cytokine receptors is immobilized on.
In a more preferred embodiment, the solid support forms part of an extracorporeal device further comprising at least one of the following:
(i) a primary filter to separate ultrafiltrate or plasma from the patient's blood;
(ii) a centrifuge to separate ultrafiltrate or plasma from the patient's blood;
(iii) a filter which removes components of a molecular weight of 120,000 Da or less from the blood, plasma or blood fraction;
(iv) a centrifuge which removes components of a molecular weight of 120,000 Da or less from the blood, plasma or blood fraction;
(v) means for administering radiation to patent's tissue; and/or
(vi) one or more cannula(s) and tubing(s) suitable for connecting the device to the patient.
As used herein, the term "primary filter" may be understood as a filter that is connected upstream to the solid support on which the soluble cytokine receptor-binding molecules are immobilized. The primary filter may protect said solid support from cells. When a primary filter is used, preferably only the flow-through of the primary filter, thus the ultrafiltrate, gets in contact with said solid support.
As used herein, the term "ultrafiltrate" may be understood in the broadest sense as a solution, emulsion or suspension from which parts of the high- molecular weight components have been removed. Preferably, the ultrafiltrate is a solution from which at least the blood cells (e.g., red blood cells (RBCs) and lymphocytes) have been removed. Even more preferably, also the cellular fragments such as e.g., platelets have been removed. When cells and cellular fragments have been removed from blood, the person skilled in the art will recognize plasma. Optionally, further one or more coagulation factors may be removed. Then, the person skilled in the art will recognize serum. Optionally, in the ultrafiltrate, also protein fraction(s) above a given size exclusion level may be removed. The size exclusion level may be more than 1 ,000 Da, more than 10,000 Da, more than 25,000 Da, more than 50,000 Da, more than 75,000 Da, more than 100,000 Da more than 125,000 Da, more than 150,000 Da, more than 175,000 Da, more than 200,000 Da, more than 250,000 Da, or more than 300,000 Da. Preferably, molecules of a molecular weight of more than 120,000 Da may be removed from the ultrafiltrate.
The ultrafiltrate may be generated by any means known in the art. Exemplarily, it may be generated by means of a filter or by centrifugation. Centrifugation may be any centrifugation of liquids known in the art. Centrifugation may be conducted batch-wise of in a continuous flow method. Preferably, the centrifugation is conducted in a continuous flow method. Filtration and centrifugation may be combined with another, in particular in a continuous flow method, or may be combined with any other method known in the art. Optionally, centrifugation may be gradient centrifugation (e.g., sucrose gradient centrifugation, equilibrium centrifugation).
Before the body fluid is recirculated into the patient, the cells and/or protein faction(s) may optionally be reunited with the ultrafiltrate from which the soluble cytokine receptor has been removed. Preferably, at least most of the cells are added to the purified ultrafiltrate prior to being re- injected into the patient.
The term "administering radiation to patent's tissue" may comprise, but may not be limited to expose the patient, a patient's limb, a patient's organ, or a patient's tissue to any kind of radiation used for therapeutic purposes, such as, e.g., x-ray radiation, ultraviolet (UV) radiation (e.g., UV-A, UV-B, and/or UV-C radiation), alpha radiation, beta radiation, gamma radiation, or cosmic radiation. Radiation therapy may also include, but may not be limited to Intensity-Modulated Radiation Therapy (IMRT), 3-Dimensional Conformal Radiotherapy (3DCRT), Stereotactic body radiation therapy (SBRT), Stereotactic radiosurgery (SRS), image-guided radiation therapy (IGRT), Particle Therapy (e.g, proton therapy), Brachytherapy, Radioisotope Therapy (RIT) (e.g., with iodine- 131 , lutetium-177,
strontium-89 and samarium (153Sm) lexidronam and/or yttrium-90). Preferably, a tumor and/or metastases of the patient are subjected to radiation.
As indicated above, the present invention refers to the sensitization of a tumor cell to a treatment with a chemotherapeutic agent. In this context, the chemotherapeutic agent may be any chemotherapeutic agent known in the art or a combination of two or more of the chemotherapeutics drugs in the arts.
Exemplarily, the chemotherapeutic agent may be selected from the group consisting of alkylating agents (e.g., melphalan, mechlorethamine, cyclophosphamide, chlorambucil, Ifosfamide), anti-metabolites (e.g., 5-fluorouracil, azathioprine, 6-mercaptopurine, mercaptopurine, pyrimidines, thioguanine, fludarabine, floxuridine, cytosine arabinoside (cytarabine), pemetrexed, raltitrexed, pralatrexate, methotrexate), plant alkaloids and terpenoids (e.g., vinca alkaloids (vincristine, vinblastine, vinorelbine, vindesine), taxanes (e.g., paclitaxel), Cytoxan), topoisomerase inhibitors (e.g., camptothecins: irinotecan, topotecan, etoposide, etoposide phosphate, teniposide), antineoplastica (e.g., doxorubicin (adriamycin), doxorubicin lipo, epirubicin, bleomycin)), actinomycin D, aminoglutethimide, amsacrine, anastrozole, antagonists of purine and pyrimidine bases, anthracyclines, aromatase inhibitors, asparaginase, antiestrogens, bexarotene, buserelin, busulfan, camptothecin derivatives, capecitabine, carmustine, a platin (e.g., cisplatin, carboplatin, oxaliplatin), cladribine, cytarabine, cytosine arabinoside, alkylating cytostatics, dacarbazine, daunorubicin, docetaxel, epirubicin, estramustine, etoposide, exemestane, fludarabine, fluorouracil, folic acid antagonists, formestane, gemcitabine, glucocorticoids, goserelin, hormones and hormone antagonists, hycamtin, hydroxyurea, idarubicin, irinotecan, letrozole, leuprorelin, lomustine, mercaptopurine, miltefosine, mitomycins, mitosis inhibitors, mitoxantrone, nimustine, procarbazine, tamoxifen, temozolomide, teniposide, testolactone, thiotepa, treosulfan, tretinoin, triptorelin, trofosfamide, cytostatically active antibiotics, everolimus, pimecrolimus, tacrolimus, azithromycin, spiramycin, sirolimus (rapamycin), roxithromycin, ascomycin, bafilomycin, erythromycin, midecamycin, josamycin, concancamycin, clarithromycin, troleandomycin, folimycin, tobramycin, mutamycin, dactinomycin, dactinomycin, rebeccamycin, a statin (e.g., cerivastatin, simvastatin, lovastatin, somatostatin, fluvastatin, nystatin, rosuvastatin, atorvasta'tin, pravastatin, pravastatin, pentostatin,), 4-hydroxyoxycyclophosphamide, bendamustine, thymosin a-1 , aclarubicin, fludarabine-5'-dihydrogen phosphate, hydroxycarbamide, aldesleukin, pegaspargase, cepharanthine, epothilone A and B, azathioprine, mycophenolate mofetil, c-myc antisense, b-myc antisense, betulinic acid, camptothecin, melanocyte stimulating hormone (a-MSH), activated protein C, IL- Ι β inhibitor, fumaric acid and esters thereof, dermicidin, calcipotriol, taclacitol, lapachol, β-
lapachone, podophyllotoxin, betulin, podophyllic acid 2-ethyl hydrazide, sagramostim, (rhuGM-CSF), peginterferon a-2b, lenograstim (r-HuG-CSF), filgrastim, macrogol, cephalomannine, selectin (cytokine antagonist), CETP inhibitor, cadherins, cytokinin inhibitors, COX inhibitor (COX-2 or COX-3 inhibitor), angiopeptin, ciprofloxacin, fluroblastin, bFGF antagonists, probucol, prostaglandins, 1 , 1 l-dimethoxyeanthin-6-one, 1- hydroxy-1 l-methoxycanthin-6-one, scopoletin, colchicine, NO donors, pentaerythrityl tetranitrate, sydnonimines, S-nitroso derivatives, staurosporine, β-estradiol, a-estradiol, estriol, estrone, ethinyl estradiol, fosfestrol, medroxyprogesterone, estradiol cypionates, estradiot benzoates, tranilast, kamebakaurin, verapamil, ciclosporin A, paclitaxel and derivatives thereof such as 6- -hydroxy paclitaxel, baccatin, taxotere, mofebutazone, acemetacin, diclofenac, lonazolac, dapsone, o-carbamoyl-phenoxy-acetic acid, lidocaine, ketoprofen, mefenamic acid, piroxicam, meloxicam, chloroquine phosphate, penicillamine, hydroxychloroquine, auranofin, sodium aurothiomalate, oxaceprol, celecoxib, β-sitosterol, ademetionine, myrtecaine, polidocanol, nonivamide, levomenthol, benzocaine, aescin, elipticine, D-24851 (Calbiochem), colcemid, cytochalasin A-E, indanocine, nocodazole, bacitracin, vitronectin receptor antagonists, azelastine, free nucleic acids, nucleic acids incorporated into virus transmitters, DNA and RNA fragments, plasminogen activator inhibitor- 1 , plasminogen activator inhibitor-2, antisense oligonucleotide, VEGF inhibitors, IGF- 1 , active agents from the group of antibiotics such as cefadroxil, cefazolin, cefaclor, cefoxitin, gentamicin, penicillins, dicloxacillin, oxacillin, sulfonamides, metronidazole, antithrombotics, argatroban, aspirin, abciximab, synthetic antithrombin, bivalirudin, Coumadin, enoxaparin, GpIIb/IIIa platelet membrane receptor, antibodies to factor Xa inhibitor, heparin, hirudin, r-hirudin, PPACK, protamine, prourokinase, streptokinase, warfarin, urokinase, vasodilators, dipyramidole, trapidil, nitroprussides, PDGF antagonists, triazolopyrimidine, seramin, ACE inhibitors, captopril, cilazapril, lisinopril, enalapril, losartan, thioprotease inhibitors, prostacyclin,, vapiprost, interferon α, β and γ, histamine antagonists, serotonin blockers, apoptosis inhibitors, apoptosis regulators, NF-kB or Bcl- xL antisense oligonucleotides, halofuginone, nifedipine, tocopherol, molsidomine, tea polyphenols, epicatechin gallate, epigallocatechin gallate, boswellic acids and derivatives thereof, leflunomide, anakinra, etanercept, sulfasalazine, tetracycline, triamcinolone, procainimide, retinoic acid, quinidine, disopyramide, flecainide, propafenone, sotalol, amiodarone, natural and synthetically obtained steroids such as bryophyllin A, inotodiol, maquiroside A, mansonine, strebloside, hydrocortisone, betamethasone, dexamethasone, fenoprofen, ibuprofen, indomethacin, naproxen, phenylbutazone, acyclovir, ganciclovir, zidovudine, antimycotics, clotrimazole, flucytosine, griseofulvin, ketoconazole, miconazole, terbinafine, chloroquine, mefloquine, quinine, natural terpenoids, hippocaesculin, barringtogenol-C21-angelate 14-dehydroagrostistachin, agroskerin, agrostistachin, 17-hydroxyagrostistachin, ovatodiolids, 4,7-oxycycloanisomelic acid,
baccharinoids B l , B2, B3 and B7, tubeimoside, bruceanol A, B and C, bruceantinoside C, yadanziosides N and P, isodeoxyelephantopin, tomenphantopin A and B, coronarin A, B, C and D, ursolic acid, hyptatic acid A, zeorin, iso-iridogermanal, maytenfoliol, effusantin
A, excisanin A and B, longikaurin B, sculponeatin C, kamebaunin, leukamenin A and B, 13, 18-dehydro-6-alpha-senecioyloxychaparrine, taxamairin A and B, regenilol, triptolide, cymarin, apocymarin, aristolochic acid, anopterin, hydroxyanopterin, anemonin, protoanemonin, berberine, cheliburin chloride, cicutoxin, sinococuline, combrestatin A and
B, cudraisoflavone A, curcumin, dihydronitidine, nitidine chloride, 12-beta- hydroxypregnadiene-3,20-dione bilobol, ginkgol, ginkgolic acid, helenalin, indicine, indicine-N-oxide, lasiocarpine, inotodiol, glycoside la, justicidin A and B, larreatin, malloterin, mallotochromanol, isobutyrylmallotochromanol, marchantin A, maytansine, lycoridicin, margetine, pancratistatin, liriodenine, bisparthenolidine, oxoushinsunine, aristolactam-AII, periplocoside A, ghalakinoside, deoxypsorospermin, psychorubin, ricin A, sanguinarine, manwu wheat acid, methylsorbifolin, chromones of spathelia, stizophyllin, akagerine, dihydrousambaraensine, hydroxyusambarine, strychnopentamine, strychnophylline, usambarine, usambarensine, daphnoretin, lariciresinol, methoxylariciresinol, syringaresinol, umbelliferone, afromoson, acetylvismione B, desacetylvismione A, vismione A and B), radiation therapy (e.g, Intensity-Modulated Radiation Therapy (IMRT), 3-Dimensional Conformal Radiotherapy (3DCRT), Stereotactic body radiation therapy (SBRT), Stereotactic radiosurgery (SRS), image- guided radiation therapy (IGRT), Particle Therapy (e.g, proton therapy), Brachytherapy, Radioisotope Therapy (RIT) (e.g., with iodine-13 1 , lutetium- 177, strontium-89 and samarium (, 5 Sm) lexidronam and/or yttrium-90)), antiangiogenic therapy (e.g., carboxyamidotriazole, TNP-470, CM101 , , Suramin, SU5416, Thrombospondin, VEGFR antagonists, angiostatic steroids + heparin, Cartilage-Derived Angiogenesis Inhibitory Factor, matrix metalloproteinase inhibitors, 2-methoxyestradiol, Tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, soluble VEGFR- 1 and NRP- 1 , Angiopoietin 2, angiostatin (e.g., TSP-1 and TSP-2 angiostatin), endostatin, vasostatin, canstatin, calreticulin, platelet factor-4, TIMP and CDAI, Meth-1 and Meth-2, CXCL lOprothrombin (kringle domain-2), antithrombin III fragment prolactin, VEGI, SPARC, osteopontin, maspin, proliferin-related protein, restin ), kinase inhibitors (e.g., imatinib, imatinib mesylate, gefitinib, erlotinib, pazopanib, apatinib), polyclonal or monoclonal antibodies (e.g., rituximab, trastuzumab, cetuximab, bevacizumab, basiliximab, daclizumab), proteasome inhibitors (e.g., bortezomib), cytokine or hormone therapy (e.g., selective estrogen receptor modulator tamoxifen, or with IFN-a, IFN-β, IFN- γ, IL-4, IL-12, IL-18, platelet factor-4)), PARP inhibitors (e.g., iniparib, olaparib) and/or combinations of two or more thereof.
In a preferred embodiment, the chemotherapeutic agent is an alkylating agent, preferably a nitrogen mustard alkylating agent, in particular Melphalan.
The person skilled in the art will know how to administer the particular chemotherapeutic agent to the patient. Depending on its chemical nature, it may be injected (e.g., subcutaneously (is.), intraperitoneal ly (i.p.) or intravenously ( .v.), intramusculary (i.m.), intraarterially (i.a.)), may be administered orally (e.g., via a pill, a capsule, a sirup, a juice), nasally (e.g., via a spray) or subdermally (e.g., via an ointment or a plaster).
It will be understood that the chemotherapeutic agent may also comprise one or more pharmaceutically acceptable carriers. A pharmaceutically acceptable carrier according the present invention may be any additive that is pharmaceutically acceptable, therefore, any additive that is non-toxic to the patient. Exemplarily, a pharmaceutically acceptable carrier may comprise a solvent such as, e.g., water, dimethyl sulfoxide (DMSO), ethanol, vegetable oil, paraffin oil or combinations thereof. Furthermore, a carrier may contain one or more detergents, one or more foaming agents (e.g., sodium lauryl sulfate (SLS)/ sodium doceyl sulfate (SDS)), one or more coloring agents (e.g., Ti02, food coloring), one or more vitamins, one or more salts (e.g., sodium, potassium, calcium, zinc salts), one or more humectants (e.g., sorbitol, glycerol, mannitol, propylene glycol, polydextrose), one or more enzymes, one or more preserving agents (e.g., benzoic acid, methylparabene), one or more texturing agents (e.g., carboxymethyl cellulose (CMC), polyethylene glycol (PEG), sorbitol), one or more emulsifiers , one or more bulking agents, one or more glacing agents, one or more separating agents, one or more antioxidants, one or more herbal and plant extracts, one or more stabilizing agents, one or more polymers (e.g., hydroxypropyl methacrylamide (HPMA), polyethylene imine (PEI), carboxymethyl cellulose (CMC), polyethylene glycol (PEG)), one or more uptake mediators (e.g., polyethylene imine (PEI), dimethyl sulfoxide (DMSO), a cell-penetrating peptide (CPP), a protein transduction domain (PTD), an antimicrobial peptide, etc.) one or more antibodies, one or more sweeteners (e.g., sucrose, acesulfame K, saccharin Na, stevia), one or more counterstain dyes (e.g., fluorescein, fluorescein derivatives, Cy dyes, an Alexa Fluor dyes, S dyes, rhodamine, quantum dots, etc.), one or more homeopathic ingredients, one or more gustatory substances and/or one or more fragrances. The formulation may also be a retard formulation maintaining the blood level of the chemotherapeutic agent at a therapeutic level for a longer time such as few days or even a week or longer.
The molecule binding to at least one soluble cytokine receptor according to the present invention may be contacted with the body fluid of the patient at any time before, during or
after the chemotherapeutic agent is administered to the patient for the treatment or prevention of a neoplasia, preferably cancer.
In a preferred embodiment, the molecule is contacted with the body fluid of the patient prior to, concomitantly with and/or subsequent to administering the chemotherapeutic agent to said patient.
When the molecule is contacted with the body fluid of the patient prior to administering the chemotherapeutic agent to said patient, it may be a pre-treatment for making the tumor cells in the patient more sensitive to the subsequently administered chemotherapeutic agent. In this context, preferably, the molecule is contacted with the body fluid of the patient not more than a month, more preferably not more than two weeks, even more preferably not more than one week, even more preferably not more than five days, even more preferably not more than four days, even more preferably not more than three days and most preferably not more than two days before the administration of the chemotherapeutic agent to said patient. The body fluid of the patient may also be contacted with the molecule according to the present invention few hours or even few minutes before the chemotherapeutic agent is administered to said patient.
When the molecule is contacted with the body fluid of the patient concomitantly with administering the chemotherapeutic agent to said patient, the body fluid of the patient may be contacted with the body fluid of the patient while the chemotherapeutic agent is administered.
When the molecule is contacted with the body fluid of the patient subsequent to administering the chemotherapeutic agent to said patient, it may be an after-treatment for making or maintaining the tumor cells in the patient more sensitive to the previously administered chemotherapeutic agent. In this context, preferably, the molecule is contacted with the body fluid of the patient not more than a month, more preferably not more than two weeks, even more preferably not more than one week, even more preferably not more than five days, even more preferably not more than four days, even more preferably not more than three days and most preferably not more than two days after the administration of the chemotherapeutic agent to said patient is terminated. The body fluid of the patient may also be contacted with the molecule according to the present invention few hours or even few minutes after the chemotherapeutic agent is administered to said patient.
Preferably, the contacting of the molecule binding to at least one soluble cytokine receptor may lower the concentration of said soluble cytokine receptor in the body fluid of the
patient before, during and/or after the administration of the chemotherapeutic agent to the patient.
In a preferred embodiment, the concentration of the soluble cytokine receptor is lowered in the body fluid of the patient when the chemotherapeutic agent is administered to said patient.
As indicated above, this may preferably be achieved by a single or a repeated treatment previous to or concomitantly with the administration of the chemotherapeutic agent to the patient.
Herein, in a particularly preferred embodiment, the time interval between contacting said molecule with the body fluid of the patient and administering said chemotherapeutic agent is not longer than seven days, preferably not longer than 5 days, in particular not longer than 3 days.
It will be understood that the contacting of the body fluid of the patient and/or administering of the chemotherapeutic agent may be repeated two, three, four, five or even more often. Then the treatment is a repeated treatment.
In a preferred embodiment, the molecule is contacted with the body fluid of the patient repeatedly, preferably at least three times.
Preferably, by subjecting the body fluid of the patient, the concentration of the soluble cytokine receptor of interest is maintained at a lower level compared to the level observable without contacting the body fluid with the molecule according to the present invention for at least twelve h, at least 24 h, at least 48 h or even a week or longer.
Preferably, also the chemotherapeutic agent is administered to the patient repeatedly, preferably at least three times. Preferably, the concentration of the chemotherapeutic agent is maintained at a therapeutically active level for at least twelve h, at least 24 h, at least 48 h or even a week or longer. This may be achieved by repeated administration and/or by using a retard and/or depot administration method(s) well-known in the art.
Most preferably, the concentration of the soluble cytokine receptor of interest is maintained at a lower level compared to the level observable without contacting the body fluid with the molecule according to the present invention and, concomitantly, the
concentration of the chemotherapeutic agent is maintained at a therapeutically active level for at least twelve h, at least 24 h, at least 48 h or even a week or longer.
As indicated before, the term "body fluid" may be understood in the broadest sense as any fluid obtainable from a body such as, e.g., blood, urine, cerebrospinal fluid, lymph, saliva and/or one or more secret(s) from any gland(s).
In a preferred embodiment, the body fluid is selected from the group consisting of blood, plasma, lymph and extracellular matrix.
Most preferably, the body fluid is blood, in particular blood in a patient who may bear one or more tumor cell(s) or who is at risk of having or developing one or more tumor cell(s).
As indicated above, the patient may have or may have no clinical symptoms of a neoplasia, in particular cancer.
In a preferred embodiment, the patient is at least partly resistant to the chemotherapeutic agent and/or is suffering from at least one undesired side effect caused by said chemotherapeutic agent.
As used herein, the term "partly resistant" may be understood in the broadest sense as a decrease in sensitivity to the chemotherapeutic agent. A partly resistant cell may require a chemotherapeutic agent concentration that is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 2foId, at least 3fold or even higher concentration to show the desired effect, i.e., for most chemotherapeutic agents to become apoptotic.
An undesired side effect may be, beside others, selected from the group consisting of hair loss, depression of the immune system, infections due to naturally occurring microorganisms in the patient's own gastrointestinal tract (including oral cavity) and skin anemia, cardiotoxicity (heart damage), hepatotoxicity (liver damage), nephrotoxicity (kidney damage), ototoxicity (damage to the inner ear), producing vertigo, encephalopathy (brain dysfunction), immunosuppression and myelosuppression, chemotherapy-induced nausea and vomiting (CINV), secondary neoplasm, infertility, teratogenic effects, neurological adverse effects, tumor lysis syndromered skin (erythema), dry skin, damaged fingernails, a dry mouth (xerostomia), water retention, and sexual impotence. Some medications can trigger allergic and pseudoallele reactions. As used herein, the terms "undesired side effect", "adverse effect" and "adverse side effect" may be understood interchangeably.
As indicated above, the molecule binding to at least one soluble cytokine receptor according to the present invention may be used for the treatment or prevention of any neoplasia.
In a preferred embodiment, the molecule is for use in a method for treating cancer in the patient.
As used herein, the treatment of cancer may also include the prevention of a recurrence of cancer in a patient who has been subjected to an anticancer treatment before.
A further aspect of the present invention refers to a body fluid from which at least one soluble cytokine receptor has been removed for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent.
In this context, the term "body fluid" as described above may also include any fluid obtainable from a body after one or more processing step(s) (e.g., centrifugation, filtration, cross filtration, precipitation and/or any other known method for fractioning biological fluids) such as, e.g., blood serum or blood plasma. As used herein, the terms "blood serum" and "serum" may be understood interchangeably. Likewise, the terms "blood plasma" and "plasma" may be understood interchangeably. Preferably, the body fluid is blood, blood plasma, blood serum or lymph.
Preferably, the body fluid may be obtained from the same patient who is subsequently treated therewith after at least one soluble cytokine receptor has been removed (autologous graft). Then, the obtained body fluid from which the soluble cytokine receptor has been removed may be re-injected or re-circulated into the patient the sample has been extracted from. Most preferably, the patient will retrieve his own blood (autologous blood) that is returned into his blood stream after being treated by means of the molecule and/or the method of the present invention.
Preferably, the body fluid is withdrawn from the patient, treated by means of the molecule and/or the method of the present invention and, subsequently, immediately conducted back into the patient's blood stream. However, the patient's autologous blood may also be stored before treatment and/or after treatment and conducting it back into the patient's blood stream.
Alternatively, the body fluid may be obtained from an individual and is infused into another patient (xenograft) or a mixture of autologous and heterologous body fluid(s).
The body fluid may more preferably be used directly obtained from the patient or within few minutes or few days. When the samples are stored for more than few hours, the samples may preferably be stored at room temperature or in the fridge. As used in the context of the present invention, the terms "room temperature" and "ambient temperature" may be understood interchangeably. Alternatively, the samples may also be stored in a frozen, deep-frozen or freeze dried state and may then be stored at any temperature below the freezing point, such as, e.g., at -20°, -80°C or in liquid nitrogen. A freeze-dried powder may also be stored at ambient temperature. Obtaining the body fluid from a patient is typically of no health risk for the patient and can be also conducted by persons who are no medical experts such as, e.g., even the patient at home.
As used herein, the term "obtained from a patient" may be understood in the broadest sense as receiving a body fluid from the body of a patient by any means. Exemplarily, blood may be collected from a blood vessel, lymph may be corrected from a lymph vessel, cerebrospinal liquid may be obtained from the cerebrospinal lumen and/or urine and/or sweat may be collected. It will be understood that the body fluid may also be processed further. Exemplarily, blood plasma or blood serum may be extracted from the blood by any means known in the art. The body fluid may be used in any method of the present invention or may be stored at appropriate conditions for up to one hour, up to two hours, up to six hours, up to twelve hours, up to a day or even longer. A sample of body fluid stored for more than one day may be designated as a preserved sample.
As used herein, the term "preserved sample" may be understood in the broadest sense as any sample that has been stored for more than one day, more than two days, more than a week, more than two weeks, more than a month, more than two months, more than six months or more than a year.
The body fluid sample may be stored as the pure body fluid or may be stored as a sample further comprising other components of the sample as summarized in detail above. In general, all storage conditions suitable for the body fluid may be used. Exemplarily, the body fluid sample may be stored at room temperature, at 4°C, at -20°C, at -80°C or in liquid nitrogen. Therefore, the body fluid sample may be stored in a liquid or frozen state. Alternatively, the body fluid sample may be stored in a freeze-dried or dried state. The preserved sample may exemplarily be an autologous or heterologous blood preservation, a serum or plasma preservation, or a lymph preservation. Preferably, a blood preservation is an autologous blood preservation.
Most preferably, the body fluid is blood that is obtained from a patient and is re-injected and re-circulated into said patient by any means known in the art. For instance, the sample may be injected by means of a tubing and/or an acus, a needle, a spicule or the like. These means are well-known in the context of dialyzers and kidney machines and can be used without particular expert skills.
As the present invention refers to the removal of the at least one soluble cytokine receptor from a body fluid, this removal may have an impact on the whole organism systemically, independent on where the tumor is located. Therefore, the effect is independent on barriers, such as the blood-brain barrier, the blood-testis barrier, the blood-milk barrier or the mother-embryo/fetus barrier. Therefore, the molecule of the present invention may also enable the systemic treatment of target tissue beyond the barrier. A patient suffering from a brain disease such as, e.g., e brain tumor (e.g., an astrocytome, or a glioblastome) may be treated by systemic treatment without targeting the brain directly. A fetus or embryo may be treated indirectly by treating the pregnant mother systemically. As used herein, the terms "systemic treatment" or "treating systemically" may be understood in the broadest sense as the treatment of a subject in total. Exemplarily, a body fluid such as, e.g., blood, may be extracted somewhere from the patient's body (e.g., from the basilica vein), conducted through the extracorporeal device of the present invention and, subsequently, being injected or recirculated somewhere in the patient's body (e.g., recirculated in the same or the other basilica vein), whereas the tissue to be treated (e.g., cancer tissue) may be located somewhere else in the patient's body (e.g., somewhere in the inner organs). Nevertheless, the treatment may be successful as a body fluid such as blood is circulating through the entire body of the patient. A treatment may be successful when the local concentration, but also when the overall concentration of the soluble cytokine receptor in the patient is depleted.
The therapy may also include the oral intake of an agent or a pharmaceutically acceptable composition thereof, the injection of an agent or a pharmaceutically acceptable composition thereof, the perfusion of an agent or a pharmaceutically acceptable composition thereof. Further, the removal of the soluble cytokine receptor may be combined with any surgical procedure known in the art such as, e.g., the section or resection of the tumor, the amputation of a limb, a breast, a testicle, or a certain tissue or parts thereof. Moreover, the removal of the soluble cytokine receptor may be combined with radiation therapy.
As already indicated above, in a preferred embodiment, the body fluid is selected from the group consisting of blood, plasma, lymph and extracellular matrix.
More preferably, the body fluid is blood. Most preferably, the body fluid is autologous blood, i.e., blood obtained from a patient from which TNFR has been removed re-infused into the same patient. In this context, the soluble cytokine receptor may be removed from the body fluid by any means.
As used herein, "TNFR" without indicating may be sTNFR2 or sTNFRl .
In a preferred embodiment, the soluble cytokine receptor has been removed by means of a molecule according to the present invention as defined above.
All embodiments described above also apply to the following aspect referring to a method of the present invention.
In a further aspect, the present invention refers to chemotherapeutic agent for use in a method for treating a tumor in a patient, wherein at least one soluble cytokine receptor has been removed from a body fluid of said patient by means of a molecule according the present invention as defined above for sensitizing a tumor cell of said tumor in said patient to a treatment with said chemotherapeutic agent.
As indicated above, in a preferred embodiment, the patient is a cancer patient, preferably wherein said patient is at least partly resistant to the chemotherapeutic agent and/or is suffering from at least one undesired side effect caused by said chemotherapeutic agent.
In a further aspect, the present invention also relates to a method for sensitizing a tumor patient to a treatment with a chemotherapeutic agent, comprising the step of removing soluble TNF receptor 2 (sTNFR2) from the blood of said patient.
As described in Examples 1 and 2, the present inventors have found that by removing soluble TNF receptor 2 from the blood, the treated subject is sensitized for the treatment with a chemotherapeutic agent. Consequently, by removing sTNFR2 from the blood from the patient, it is possible to reduce the dose of the chemotherapeutic agent, which reflects an important improvement in tumor treatment.
The definitions and embodiments laid out in detail above in the context of the preceding aspects, i.e., in the context of the molecule, the body fluid and the chemotherapeutic agent according to the present invention, also apply to this method according to the present invention.
Optionally, the method may be combined with the removal of one or more other plasma protein(s), preferably cytokines, chemokines, soluble cytokine receptors, other soluble decoy receptors, angiogenic factors, growth factors, and bone morphogenic factors more preferably molecules binding to sILRs, in particular molecules binding to sIL2R.
In a preferred embodiment, the method is for treating cancer in the patient, preferably further comprising administering a chemotherapeutic agent.
It will be understood that the patient may also be treated by a combination therapy comprising administering two or more chemotherapeutic agent(s).
As indicated above, in a preferred embodiment, the molecule according the present invention as defined above is contacted with the body fluid of the patient prior to, concomitantly with and/or subsequent to administering the chemotherapeutic agent to said patient.
As indicated above, the time interval between contacting said molecule with the body fluid of the patient and administering said chemotherapeutic agent is not longer than seven days, preferably not longer than 5 days, in particular not longer than 3 days.
As also indicated above, in a preferred embodiment, the molecule is contacted with the body fluid of the patient repeatedly, preferably at least three times.
Any of numerous chemotherapeutic drugs can be used in the methods or uses of the invention. These compounds fall into several different categories, including, for example, alkylating agents, antineoplastic antibiotics, antimetabolites, and natural source derivatives.
Examples of alkylating agents that can be used in the invention include busulfan, caroplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide (i.e., Cytoxan), dacarbazine, ifosfamide, lomustine, mecholarethamine, melphalan, procarbazine, streptozocin, and thiotepa.
Examples of antineoplastic antibiotics include bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitomycin (e.g., mitomycin C), mitoxantrone, pentostatin, and plicamycin.
Examples of antimetabolites include fluorodeoxyuridine, cladribine, cytarabine, floxuridine, fludarabine, flurouracil (e.g., 5-fluorouracil (5FU)), gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and thioguanine.
Examples of natural source derivatives include docetaxel, etoposide, irinotecan, taxanes (e.g. paclitaxel), teniposide, topotecan, vinblastine, vincristine, vinorelbine, prednisone, and tamoxifen.
Additional examples of chemotherapeutic agents that can be used in the invention include asparaginase and mitotane.
Furthermore, also C2 ceramide can be used.
In an especially preferred embodiment, the chemotherapeutic drug is selected from the group consisting of actinomycin-D, mitomycin C, cisplatin, doxorubicin, etoposide, verapamil, podophyllotoxin, 5-FU, taxans such as paclitaxel, and carboplatin. sTNFR2 can be removed by any means known to the person skilled in the art. Preferably, sTNFR2 is removed with the help of a molecule binding to sTNFR2. Such molecules are discussed in detail above. Furthermore, such molecules also include molecules that do not bind specifically to sTNFR2, as e.g. polyclonal antibodies recognizing soluble TNF receptor 2 and soluble TNF receptor 1.
In a preferred embodiment, said molecule is an antibody against sTNFR2, preferably a monoclonal antibody against sTNFR2. Such antibodies have also been described above.
The invention further relates to a molecule binding to sTNR2 for use in a method for sensitizing a tumor patient to a treatment with a chemotherapeutic agent. Such molecules have been described in detail above, and all these embodiments also apply to this aspect of the invention.
In a preferred embodiment, the molecule is an antibody against sTNFR2, preferably a monoclonal antibody against sTNFR2.
The invention further relates to a method for treating a tumor in a patient, comprising administering to a patient a chemotherapeutic drug in an amount sufficient for the treatment of the tumor, wherein from the blood of said patient sTNFR2 has been removed.
The treatment of tumors with chemotherapeutic agents is a standard procedure known to the person skilled in the art. All embodiments defined above also apply to this aspect of the invention. Examples of chemotherapeutic agents which can be used in the context of the present invention are given above.
Furthermore, the present invention also relates to a chemotherapeutic agent for use in a method for treating a tumor in a patient, wherein from the blood of said patient sTNFR2 has been removed. All embodiments discussed above also apply to this aspect of the invention.
The invention is further explained by the following example and figures, which are intended to illustrate, but not limit the scope of the present invention.
Figures
Figure 1 shows an exemplary treatment scheme.
Figure 2 shows the apheresis equipment. In the first part of the system (single arrow, — blood was pumped from the animal (A. carotis) via a plasma separator and retraced to the animal by a venous catheter. The separated plasma entered the second circuit (double- lined arrow, — and passed the adsorber before it was returned to the rat ( V. jugular is).
Figure 3 shows the mean tumor diameter in tumor-bearing Brown Norway rats treated with Sham apheresis (dashed line, open circles) or sTNFR2 apheresis (solid line, filled squares), respectively, and 0.25 mg/kg melphalan. The results of two independent study parts, study part I (3 A) and study part II (3B), are shown.
Figure 4 shows the change of mean tumor diameter during course of treatment of tumor- bearing Wag/Rij rats treated with Sham apheresis and 0.25 mg/kg low dose melphalan (Sham low, solid line, diamonds) or sT FR2 apheresis (sTNFR2 low, dotted line, squares), respectively Sham apheresis or sTNFR2 apheresis at high melphalan concentrations of 0.50 mg/kg (Sham high, dotted line, triangles, respectively sTNFR2 high, solid line, circles)
Figure 5 shows the body weight of Wag/Rij rats during the course of treatment with low doses of melphalan (0.25 mg/kg), Sham apheresis (Sham low, solid line, diamonds), sTNFR2 apheresis (sTNFR2 low, dotted line, squares) and with high doses of melphalan (0.50 mg/kg) and Sham apheresis (Sham high, dotted line, triangles), respectively sTNFR2 apheresis (sTNFR2 high, solid line, circles).
Figure 6 shows the mean tumor diameter measured in tumor-bearing WAG/Rij rats during the course of treatment. CO-low and CO-high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high). Oncosorb-low are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2, sTNFRl and IL-2R and repetitive administration of 0.25 mg/kg Melphalan.
Figure 7 shows the body weight of tumor-bearing WAG/Rij rats during the course of treatment. CO-low and CO-high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high). Oncosorb-low are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2, sTNFRl and IL-2R and repetitive administration of 0.25 mg/kg Melphalan.
References
US 4,708,713
US 6,620,382
WO 01/37873
WO 05/107802
Brunstein F, Hoving S, Seynhaeve AL, van Tiel ST, Guetens G, de Bruijn EA, Eggermont AM, ten Hagen TL; Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies; J Natl Cancer Inst. 2004 Nov 3;96(21): 1603-10.
Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM; Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat; Br J Surg. 1996 Apr;83(4):551 -5.
Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL; Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats; Cancer Res. 2005 May 15;65(10):4300-8.
Lentz M, Kumar K; Reduction of plasma levels of soluble tumor necrosis factor and interleukin-2 receptors by means of a novel immunoadsorption column, Ther Apher Dial. 2008 Dec; 12(6):491 -9.
Examples
Example 1
Example 1 shows the influence of the removal of sTNFR2 in Wag/Rij rats bearing the immunogenic ROS-1 osteosarcoma on tumor growth and animal weight in the presence of systemically administered melphalan.
Aim
The project aimed to confirm the efficacy of the combination of Melphalan chemotherapy and the removal of sTNFR2 by apheresis in a tumor model using Wag/Rij rats bearing the immunogenic ROS-1 osteosarcoma. In addition, the experiments also aimed to find the optimal dosage of highly toxic Melphalan, combined with apheresis treatment.
1. Material and Methods
1.1. Animals
WAG/Rij rats with a mean body weight of 200 g (N = 20), were purchased from Harlan Laboratories (Niederlande) on 5th of April 2012. As soon as the animals arrived in the test facility, they were housed individually in separated cages under following conditions:
• Temperature of 21+2°C
• Relative humidity (45-65%)
• 12-h/12-h dark/light cycle (lights on at 06:00 AM)
• Ad libitum access to tap-water and commercial pelleted laboratory chow (Art. No. VI 536; Ssniff® Spezialdiaten GmbH, D-59494 Soest, Germany)
During the study strict hygiene conditions were maintained. One to two weeks of acclimatization were allowed. During this period, the rats were periodically handled in order to limit animal stress during the study phase.
1.2. Preparation of Adsorber Columns
The preparation of columns was done by Biopheresis GmbH in Heidelberg. NHS activated 1 ml Sepharose columns were purchased from GE Healthcare (Order No. 17-0716.01). Based on the amount of antibodies used for human treatment using the OncoSorb® column, 0.12 mg of affinity purified goat anti -mouse sTNFR2 antibodies (purchased from R&D Systems Order No. AF-426-PB) were coupled according to the manufacturer's procedure to NHS activated Sepharose. The antibodies were able to remove secreted rat sTNFR2 molecules out of rat plasma as shown by affinity purification of the receptor from
rat plasma. The antibodies of one type were from the same batch to ensure optimal comparability.
1.3. Tumor tissue handling and transfer:
Frozen ROS-1 tumor cells, delivered from Prof. T. Ten Hagen in March 2012 and stored at -70°C up to the culturing, were thawed on 3rd of March and transferred in Minimum
Essential Medium Eagle (SIGMA- ALDRICH, M4655) containing 10% fetal calf serum (FCS) 2012. After cultivation in a culture flask with DMEM and 10% FCS during 8 days, the cells were adhered by trypsination and counted. 1.5 Mill, cells per animal were injected subcutaneously in tested Wag rij rats on 1 1th of April.
Under light inhalation anaesthesia (Sevorane®), ROS-1 tumor cells (1.500.000 in 500 μΐ per animal) were injected under the skin of the left flank region of the WAG rat to induce cancer growth (the method was detailed by Prof, ten Hagen; Rotterdam).
Rats with palpable tumors were instrumented with a chronic arterial and venous catheter. The catheters were inserted under general anaesthesia (i.p. injection of 0.8 mg Rompun®, Bayer and 4 mg Ketamin®, Sanofi, Germany) into the Arteria carotis and the Vena jugularis. Catheters were flushed with heparinized saline three times per week before the study.
When the tumor was grown to a mean diameter of >11 ± 3 mm, first chemotherapy and apheresis therapy was initiated on the following day.
1.4. Apheresis equipment
Before each apheresis treatment, a heparin bolus was given (90 IU/100 g body weight (b.w.)). The extracorporeal system was fully filled with heparinized saline and thereafter, the catheter endings were connected with the extracorporeal system as shown in Figure 2.
In the first part of the system, blood was pumped (multi-channel pump, Petro Gas Ausriistungen, Berlin, Germany) from the animal (A. carotis) via a plasma separator (Saxonia medical and Alpha Plan, Radeberg, Germany) and retraced to the animal by a venous catheter. The separated plasma entered the second circuit and passed the adsorber before it was returned to the rat (V. jugularis).
The following parameters were measured before and after each apheresis:
1. Bound sTNFR2 was determined by elution of the respective (bound) protein from the column after each apheresis by analysis of the eluate.
2. The following parameters were determined before and after each plasmapheresis: a. ) Hematocrit
b. ) White blood cell counts
c. ) Body temperature (one hour after the end of apheresis)
d. ) Body weight
e. ) Plasma was sampled (300 μΐ blood) for later determination of concentrations of TNF-a and IL-2.
The rats were sacrificed 21 days after first apheresis treatment. 50 % of the tumor (maximally a piece of 2 x 2 cm) was fixed in formalin to determine necrotic tissue and a comparable piece was shock-frozen and stored at -70°C for later histological investigation.
1.5. Preparation of the columns before and after apheresis:
Before each plasmapheresis each column was flushed with at least 6 ml 0.9% saline. After the apheresis treatment, each column was treated in the following way:
1. It was rinsed with 12 ml 0.9% saline.
2. It was washed with 3 ml glycine buffer (pH 2.8) to elute the bound proteins/factors.
3. It was washed with 6 ml 0.9% saline.
4. Column was kept in PBS-azide (for storage).
The eluate from each column was frozen for further analyses.
1.6. Chemotherapy and Apheresis:
The apheresis treatment was combined with intra-venous chemotherapy directly after the apheresis treatment . All animals were repeatedly administered a chemotherapeutic drug (Melphalan: Alkeran® , GlaxoSmithKline).
Each animal was treated with up to 6 apheresis cycles in intervals of 2-3 days (2-3 cycles per week). The duration of each plasmapheresis was one hour.
The adsorbers for the plasmapheresis procedure with a volume of 1 ml were provided by BioPheresis GmbH.
1.7. Treatment scheme
Table 1: Treatment scheme
The first apheresis therapy was initiated directly when the tumor was grown to a mean diameter of 11±3 mm, followed by application of melphalan chemotherapy (day 0). On day 2, the second apheresis was performed and also the second Melphalan injection was administered. Melphalan was administered two times per week, for two weeks (four injections). Apheresis treatments were performed three times per week, for two weeks.
The animals were monitored without further treatment up to day 21.
Groups:
Sham: Sarcoma wearing rats with Sham apheresis (using the "empty HiTrap column") and 0.25 mg/kg low dose Melphalan (n=2) respectively 0.50 mg/kg (high dose) Melphalan (n=2)
sTNFR2 Sarcoma wearing rats with TNFR2 apheresis and low dose (0.25 mg/kg)
Melphalan (n=2) respectively 0.50 mg kg (high dose) Melphalan (n=2)
1.8. Monitored parameters:
Parameters monitored daily
• Body weight daily
• Health status
• Tumor growth, daily measurement of tumor size with a calliper
Parameters monitored before and after apheresis:
• Hematocrit
• Body temperature
At the end of the study, 21 days after tumor tissue transplantation, the tumor tissue was taken out, weighted and conserved for optional later histological investigation.
2. Ethics
The study was be performed under the animal license of the Institut fur Diabetes "Gerhard Katsch" GmbH , Karlsburg, Germany. Procedures related to this study have been reviewed and approved for the Institut fur Diabetes "Gerhard Katsch" GmbH, Karlsburg, Germany by the Animal Ethics Committee of the Country Mecklenburg- Vorpommern, Schwerin,
3. Data handling and mathematical analysis
All data were documented for statistical evaluations with Excel 2003. For calculation of the tumor size, the mean tumor diameter was calculated each day for each animal. Results were expressed as the means ± SD for each experimental group. By separate analysis the
tumor diameter for each study part and the comparable tendency concerning the tumor growth depression was shown. The body weight and the tumor diameter were analyzed in dependence of the days after the first apheresis.
4. Results
4.1. Follow-up parameter
Tumour growth (delta mean tumour diameter)
The animals met inclusion criteria (mean diameter 1 1 ± 3 mm) 26 to 29 days after tumor cell injection. In the group of Sham apheresis / melphalan treated rats tumour size increased continuously during the twenty-one days of monitoring. In the sTNFR2 / melphalan group a tendency to a reduced tumour growth was shown from day 5 on.
The described effects are summarized in Table 2 and shown in figure 4 as the change of tumor size compared to initial size (delta mean diameter).
Sham low and Sham high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high). sTNFR2 high and low, respectively, are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2.
The data demonstrate that removal of sTNFR2 by apheresis had a significant impact to reduce tumor growth even in the animals that were treated with the lower dose of 0.25 mg/kg Melphalan. The reduction of tumor growth was comparable to that observed with control animals that were treated with a higher dose of 0.50 mg/kg melphalan and that had been treated with a Sham apheresis that does not remove sTNFR2.
It appears that removal of sTNFR2 is sensitizing the tumor for melphalan treatment, which would allow a reduction of melphalan level in the plasma, which is beneficial for better toleration of the cytotoxic substance melphalan.
Sham low day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 47 0.00 1.04 1.67 1.73 1.17 2.23 2.87 2.33 2.11 2.56 3.74 3.43 1.90 6.39 6.67 6.80 7.93 7.05 8.57 8.99 8.87 14,21
S 30 0.00 -0.62 0.39 0.30 1.28 0.74 2.01 1.98 3.40 3.47 2.83 4.93 4.57 5.82 5.22 7.20 7.12 7.44 9.68 7.55 8.66 mean 0.00 0.21 1.03 1.01 1.23 1.49 2.44 2.15 2.75 3.01 3.29 4.18 3.23 6.10 5.94 7.00 7.52 7.24 9.12 8.27 8.77
SD 0.00 1.17 0.91 1.01 0.08 1.05 0.61 0.25 0.91 0.65 0.64 1.06 1.88 0.41 1.03 0.28 0.57 0.27 0.78 1.02 0.15
STNFR2 low day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 40 0.00 1.34 2.53 0.98 0.21 2.48 1.14 2.52 1.10 3.44 3.50 4.16 3.62 4.05 4.99 5.32 6.14 6.24 7.09 6.34 8.85 8,42
S 48 0.00 -0.55 0.27 -1.00 0.58 0.73 0.92 1.11 0.78 1.60 -2.07 1.81 2.16 3.50 3.34 3.25 2.34 3.80 4.26 5.55 4.95 mean 0.00 0.39 1.40 -0.01 0.40 1.61 1.03 1.82 0.94 2.52 0.72 2.98 2.89 3.78 4.17 4.28 4.24 5.02 5.67 5.95 6.90
SD 0.00 1.33 1.60 1.41 0.26 1.24 0.16 1.00 0.23 1.30 3.94 1.66 1.03 0.39 1.17 1.47 2.69 1.73 2.01 0.56 2.76
Sham high day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 39 0.00 0.10 1.48 0.33 -0.26 0.61 1.88 2.12 1.60 2.67 1.82 4.50 3.74 4.47 6.62 4.79 5.75 6.63 6.26 5.82 7.84 7,14
S 42 0.00 -1.55 -1.60 -0.20 2.04 0.66 1.25 0.38 -0.33 0.51 1.73 2.77 0.09 1.50 1.47 1.64 2.57 1.94 0.42 5.24 3.01 mean 0.00 -0.72 -0.06 0.06 0.89 0.64 1.56 1.25 0.63 1.59 1.78 3.63 1.92 2.98 4.04 3.21 4.16 4.28 3.34 5.53 5.42
SD 0.00 1.16 2.17 0.38 1.62 0.03 0.44 1.23 1.36 1.52 0.06 1.23 2.58 2.10 3.64 2.22 2.25 3.32 4.13 0.41 3.41
STNFR2 high day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 21 0.00 -0.36 0.26 -0.23 0.72 0.85 -0.58 1.68 1.89 1.37 1.68 2.91 3.12 3.76 3.33 3.20 4.70 4.69 4.91 5.64 6.79 6,97
S 45 0.00 0.68 -0.67 0.38 0.78 1.29 0.94 0.48 1.94 3.79 2.72 2.40 3.44 2.75 2.77 3.46 3.16 3.30 6.29 5.91
mean 0.00 0.16 -0.21 0.08 0.75 1.07 0.18 1.08 1.92 2.58 2.20 2.66 3.28 3.25 3.05 3.33 3.93 3.99 5.60 5.78
SD 0.00 0.74 0.66 0.43 0.04 0.31 1.08 0.85 0.04 1.71 0.73 0.36 0.22 0.71 0.39 0.19 1.09 0.98 0.97 0.19
Table 2. Delta mean tumor diameter, the difference to tumor diameter measured at each animal at the days of the first apheresis, in mm. Sham low and Sham high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high). sTNFR2 high and low, respectively, are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2.
Body weight
Two days after tumour tissue transfer, the rats had a body weight of 242 ± 8 g. The procedure of catheter insertion was followed by a decline of body weight during the next days and the initial body weight was reached again after 4 to 7 days. The start of apheresis treatments and Melphalan applications was followed by a decline in body weight gain surprisingly only in the Sham apheresis control group. The interruption of Melphalan treatment from day 2 to 7 followed by a slight reincrease of body weight in the both groups and the treatment with chemotherapeutic on day 7 induced a slight reduction again.
In the groups treated with TNFR-2 apheresis no prominent decline of body weight was induced by the Melphalan treatment.
It appears that removal of TNFR-2 by apheresis has a similar effect in a rat model as the administration of TNF in limb perfusion experiments, as published by Prof. Timo ten Hagen. He has shown that the Melphalan uptake in tumor tissue is enhanced after addition of TNF. This could lead to a reduction of melphalan level in the plasma, which is beneficial for better toleration of the cytotoxic substance Melphalan.
Body weight development of WG rats injected with sarcoma cells and treated with apheresis and Melphalan from day 0 on are summarized in Table 3 and shown in figure 5, where means of two animals per group are shown.
Sham low and Sham high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high). sTNFR2 high and low, respectively, are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2.
Sham low day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 47 269 266 272 264 265 269 272 276 269 275 268 279 268 273 274 279 284 282 285 290 293 292
S 30 264 256 256 263 264 264 262 268 265 269 257 266 263 268 271 275 277 282 283 280
mean 267 261 264 264 265 267 267 272 267 272 263 273 266 271 273 277 281 282 284 285
SD 4 7 11 1 1 4 7 6 3 4 8 9 4 4 2 3 5 0 1 7
STNFR2
low day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 40 283 278 282 278 284 275 282 283 281 288 280 286 282 286 290 294 295 301 304 306 308
S 48 266 263 270 267 274 273 276 282 280 286 282 287 278 288 290 292 295 299 301 303
mean 275 271 276 273 279 274 279 283 281 287 281 287 280 287 290 293 295 300 303 305
SD 12 11 8 8 7 1 4 1 1 1 1 1 3 1 0 1 0 1 2 2
Sham high day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 39 275 266 269 261 268 268 272 270 276 268 266 267 269 275 280 280 282 283 287 287
S 42 266 252 243 243 245 250 249 254 251 255 252 259 254 263 268 269 272 278 283 281 mean 271 259 256 252 257 259 261 254 261 266 260 263 261 266 272 275 276 280 283 284
SD 6 10 18 13 16 13 16 n.a. 13 15 11 5 9 4 5 8 6 3 0 4
STNFR2
high day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 21 265 272 278 275 276 263 269 275 266 265 262 266 268 275 278 280 284 287 294 295 290
S 45 300 293 294 289 290 289 295 299 298 298 290 300 298 300 295 302 305 309 307
mean 283 283 286 282 283 276 282 287 282 282 276 283 283 288 287 291 295 298 301
SD 25 15 11 10 10 18 18 17 23 23 20 24 21 18 12 16 15 16 9
Table 3. Body weight (g) during the course of treatment. The first apheresis started on day 0. Sham low and Sham high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high). sTNFR2 high and low, respectively, are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR.2.
Hematocrit, Body temperature
No significant difference between the different groups has been observed during the observation period.
5. Conclusions
• Plasmapheresis was well tolerated in all animals.
• Removal of sTNFR2 by plasmapheresis in the presence of melphalan (0.25 mg/ kg rat body weight twice per week) has a tumor growth inhibiting effect.
• The data indicate that the tumor is sensitized for melphalan by removal of sTNFR2 with apheresis.
Example 2
Example 2 shows the influence of the removal of sTNFR2 simultaneous with sTNFR2 and IL-2R (Oncosorb® columns) in Wag/Rij rats bearing the immunogenic ROS-1 osteosarcoma on tumor growth and animal weight in the presence of systemically administered melphalan.
Aim
The project aimed to study if the efficacy of the combination of Oncosorb® Apheresis (the simultaneous removal of sTNFR2, sTNFRl and IL-2R) and Melphalan in a tumor model is comparable to the removal of sTNFR2 alone. In addition, the experiments also aimed to find the optimal dosage of low toxic Melphalan, combined with Oncosorb® apheresis treatment.
1. Material and Methods
1.1. Animals
WAG/Rij rats with a mean body weight of 200 g were purchased from Harlan Laboratories (Niederlande) on 5th of April 2012. They were housed individually in separated cages under identical conditions as described for example 1. The rats were periodically handled in order to limit animal stress during the study phase.
1.2. Preparation of Adsorber Columns
The preparation of columns was done by Biopheresis GmbH in Heidelberg. The procedure, reagents and consumables were identical as described for example 2, except that instead of sTNFR2 antibodies alone, a combination of 3 antibodies equivalent to that used in Oncosorb® columns for use in humans was used: For the 1 ml "Oncosorb®" columns used in example 2 a mixture of 0.12 mg of affinity purified goat anti-mouse sTNFR2 antibodies
(purchased from R&D Systems Order No. AF-426-PB), 0.12 mg of affinity purified goat anti-mouse sTNFRl antibodies (purchased from R&D Systems Order No. AF-425-PB) and 0.2 mg of affinity purified mouse anti-rat IL-2R ALPHA CHAIN antibodies (purchased from AbD SEROTEC Order No. MCA273EL) was immobilized on each 1 ml HiTrap Adsorber column. sTNFR2 antibodies were from the same batch as used in Example 1 to ensure optimal comparability.
1.3. Tumor tissue handling and transfer:
Tumor tissue handling and transfer was identical as described in Example 1.
1.4. Apheresis equipment
Apheresis equipment and procedure of apheresis treatment (including handling / rinsing of Adsorber columns before and after apheresis) was identical as for Example 1.
1.5. Chemotherapy and Apheresis:
The application of chemotherapy and the apheresis procedure was identical as for Example 1.
1.6. Treatment scheme
The first apheresis therapy was initiated directly when the tumor was grown to a mean diameter of 1 1±3 mm, followed by application of melphalan chemotherapy (day 0). On day 2, the second apheresis was performed and also the second Melphalan injection was administered. Melphalan was administered two times per week, for two weeks (four injections). Apheresis treatments were performed three times per week, for two weeks. The animals were monitored without further treatment up to day 21.
Table 4: Treatment scheme
Groups:
Control (CO) Sarcoma wearing rats with Sham apheresis (using the "empty HiTrap column") and 0.25 mg/kg low dose Melphalan (n=2) respectively 0.50 mg/kg (high dose) Melphalan (n=2)
Oncosorb® Sarcoma wearing rats with Oncosorb® apheresis and low dose (0.25
mg/kg) Melphalan medication (n=4)
1.7. Monitored parameters:
Parameters monitored daily
• Tumor growth (measurement of tumor size with a calliper)
• Body weight
Parameters monitored before and after apheresis:
• Hematocrit
• Body temperature
At the end of the study, 21 days after tumor tissue transplantation, the tumor tissue was taken out, weighted and conserved for optional later histological investigation.
2. Ethics
The study was be performed under the animal license of the Institut fur Diabetes "Gerhard Katsch" GmbH , Karlsburg, Germany. Procedures related to this study have been reviewed and approved for the Institut fur Diabetes "Gerhard Katsch" GmbH, Karlsburg, Germany by the Animal Ethics Committee of the Country Mecklenburg- Vorpommern, Schwerin,
3. Data handling and mathematical analysis
Data handling and mathematical analysis was identical as described for example 1 and 2.
4. Results
4.1. Follow-up parameter
Tumour growth (delta mean tumour diameter)
The animals met inclusion criteria (mean diameter 11 ± 3 mm) 26 to 29 days after tumor cell injection.
In the group of sham apheresis treated rats given low doses of Melphalan (CO-low), tumour size increased continuously during the twenty-one days of monitoring. The high dose Melphalan given on days 0, 2, 7 and 9, respectively, combined with sham apheresis treatment (CO-high) reduced tumour growth significantly during treatment.
Surprisingly, the tumor growth inhibiting effect of Oncosorb® apheresis in combination with low doses Melphalan treatment (Oncosorb®-low), was equally strong as that of high dose melphalan treatment and Sham apheresis (CO-high). A reduced tumour growth was observed both during treatment from day 2 to 9 (compared with CO-low) as well as after the end of the apheresis treatment and chemotherapeutic medication period from day 12 on.
4.2. Additional Findings
Several animals showed inflammatory reactions or reactions similar to an inflammatory reaction, i.e., fluid accumulation around the tumor. These reactions explain the outlier at day 10. For series conducted with Oncosorb® and a high dose of Melphalan, the aforementioned effect was more severe and partly led to outliers that are not shown.
Sham Apheresis + (4 x 0.25 mg/kg) low dose Melphalan
day after treatment start
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 47 0.00 3.04 5.79 5.85 5.29 6.350 6.99 6.45 6.23 6.68 7.86 7.55 6.02 10.51 10.79 10.92 12.05 11.17 12.69 13.11 12.99 18.3
S 30 0.00 -0.61 0.39 0.30 1.28 0.75 2.01 1.98 3.39 3.47 2.83 4.93 4.57 5.81 5.22 7.20 7.12 7.44 9.68 7.55 8.65 10.7
S 35 0.00 0.21 1.67 3.39 4.20 5.29 4.29 3.84 5.89 6.09 6.16 6.67 9.69 8.58 9.25 10.03 11.43 9.55 13.61 14.59 13.2 mean 0.00 0.88 2.62 3.18 3.59 4.13 4.43 4.22 4.48 5.34 5.59 6.21 5.75 8.67 8.19 9.12 9.73 10.01 10.64 11.42 12.08 14.1
SD 0.00 1.91 2.82 2.78 2.07 2.98 2.49 3.16 1.52 1 .67 2.55 1.31 1.08 2.51 2.81 1.86 2.48 2.24 1.78 3.36 3.07 3.85
CO-high Sham Apheresis + (4 x 0.5 mg/kg) high dose Melphalan
day after treatment start
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 39 0.00 0.10 1.48 0.33 -0.25 0.61 1.88 2.12 1.60 2.67 1.82 4.50 3.74 4.46 6.62 4.78 5.75 6.63 6.26 5.82 7.84 7.13
S 42 0.00 -1.55 -1.60 -0.20 2.04 0.65 1.25 0.38 -0.33 0.52 1.73 2.77 0.09 1.50 1.47 1.64 2.57 1.94 0.42 5.24 3.01 6.48 mean 0.00 -0.72 -0.06 0.06 0.89 0.63 1.56 1.25 0.63 1.59 1.78 3.63 1.91 2.98 4.05 3.21 4.16 4.28 3.34 5.53 5.42 6.80
SD 0.00 1.16 2.17 0.38 1.62 0.03 0.45 1 .23 1.36 1.52 0.06 1.23 2.59 2.09 3.64 2.22 2.25 3.32 4.13 0.41 3.41 0.46
Oncosorb- low Oncosorb Apheresis + (4 x 0.25 mg/kg) low dose Melphalan
day after treatment start
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 29 0.00 1.14 1.48 0.59 3.08 2.01 2.99 2.70 3.38 3.09 14.10 11.82 9.33 8.58 8.31 7.01 8.84 8.61 7.84 8.11 8.86 9.37
S 28 0.00 -0.76 -1.63 -0.95 0.23 0.20 -0.59 0.03 0.50 -0.80 0.38 1.20 -0.83 1.08 2.89 2.07 4.94 4.42 3.10 3.66 4.49 4.02
S 22 0.00 1.04 0.94 1.35 2.09 2.30 2.51 0.93 2.65 4.35 4.52 5.89 4.45 4.07 4.66 4.95 7.10 7.78 10.51 9.90 3.33 13.0
mean 0.00 0.47 0.26 0.33 1.80 1.50 1.64 1.22 2.18 2.21 6.33 6.30 4.31 4.57 5.29 4.67 6.96 6.94 7.15 7.23 5.56 8.8
SD 0.00 1.07 1.66 1.17 1.45 1.13 1.94 1.36 1 .50 2.68 7.04 5.32 5.08 3.78 2.76 2.48 1.95 2.22 3.75 3.21 2.92 4.5
Table 5. Delta mean tumor diameter, the difference to tumor diameter measured at each animal at the days of the first apheresis, in mm. Sham low and Sham high are control data where animals have been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high). sTNFR2 high and low, respectively, are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2.
Body weight
The body weight (cf., Figure 7) of the tested animals at the start of treatment was comparable between the investigated groups. Two days after tumor tissue transfer the rats had a weight of 242 ± 8 g. The procedure of catheter insertion followed a decline of body weight for several days. The initial body weight was reached again after 4 to 7 days.
The body weight of Melphalan/apheresis treated animals was followed by a decline in body weight gain in the both control groups (CO-low and CO-high). The weight loss was more prominent and with a longer duration in the group administered the higher Melphalan dose (CO-high; 0.5 mg/kg). The interruption of Melphalan treatment from day 2 to 7 was followed by a slight increase of body weight in the both groups. Repetitive treatment with chemotherapeutic agent on day 7 induced once more a slight body weight reduction.
In the both groups treated with Oncosorb® apheresis (Oncosorb® -low and Oncosorb® - high) nearly the same body weight behaviour during apheresis treatment was seen as in the control groups.
CO-low
day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 47 269 274 269 266 272 264 265 269 272 276 269 275 268 279 268 273 274 279 284 282 285 290 S 30 264 256 256 263 264 264 262 268 265 269 257 266 263 268 271 275 277 282 283 280 286 285 S 35 269 261 265 263 267 264 267 273 265 272 265 272 268 273 277 279 276 283 285 283 284 286 mean 267 265 263 265 268 264 264 269 269 273 263 271 266 274 270 274 276 281 284 281 286 288 SD 4 13 9 2 6 0 2 1 5 5 8 6 4 8 2 1 2 2 1 1 1 4
CO-high
day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
S 39 275 266 269 261 268 268 272 270 276 268 266 267 269 275 280 280 282 283 287 287 288
10 S 42 266 252 243 243 245 250 249 254 251 255 252 259 254 263 268 269 272 278 283 281 284 288 mean 271 259 256 252 257 259 261 254 261 266 260 263 261 266 272 275 276 280 283 284 286 288 SD 6 10 18 13 16 13 16 13 15 11 5 9 4 5 8 6 3 0 4 2 0
Oncosorb-low
day
Animal-No. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 li
S 29 277 283 269 275 276 277 279 284 287 287 292 286 296 291 301 296 303 300 306 308 312 312 S 28 269 261 267 265 270 267 272 277 272 277 272 279 276 277 280 283 284 287 290 289 291 290 S 22 240 247 239 243 237 245 242 248 254 249 253 247 247 249 256 257 261 261 264 266 272 273 S 26 253 262 254 261 256 262 257 262 263 260 262 253 253 255 259 259 259 259 283 269 272 273 mean 260 263 257 261 260 263 263 268 269 268 270 266 268 268 274 274 277 277 286 283 287 287 SD 17 15 14 13 17 13 16 16 14 17 17 19 22 19 21 19 21 20 17 20 19 18
Table 6. Body weight (g) during the course of treatment. The first apheresis started on day 0. CO-low and CO-high are control data where animals ha been treated with "empty HiTrap columns" (containing 1 ml NHS activated Sepharose, that have undergone the same blocking procedure as antibody loaded columns), and repetitive administration of 0.25 mg/kg (low) respectively 0.50 mg/ml (high). Oncosorb-low are data where animals have been treated with apheresis using specifically loaded apheresis columns that can specifically bind sTNFR2, sTNFRl and IL-2R and repetitive administratio of 0.25 mg/kg Melphalan.
Hematocrit, Body temperature
No significant difference between the different groups has been observed during the observation period, indicating that the removal of sTNFR2 together with sTNFRl and IL- 2R by apheresis was well tolerated.
5. Conclusions
• Removal of sTNFR2 together with sTNFRl and IL-2R by Oncosorb® apheresis treatment in combination with low dose melphalan treatment (0.25 mg/ kg rat body weight twice per week) has a tumor growth inhibiting effect equivalent to high dose melphalan (0.50 mg/ kg rat body weight twice per week) and sham apheresis
• As a consequence, removing sTNFR2 together with sTNFRl and IL-2R by apheresis allows to reduce the concentration of Melphalan during a typical chemotherapy, thus reducing the strong side effects of highly toxic chemotherapy.
• Removal of sTNFR2, sTNFRl and IL-2R by Oncosorb® plasmapheresis in the presence of melphalan (0.25 mg/ kg rat body weight twice per week) has no effect on body weight loss, body temperature and Hematocrit compared to the control groups
• As in Example 1, this demonstrates that Plasmapheresis was well tolerated in all animals.
Claims
1. A molecule binding to soluble tumor necrosis factor receptor 2 (sTNFR2) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is used to remove sTNFR2 from a body fluid of said patient.
2. The molecule for use according to claim 1, wherein said molecule is immobilized on a solid support that is contacted with a body fluid of said patient.
3. The molecule for use according to any of claims 1 or 2, wherein further another soluble cytokine receptor of an immunomodulatory cytokine is removed from the body fluid of said patient, preferably said receptor is a receptor of a proinflammatory cytokine, more preferably a receptor of a Thl-type cytokine, in particular wherein the soluble cytokine receptor is selected from the group consisting of soluble tumor necrosis factor receptor 1 (sTNFRl), soluble interleukin-2 receptor (sIL2R), soluble interleukin- 1 receptor (sILlR), soluble interleukin-6 receptor (sIL6R), soluble interleukin- 12 receptor (sIL12R), soluble interleukin- 18 receptor (sIL18R), soluble interleukin-23 receptor (sIL23R), soluble granulocyte macrophage colony-stimulating factor receptor (sGM-CSFR), soluble transforming growth factor beta receptor (sTGFpR) or soluble interferon gamma receptor (sIFNyR), and/or
wherein the soluble cytokine receptor is a soluble tumor necrosis factor receptor or a soluble interleukin receptor, more preferably wherein said soluble cytokine receptor is selected from the group consisting of:
i) sTNFRl ; and
ii) sIL2R.
4. The molecule for use according to any one of claims 1 to 3, wherein said molecule is selected from the group consisting of:
(i) an antibody, preferably a monoclonal antibody, a single domain antibody, an antibody fragment or an antibody mimetic;
(ii) a cofactor,
(iii) a cytokine, in particular tumor necrosis factor alpha (TNFSF2) or TNFSF2 mutein;
(iv) a synthetic polypeptide, in particular Staphylococcus aureus Protein A, human LDL receptor, lipocalin or fibronectin; and/or
(v) a small molecule, in particular an ensemblin, a macrocyclic scaffold, an Aptamers and/or a peptide staple;
more preferably wherein said molecule is an antibody, in particular wherein said molecule is a monoclonal antibody or a single domain antibody.
The molecule for use according to any one of claims 1 to 4, wherein the solid support forms part of an extracorporeal device through which the patient's body fluid can be circulated prior to being returned into said patient or forms part of an implant, in particular wherein said solid support is an extracorporeal device comprising at least one of the following:
(i) a column, in particular an adsorbent column;
(ii) a filter, in particular a capillary membrane filter with a pore size of between about 0.04 and 0.05 μιη or a parallel plate filter with a pore size of between about 0.04 and 0.08 μηι;
(iii) semi-permeable material, preferably a membrane, in particular a dialysis membrane;
(iv) a bead, in particular a microbead or a nanobead; and/or
(v) the surface of said device, in particular the surface of a tubing of said device.
The molecule for use according to any one of claims 1 to 5, wherein the solid support forms part of an extracorporeal device further comprising at least one of the following:
(i) a primary filter to separate ultrafiltrate or plasma from the patient's blood;
(ii) a centrifuge to separate ultrafiltrate or plasma from the patient's blood;
(iii) a filter which removes components of a molecular weight of 120,000 Da or less from the blood, plasma or blood fraction;
(iv) a centrifuge which removes components of a molecular weight of 120,000 Da or less from the blood, plasma or blood fraction;
(v) means for administering radiation to patent's tissue; and/or
(vi) one or more cannula(s) and tubing(s) suitable for connecting the device to the patient.
The molecule for use according to any one of claims 1 to 6, wherein the chemotherapeutic agent is an alkylating agent, preferably a nitrogen mustard alkylating agent, in particular Melphalan.
8. The molecule for use according to any one of claims 1 to 7, wherein said molecule is contacted with the body fluid of the patient prior to, concomitantly with and/or subsequent to administering the chemotherapeutic agent to said patient.
9. The molecule for use according to any one of claims 1 to 8, wherein the time interval between contacting said molecule with the body fluid of the patient and administering said chemotherapeutic agent is not longer than seven days, preferably not longer than 5 days, in particular not longer than 3 days.
10. The molecule for use according to any one of claims 1 to 9, wherein said molecule is contacted with the body fluid of the patient repeatedly, preferably at least three times.
1 1. The molecule for use according to any one of claims 1 to 10, wherein the body fluid is selected from the group consisting of blood, plasma, lymph and extracellular matrix.
12. The molecule for use according to any one of claims 1 to 1 1, wherein the patient is at least partly resistant to the chemotherapeutic agent and/or is suffering from at least one undesired side effect caused by said chemotherapeutic agent.
13. The molecule for use according to any one of claims 1 to 12, wherein said molecule is for use in a method for treating cancer in the patient.
14. A body fluid from which at least one soluble cytokine receptor has been removed for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent.
15. The body fluid for use according to claim 14, wherein said body fluid is selected from the group consisting of blood, plasma, lymph and extracellular matrix.
16. The body fluid for use according to claim 14 or 15, wherein the soluble cytokine receptor has been removed by means of a molecule as defined in any one of claims 1 to 13.
17. A chemotherapeutic agent for use in a method for treating a tumor in a patient, wherein at least one soluble cytokine receptor has been removed from a body fluid of said patient by means of a molecule as defined in any one of claims 1 to 13 for sensitizing a tumor cell of said tumor in said patient to a treatment with said chemotherapeutic agent.
18. The chemotherapeutic agent for use according to claim 17, wherein the patient is a cancer patient, preferably wherein said patient is at least partly resistant to the chemotherapeutic agent and/or is suffering from at least one undesired side effect caused by said chemotherapeutic agent.
19. A method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, comprising the step of removing at least one soluble cytokine receptor from the patient's body fluid, preferably by means of a molecule as defined in any one of claims 1 to 13.
20. The method according claim 19, wherein said method is for treating cancer in the patient, preferably further comprising administering a chemotherapeutic agent.
21. The method according to claim 19 or 20, wherein the molecule as defined in any one of claims 1 to 13 is contacted with the body fluid of the patient prior to, concomitantly with and/or subsequent to administering the chemotherapeutic agent to said patient.
22. The method according to any one of claims 19 to 21, wherein the time interval- between contacting said molecule with the body fluid of the patient and administering said chemotherapeutic agent is not longer than seven days, preferably not longer than 5 days, in particular not longer than 3 days.
23. The method according to any one of claims 19 to 22, wherein said molecule is contacted with the body fluid of the patient repeatedly, preferably at least three times.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/002340 WO2012163544A1 (en) | 2011-06-01 | 2012-06-01 | Removal of soluble tumor necrosis factor receptor 2 (stnfr2) |
EPPCT/EP2012/002340 | 2012-06-01 | ||
EP12196527.1 | 2012-12-11 | ||
EP12196527 | 2012-12-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013179143A2 true WO2013179143A2 (en) | 2013-12-05 |
WO2013179143A3 WO2013179143A3 (en) | 2014-05-01 |
Family
ID=47500945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/001583 WO2013179143A2 (en) | 2012-06-01 | 2013-05-31 | Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013179143A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9623081B2 (en) | 2014-10-03 | 2017-04-18 | Ntercept, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
US10653790B2 (en) | 2015-07-29 | 2020-05-19 | Nanotics, Llc | Compositions and methods related to scavenger particles |
US11065345B2 (en) | 2017-01-04 | 2021-07-20 | Nanotics, Llc | Methods for assembling scavenging particles |
US11345725B2 (en) | 2019-09-16 | 2022-05-31 | Research Foundation Of The City University Of New York | Bis-thioether stapled peptides as inhibitors of PRC2 function |
CN114773484A (en) * | 2021-02-05 | 2022-07-22 | 华南理工大学 | Recombinant fusion protein capable of adsorbing cell factors, nano assembly and preparation method and application of nano assembly |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708713A (en) | 1984-11-16 | 1987-11-24 | Anisa Medical, Inc. | Method and system for removing immunosuppressive components from the blood of mammals |
WO1999061085A2 (en) | 1998-05-22 | 1999-12-02 | Lentz M Rigdon | Method and compositions for treatment of cancers |
WO2001037873A2 (en) | 1999-11-10 | 2001-05-31 | Lentz M Rigdon | Method and system to remove cytokine inhibitor in patients |
WO2005107802A2 (en) | 2004-04-30 | 2005-11-17 | Biopheresis Technologies, Llc | Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012163544A1 (en) * | 2011-06-01 | 2012-12-06 | Biopheresis Technologies, Inc. | Removal of soluble tumor necrosis factor receptor 2 (stnfr2) |
-
2013
- 2013-05-31 WO PCT/IB2013/001583 patent/WO2013179143A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708713A (en) | 1984-11-16 | 1987-11-24 | Anisa Medical, Inc. | Method and system for removing immunosuppressive components from the blood of mammals |
WO1999061085A2 (en) | 1998-05-22 | 1999-12-02 | Lentz M Rigdon | Method and compositions for treatment of cancers |
US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
WO2001037873A2 (en) | 1999-11-10 | 2001-05-31 | Lentz M Rigdon | Method and system to remove cytokine inhibitor in patients |
WO2005107802A2 (en) | 2004-04-30 | 2005-11-17 | Biopheresis Technologies, Llc | Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
Non-Patent Citations (4)
Title |
---|
BRUNSTEIN F; HOVING S; SEYNHAEVE AL; VAN TIEL ST; GUETENS G; DE BRUIJN EA; EGGERMONT AM; TEN HAGEN TL: "Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies", J NATL CANCER INST., vol. 96, no. 21, 3 November 2004 (2004-11-03), pages 1603 - 10, XP002419450 |
HOVING S; BRUNSTEIN F; AAN DE WIEL-AMBAGTSHEER G; VAN TIEL ST; DE BOECK G; DE BRUIJN EA; EGGERMONT AM; TEN HAGEN TL: "Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats", CANCER RES., vol. 65, no. 10, 15 May 2005 (2005-05-15), pages 4300 - 8 |
LENTZ M; KUMAR K: "Reduction of plasma levels of soluble tumor necrosis factor and interleukin-2 receptors by means of a novel immunoadsorption column", THER APHER DIAL., vol. 12, no. 6, December 2008 (2008-12-01), pages 491 - 9, XP055001372, DOI: doi:10.1111/j.1744-9987.2008.00640.x |
MANUSAMA ER; NOOIJEN PT; STAVAST J; DURANTE NM; MARQUET RL; EGGERMONT AM: "Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat", BR J SURG., vol. 83, no. 4, April 1996 (1996-04-01), pages 551 - 5 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9623081B2 (en) | 2014-10-03 | 2017-04-18 | Ntercept, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
US9907831B2 (en) | 2014-10-03 | 2018-03-06 | Nanotics, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
US10420817B2 (en) | 2014-10-03 | 2019-09-24 | Nanotics, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
US10888602B2 (en) | 2014-10-03 | 2021-01-12 | Nanotics, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
US11771744B2 (en) | 2014-10-03 | 2023-10-03 | Nanotics, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
US10653790B2 (en) | 2015-07-29 | 2020-05-19 | Nanotics, Llc | Compositions and methods related to scavenger particles |
US11065345B2 (en) | 2017-01-04 | 2021-07-20 | Nanotics, Llc | Methods for assembling scavenging particles |
US11345725B2 (en) | 2019-09-16 | 2022-05-31 | Research Foundation Of The City University Of New York | Bis-thioether stapled peptides as inhibitors of PRC2 function |
CN114773484A (en) * | 2021-02-05 | 2022-07-22 | 华南理工大学 | Recombinant fusion protein capable of adsorbing cell factors, nano assembly and preparation method and application of nano assembly |
CN114773484B (en) * | 2021-02-05 | 2023-07-11 | 华南理工大学 | Recombinant fusion protein for adsorbing cytokines, nano assembly, and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2013179143A3 (en) | 2014-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012163544A1 (en) | Removal of soluble tumor necrosis factor receptor 2 (stnfr2) | |
WO2013179143A2 (en) | Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors | |
Tazzyman et al. | Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth | |
Lin et al. | Roles of neutrophils in glioma and brain metastases | |
EP3672604A1 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
WO2017165439A1 (en) | Methods for improving the therapeutic index for a chemotherapeutic drug | |
JP2013512254A5 (en) | ||
JP2015521176A5 (en) | ||
Sun et al. | Synthesis and characterization of a silica-based drug delivery system for spinal cord injury therapy | |
EP3448363B1 (en) | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine | |
CN111868087A (en) | anti-CD 33 and anti-CD 7 combination therapy | |
CA3149308A1 (en) | Treatment of immune evasive tumors | |
JP2009518418A (en) | Interleukin 11 composition and method of use | |
US20230210953A1 (en) | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer | |
Ito et al. | Maitake beta-glucan enhances granulopoiesis and mobilization of granulocytes by increasing G-CSF production and modulating CXCR4/SDF-1 expression | |
Sun et al. | Local biomaterial-assisted antitumour immunotherapy for effusions in the pleural and peritoneal cavities caused by malignancies | |
US20070178104A1 (en) | Methods and means for treating solid tumors | |
US20050163778A1 (en) | Extracorporeal photopheresis in combination with anti-TNF treatment | |
US20230287075A1 (en) | Dual cytokine fusion proteins comprising multi-subunit cytokines | |
CA3151815A1 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
US20160158368A1 (en) | Methods and compositions for the treatment of histiocytosis | |
CN107299138B (en) | Gene screening method for treating tumor and accelerating tumor re-proliferation after chemotherapy by CXCL4 monoclonal antibody | |
AU2020208472A1 (en) | Fibroblasts and microvesicles thereof for reduction of toxicity associated with cancer immunotherapy | |
Sun et al. | CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies | |
Zhu et al. | The role of innate immune cells as modulators of the tumor microenvironment in the metastasis and treatment of pancreatic cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13758979 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13758979 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13758979 Country of ref document: EP Kind code of ref document: A2 |